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Abstract 
Background: Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative disease. 
TDP-43 is found in pathological protein aggregates in neurons and glia in ALS and it is 
part of some mRNA transport granules. MBP messenger RNA (mRNA) must be 
transported to the oligodendrocyte processes for correct myelination. If TDP-43 were 
part of MBP mRNA transport granules, its aggregation could lead to loss of MBP in the 
CNS. Additionally, C9orf72 is a gene whose GGGGCC expansion mutation causes ALS. 
The expansion binds hnRNP-A2, a protein essential for the transport of MBP mRNA. 
This interaction may lead to the sequestration of hnRNP-A2, reducing its availability and 
causing a shortage of MBP in the CNS. 
Aims: To characterise the oligodendroglial pathology and the loss of MBP in our cohort 
of ALS cases, and to create zebrafish lines to investigate the development of 
oligodendroglial degeneration in sporadic ALS and C9orf72 ALS. The overarching 
hypothesis of the project is that the observed oligodendrocyte degeneration in ALS is 
primarily caused by a dysfunction of MBP mRNA transport, causing demyelination. 
Methods & Results: Using immunohistochemistry in human post mortem tissue, this 
project reports a greater, distinct ubiquitin-related glial pathology in the primary motor 
cortex of C9orf72-ALS cases. This C9orf72-related glial pathology was independent of 
the dipeptide-repeat protein inclusions usually found in the motor neurones of these 
patients. Using Western blot and qPCR, the levels of MBP and PLP, another myelin 
protein that is translated in the oligodendrocyte cell body, were measured. A reduction 
in the levels of MBP, but not those of PLP, was found in the spinal cord lateral 
corticospinal tracts of ALS cases, which was more pronounced in C9orf72 ALS. This 
reduction of the MBP levels was not accompanied by either a reduction in the number of 
axons panning that area or the levels of MBP mRNA. 
Conclusions: These results suggest that an impairment of mRNA transport is the main 
cause of the reduced MBP levels in the spinal cord of ALS patients and that 
oligodendrocyte degeneration precedes axonal degeneration in ALS. Were this 
confirmed using in vivo models of ALS, it would imply that ALS begins as a myelinopathy 
which later causes the apparition of neuronal pathology and death. None of the in vivo 
models trialled in this project were successful, but others have created promising models 
that will surely help understand oligodendroglial degeneration in ALS.
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Nogo-A: Neurite outgrowth inhibitor A 
NSC-34: Neuroblastoma spinal cord 
OPC: Oligodendrocyte precursor cell 
OPTN: Optineurin 
OSP: Oligodendrocyte-specific protein 
PAM: Protospacer-adjacent motif 
PBS: Phosphate buffer saline 
PCR: Polymerase chain reaction 
 qPCR: Quantitative PCR 
PFA: Paraformaldehyde 
PLP: Proteolipid protein 
PSP: Progressive supranuclear palsy 
14 
 
RanGAP: Ran GTPase-activating 
protein 
RanGTP: GTP-bound RAs-related 
nuclear protein 
RanGDP: GDP-bound RAs-related 
nuclear protein 
RAN-translation: Repeat-associated 
non-ATG translation 
RBM45: RNA Binding Motif Protein 45 
RGNEF: Rho guanine nucleotide 
exchange factor 
RIPA: Radioimmunoprecipitation 
assay 
RLS: RNA localisation signal 
RNA: Ribonucleic acid 
 mRNA: Messenger RNA 
 rRNA: Ribosomal RNA 
 gRNA: Guide RNA 
RNP: Ribonucleprotein 
 hnRNP: heteronuclear RNP 
ROI: Region of interest 
RRM: RNA recognition motif 
rSAP: Recombinant shrimp alkaline 
phosphatase 
RT: Room temperature 
SSC: Salt-sodium citrate 
sncRNA: Small non-coding RNA 
SOD1: Superoxide dismutase 1 
ssODN: single-stranded 
oligodeoxynucleotide donor template 
TALENS: transcription activator-like 
effector nucleases 
TARDBP: transactive response-DNA 
binding protein (gene) 
TBS: Tris buffer saline 
TBST: Tris buffer saline with tween 
TDP-43: transactive response-DNA 
binding protein 43 KDa 
            pTDP-43: Phosphorylated TDP-
43 
TEMED: N,N,N,N-tetramethylethylene 
diamine 
TSC: Trisodium citrate 
UMN: Upper motor neurone 
UTP: Uracil triphosphate 
UTR: Untranslated region 
UV: Ultraviolet 
15 
 
WISH: Whole-mount in situ 
hybridisation 
WM: White matter
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CHAPTER 1 
Introduction 
This project aims to determine whether impaired transport of the myelin basic protein 
(MBP) mRNA in oligodendrocytes is involved in the pathogenesis of amyotrophic lateral 
sclerosis (ALS).  
1.1 Amyotrophic lateral sclerosis 
ALS is a fatal, adult-onset, degenerative motor neuron disease. It is the most common of 
the motor neuron diseases: the incidence of ALS found by studies using the commonly-
used El Escorial criteria for ALS diagnosis (Brooks, 1994, Brooks et al., 2000) is 1.5-2 per 
100,000 people per year (Marin et al., 2016), with a prevalence of 5-7 per 100,000 people 
worldwide (Mitchell and Borasio, 2007, McDermott and Shaw, 2008). About 95% of ALS 
cases have an unknown cause (sporadic ALS or sALS) while 5% have a family background 
of the disease (familial ALS or FALS; Byrne et al., 2011). There is an increasing number 
of genes which have been linked to ALS (table 1.1), some of which have been used to 
model this disease in animals (e.g. in mice or zebrafish) and in cell lines. Some of the 
most commonly linked and studied genes are Cu/Zn superoxide dismutase 1 (SOD1), 
chromosome 9 open reading frame 72 (C9orf72), transactive response-DNA binding 
protein 43 (TARDBP) and fused in sarcoma/translocated in liposarcoma (FUS/TLS). 
Although ALS has historically been regarded as a disorder of the neurones of the central 
nervous system (CNS), nowadays there is mounting evidence which supports the notion 
that ALS is also caused by a dysfunction of glial cells.  
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1.1.1 Clinical features of ALS 
Classic ALS is characterized by a loss of the combined function of the upper (brain) and 
lower (brain stem and spinal cord) motor neurons (UMN and LMN respectively, 
(McDermott and Shaw, 2008)). However, some cases present with failure only in UMN, 
which can develop into primary lateral sclerosis or pseudobulbar palsy (central), or only 
in LMN, which can become a progressive muscular atrophy or a bulbar palsy (peripheral). 
ALS is localized in onset, usually affecting a particular group of muscles first (McDermott 
and Shaw, 2008). Depending on the region of onset, it can be defined as limb, bulbar or 
respiratory. While respiratory onset is found in a small population of ALS cases (2.7%) 
and bulbar onset only affects about 1 in 5 cases, limb onset, is the most prevalent and 
affects 78% of cases. Limb onset is mainly characterised by a decrease in the motor 
function of the arms or legs. This can significantly hinder the ability to perform ordinary 
tasks such as standing up, walking, holding small objects or manipulating things with 
one hand. Bulbar onset usually results in deficits in glossal muscles. Because of this, 
patients tend to find trouble articulating words to form speech, often presenting with 
fasciculation of the tongue and with dysphagia at a later stage. Patients with respiratory 
onset disease present with apnoea, night hypoventilation, and other respiratory 
complications which are the cause of some sleeping disorders and, eventually, death by 
respiratory dysfunction. 
1.1.2 Genetics of ALS 
A number of genes have been found to harbour heritable pathogenic mutations in 
familial ALS, with SOD1, TARDBP, FUS and C9orf72 being the most commonly mutated 
and the most studied. Although the ALS-causing mutations found in some of these genes 
are very common in familial ALS, they have also been found in many cases of sporadic 
ALS. Other genes which have also been linked to fALS and sALS are shown in table 1.1. 
Some of these genes whose mutations cause ALS could be related to mRNA transport, in 
19 
 
particular, TARDBP, C9orf72 and FUS, whose main functional, mutational and 
pathological aspects will be discussed below. 
1.1.3 Pathology of ALS 
The pathological picture of ALS includes degeneration of the upper and lower motor 
neurones, with other brain areas involved in many cases. Neurones and glia in affected 
regions accumulate proteins in pathological cytoplasmic inclusions. In addition, the 
axons of the affected neurones degenerate. These cytoplasmic inclusions contain 
hyperphosphorylated TDP-43 (pTDP-43) and p62. p62 is a ubiquitin-binding protein 
involved in protein degradation through the proteasome pathway which can be labelled 
to visualise misfolded protein aggregation. Inclusions tend to be round and compact or 
skein-like in shape or take the form of preinclusions which show depletion of nuclear 
TDP-43 with translocation to the cytoplasm as a fine, diffuse granularity throughout the 
cell soma (Mackenzie et al., 2013). Four stages have been defined in ALS regarding TDP-
43 pathology (Brettschneider et al., 2013): 
In stage 1, projection neurones from the neocortex, neurones from layers II, III, V, and 
VI of the motor cortex, large motor neurones from the spinal cord ventral horns, and the 
nuclei for cranial nerves V, VII, X, XI, and XII, are all immunoreactive for pTDP-43 
cytoplasmic inclusions. Oligodendrocytes supporting these neurones also show this type 
of inclusions. 
In stage 2, the above-defined neuronal pathology extends to the prefrontal cortex, some 
of the precerebellar nuclei, the reticular formation, dopaminergic neurones of the 
substantia nigra pars compacta. Oligodendrocytes that accompany neuronal projections 
from the precerebellar nuclei to the cerebellum also display pTDP43 cytoplasmic 
aggregation in stage 2. 
Stage 3 displayed pTDP-43 involvement of the prefrontal granular cortex, where only 
neurones in layer IV are spared, and by the extension of this pathology to sensory areas 
of the parietal and temporal cortices, where only pyramidal cells and their myelinating 
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oligodendrocytes present pTDP-43 pathology. The inferior colliculus, the different nuclei 
of the striatum, and the projection neurones of the claustrum also present with pTDP-43 
pathology. 
Stage 4 is characterised by an extensive pTDP-43 pathology in certain neuronal groups 
of the anteromedial temporal lobe and in the hippocampus. The hippocampal 
involvement is outlined by pTDP-43 inclusions in the dentate fascia granular cells and in 
the pyramidal neurones of the Ammon’s horn. Some stage 4 cases also show cerebellar 
involvement, particularly in the dentate nucleus. 
Macroscopically, ALS brains do not usually have striking features, although many have 
atrophy of the ventral nerve roots and medullary pyramids. A few have atrophy of the 
precentral gyrus, and ALS patients with overlapping frontotemporal dementia (FTD) 
may show a distinctive atrophy of the temporal cortex (bilateral superior temporal gyri 
and right temporal pole) and the frontal cortex (left middle and inferior frontal gyri, and 
medial premotor cortex). 
Some pathological marks are explicitly linked to certain ALS-causing genetic mutations, 
and they will be discussed below in their correspondent sections. 
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GENE 
SYMBOL 
GENE NAME CHROMOSOME 
SOD1 Cu/Zn superoxide dismutase 1 21q22.11 
ALS2 Amyotrophic lateral sclerosis 2 21q22.11 
ALS3 Unknown 18q21 
SETX Senataxin 9q34.13 
SPG11 Spastic paraplegia 11 15q14 
FUS Fused in sarcoma 16p11.2 
ALS7 Unknown 20p13 
VAPB Vesicle-associated membrane protein-associated protein B 20q13.33 
ANG Angiogenin 14q11.1 
TARDBP TAR DNA binding protein 1p36.22 
FIG4 FIG4 homolog, SAC1 lipid phosphatase domain containing 6q21 
OPTN Optineurin 10p13 
ATXN2 Ataxin 2 12q23-q24.1 
VCP Valosin-containing protein 9p13 
UBQLN2 Ubiquilin 2 Xp11.21 
SIGMAR1 Sigma non-opioid intracellular receptor 1 9p13 
CHMP2B Chromatin modifying protein 2B 3p12.1 
PFN1 Profilin 1 17p13.3 
ERBB4 V-erb-b2 avian erythroblastic leukemia viral oncogene 
homolog 4 
2q33.3-q34 
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 12q13.1 
MATR3 Matrin 3 5q31.2 
C9orf72 Chromosome 9 open reading frame 72 9p21.2 
CHCHD10 Coiled-coil-helix-coiled-coil-helix domain containing 10 22q11.23 
UNC13A Unc-13 homolog A 19p13.12 
DAO D-amino-acid oxidase 12q24 
DCTN1 Dynactin 2p13 
NEFH Neurofilament, heavy polypeptide 200kda, heavy chain 22q12.1-q13.1 
PRPH Peripherin 12q12 
SQSTM1 Sequestosome 1 5q35 
TAF15 TAF15 RNA polymerase II 17q11.1-q11.2 
SPAST Spastin 2p24 
ELP3 Elongation protein 3 homolog 8p21.1 
LMNB1 Lamin B1 5q23.2 
SARM1 Sterile Alpha and TIR Motif Containing 1 17q11.2 
MOBP Myelin-associated oligodendrocytic basic protein 3p22.1 
 
Table 1.1: Major known ALS-linked genes. List obtained from ALSoD (Abel et al., 
2013, Abel, 2013) and the latest ALS GWAS study (van Rheenen et al., 2016).  
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1.2 TDP-43 
1.2.1 TDP-43 structure and functions 
TARDBP is the gene which encodes transactive response-DNA binding protein 43 kDa 
(TDP-43). TDP-43 is the protein which has most commonly been found in pathologic 
ubiquitinated neural inclusions in ALS. The proportion of ALS patients carrying at least 
one mutant TARDBP allele is 4% of fALS cases and 2.5% of sALS cases (Mackenzie et al., 
2010). 
TDP-43 is an RNA/DNA-binding protein involved in the regulation of many steps of RNA 
processing, from transcription and alternative splicing to transport, translation and 
degradation (reviewed by Laggier-Tourenne, 2010). TDP-43 exists mostly as a thermo-
stable homodimer. It comprises two RNA recognition motif domains (RRM-1 and RRM-
2), a glycine-rich C-terminus (Kuo et al., 2009), and nuclear export and import signals 
(figure 1.1). These allow  TDP-43 to shuttle in and out of the nucleus in a manner 
dependent on its association with mRNA and/or other proteins (Ayala et al., 2008). The 
RRMs confer TDP-43 with the ability to bind preferentially to TG/UG-rich segments of 
mRNA or single-stranded (uncoiled) DNA, and thereby form dimers (Kuo et al., 2009, 
Buratti and Baralle, 2001). Multiple studies have found that only the longer glycine-rich 
domain-containing isoforms of TDP-43 are involved in splicing regulation, as this 
domain confers the ability to establish direct interactions with other mRNA-processing 
proteins (Ayala et al., 2005, Wang et al., 2004). Shorter recombinant isoforms which 
lack the glycine-rich C-terminus do not seem to have their (ribo)nucleic acid-binding 
function impaired (Buratti and Baralle, 2001), and therefore they could be responsible 
for other TDP-43 functions such as transcriptional and translational control of target 
genes and mRNAs.  
In addition, Bentmann et al. (2012) have shown that the C-terminus is necessary for 
recruiting TDP-43 to stress granules in the cytoplasm. Stress granules are mRNA-
arresting RNP structures which are formed after stress to avoid translation and regulate 
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cell metabolism. TDP-43 self-regulates its own mRNA transcription levels through the 
use of a negative feedback loop: TDP-43 protein binds the TARDBP mRNA transcript via 
the 3’ untranslated region (UTR; Ayala et al., 2011). 
1.2.2 ALS pathology related to TDP-43 
Immunohistochemical studies have shown that TDP-43 can be found in both the nucleus 
and the cytoplasm, although the nucleus harbours a much higher concentration in 
normal non-mutant cells (Ince et al., 2011). When motor neurons are stained with an 
anti-TDP-43 antibody, TARDBP ALS mutants, sporadic ALS cases and many fALS cases 
show nuclear depletion of TDP-43 in many neurones which instead can be found in the 
cytoplasm as aggregates of a hyperphosphorylated form (Neumann et al., 2006). This is 
a feature shared with other diseases, known as the TDP-43 proteinopathies (Geser et al., 
2010), such as FTLD. 
 
1.3 FUS 
 
1.3.1 FUS structure and functions 
The FUS gene encodes a protein known as Fused in sarcoma/translocated in liposarcoma 
(FUS/TLS, from now on referred to as FUS). Fifty-eight pathogenic mutations have been 
identified with a frequency of about 5% in fALS cases, and less than 1% in fALS cases 
(Lattante et al. 2013). Most of the pathogenic mutations found in ALS occur in the well-
conserved C-terminus, which has been identified as an indispensable part of FUS for 
DNA/RNA binding and alternative splicing modulation (Zinszner et al., 1997, Perrotti et 
al., 1998, Crozat et al., 1993). 
FUS is a DNA/RNA-binding protein. Among other functions, FUS regulates the 
transcription and splicing of thousands of target genes (Lagier-Tourenne et al., 2012), 
while outside the nucleus it has been shown to form part of stress granules and RNA 
transport granules, regulating localised translation in cell processes (Yasuda et al., 2013, 
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Dormann et al., 2010). The structural properties which confer FUS these properties are 
(figure 1.1): an RNA recognition motif; a zinc-finger domain; a nuclear localisation 
motif recognised by transportin; a glycine-rich domain; a glutamine-glycine-serine-
tyrosine-rich domain; and an arginine-glycine-glycine-rich domain (Mackenzie et al., 
2010, Dormann et al., 2010). 
1.3.2 ALS pathology related to FUS 
FUS is localised to both the nucleus and the cytoplasm and constantly shuttles between 
them (Zinszner et al., 1997, Andersson et al., 2008). FUS immunohistochemistry of 
control cases shows strong staining in the nucleus of neurons and glia, and fainter 
staining in their cytoplasm, indicating that a much higher concentration of FUS is usually 
found in the nucleus. Some of the FUS mutations lead to FUS aggregation in the form of 
cytoplasmic inclusions accompanied by nuclear depletion of FUS, but cases of ALS 
without mutant FUS showed just the standard pattern of FUS staining (Hewitt et al., 
2010). 
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Figure 1.1: TDP-43 and FUS/TLS protein domains. Each of the two TDP-43 
monomers that make the protein contains a nuclear localisation sequence, an RNA 
recognition motif, a nuclear export sequence, and a glycine-rich N-terminus. 
FUS/TLS is similar, containing all of the TDP-43 domains in addition to a Glu-Gly-
Ser-Tyr-rich domain, an Arg-Gly-rich domain, and a zinc finger.
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1.4 C9orf72 
 
Chromosome 9 open reading frame 72 (C9orf72) is the gene which encodes the 
homonym protein C9orf72. C9orf72 is an extremely well-conserved gene across species 
and the most commonly mutated gene in fALS and sALS accounting for around 37.6% of 
fALS cases, and 6.3% of sALS cases worldwide (Majounie et al., 2012). Around 29.3% of 
patients with C9orf72 mutations develop signs of both ALS and FTD, and this phenotype 
is diagnosed as ALS-FTD. This gene also seems to be the most commonly mutated in 
FTD. It is unclear what factors determine whether a patient harbouring the mutation 
develops ALS, FTD or both (van Blitterswijk et al., 2012). This is exemplified by a case of 
genetically identical twins harbouring the mutant C9orf72 gene, of whom one of them 
developed ALS while the other developed FTD (Xi et al., 2014). This could indicate that 
there must be C9orf72-independent factors which intervene in the development of either 
disease in patients with the mutation. 
1.4.1 C9orf72 functions 
The functions C9orf72 performs are starting to be understood. Under normal conditions, 
there are three transcript variants of the C9orf72 mRNA (figure 1.2A). Two of these 
transcripts (V2, V3) encode for the 481 a.a. isoform (C9orf72L) while the remaining 
transcript (V1) encodes for the 222 a.a. isoform (C9orf72S) (DeJesus-Hernandez et al., 
2011). At the structural level, Levine et al. (2013) determined that the C-terminus of 
C9orf72 contains the majority of the secondary structures found in “differentially 
expressed in normal and neoplastic cells” (DENN) proteins (figure 1.2B), which are 
known to interact and regulate proteins of the Rab family. They, therefore, predicted that 
C9orf72 might be associated with the fine tuning of membrane trafficking by modulating 
Rab GTPase activity. 
This Rab autophagocytic pathway has recently been explored by multiple authors. Yang 
et al., (2016) and Sullivan et al. (2016) found that the DENN domain of C9orf72 allows it 
to form a complex with SMCR8, WDR41, and ATG101, which regulates ULK1-dependent 
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activation of autophagosomes. At the same time, Webster et al. (2016) found that this 
complex is responsible for recruiting the ULK1-dependent complex to active Rab1a, thus 
initiating the formation of the autophagosome. The C9orf72/SMCR8 complex also acts 
as a GTP-exchange factor for Rab8a and Rab39b (Yang et al., 2016, Corbier and Sellier, 
2016), thus facilitating other downstream reactions involved in the formation of the 
autophagosome. Total or partial ablation of C9orf72 in different cell types has been 
shown to impair the formation of autophagosomes (Yang et al., 2016, Webster et al., 2016, 
Ugolino et al., 2016, Sullivan et al., 2016), consistent with these findings.  
In addition, C9orf72 has also been recently shown to regulate actin dynamics in motor 
neurones by promoting the dephosphorylation of cofilin, a modulator of actin fibre 
synthesis (Sivadasan et al., 2016). 
In summary, C9orf72 seems to play a role in the regulation of the immune system 
homeostasis, in the initiation of the autophagocytic pathway, and in the regulation of the 
synthesis of actin fibres in the neuronal growth cone. 
1.4.2 C9orf72 mutation in ALS 
The mutation harboured by the C9orf72 gene in ALS and FTD is a large hexanucleotide 
(GGGGCC) expansion located in intron 1 (figure 1.2A).  This was first reported by 
Renton et al. (2011) and DeJesus-Hernandez et al. (2011). However, linkage analysis 
done in multiple studies had reported that a locus in the short arm of chromosome 9 was 
linked to ALS and FTD (Vance et al., 2006, Morita et al., 2006, Boxer et al., 2011, Pearson 
et al., 2011). The mutant expansion is defined as anything more than 30 repeats 
according to Garcia-Redondo et al. (2013), but the range of the repeats usually is in the 
region of 700 to 1500 (Buchman et al. (2013). 
The mechanisms by which expanded C9orf72 exerts its pathogenic activity are still to be 
concluded. The three principal mechanisms which have been proposed so far are 
described below.  
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Figure 1.2: Human C9orf72 mRNA and protein domains. A shows the three 
different unspliced mRNA transcripts for C9orf72, including the (GGGGCC)n repeats in 
intron 1 of splice variants V1 and V3, but not in V2. The protein isoforms translated from 
each of the splice variants are below them in green. B depicts the three putative domains 
of C9orf72: A longin domain at the C terminus followed by a DENN domain and an alpha 
dDENN domain at the N terminus.  
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1.4.3 Toxic gain of function of the expanded mRNA 
Nuclear foci formed of sense and antisense forms of the expanded C9orf72 mRNA have 
been observed in neurones and glial cells from motor cortex, frontal cortex, hippocampus, 
spinal cord, and cerebellum of ALS patients harbouring the GGGGCC expansion 
(DeJesus-Hernandez et al., 2011, Donnelly et al., 2013, Gendron et al., 2013, Zu et al., 
2013, Mizielinska et al., 2013). The foci have also been shown to occur in patient-derived 
fibroblasts, lymphoblasts, peripheral blood leukocytes, and pluripotent cell-derived 
neurones (Donnelly et al., 2013, Lagier-Tourenne et al., 2013, Zu et al., 2013). In addition, 
HEK293T cells transfected with (GGGGCC)66 RNA (Gendron et al., 2013), and NSC34 
(motor neurone-like) cells with tetracycline-induceable interrupted (GGGGCC)102 
repeats (Stopford et al., 2017) also show such foci. These foci are formed by the 
hexanucleotide repeat expansion mainly, without most of the flanking regions (Donnelly 
et al., 2013). 
In vitro, sense (GGGGCC) repeats form tract length-dependent uni- and multimolecular 
RNA G-quadruplex structures and single and double R-loops during the transcription 
process between the nascent RNA and the template DNA strand (Fratta et al., 2012, 
Reddy et al., 2013, Sket et al., 2015, Reddy et al., 2014). Likewise, the antisense 
(CCCCGG) repeats form C-protonated hairpins and i-motifs (Kovanda et al., 2015). 
These structures are thermodynamically favoured by the formation of hydrogen bonds 
between four and two guanine bases respectively in the sense mRNA, and between two 
cytosine residues in the antisense mRNA. Nuclear foci formed by these stable structures 
have been hypothesised to bind and sequester RNA-binding proteins.  
Multiple studies have shown that a vast number of RNA-binding proteins are capable of 
binding sense and antisense GGGGCC tracts in vitro (Haeusler et al., 2014, Donnelly et 
al., 2013, Lee et al., 2013, Sareen et al., 2013, Xu et al., 2013, Cooper-Knock et al., 2015, 
Cooper-Knock et al., 2014, Mori et al., 2013b, Rossi et al., 2015). So far, only some of 
these proteins have been shown to co-localise with (GGGGCC)n nuclear foci in tissue 
derived from patients. These include members of the heterogeneous nuclear 
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ribonucleoproteins family (A1, F, H, K, U) as well as ALYREF, FUS, TDP-43, Pur-α, 
ADARB2, SC35, nucleolin, SRSF2 and ILF3. The binding of different proteins to C9orf72 
foci such as hnRNPs-A2/B1, hnRNP-H, eIF2α, eIF2β, and RAX has been confirmed by 
pull-down assays using cell lysates (Rossi et al., 2015, Conlon et al., 2016). Additionally, 
spectrophotometric assays determined that the heme factor binds to (GGGGCC)4 
quadruplexes, activating its catalytic activity as an oxidative molecule (Grigg et al., 2014). 
1.4.4 Haploinsufficiency 
Expansions in the C9orf72 gene cause an inefficient translation of both isoforms of the 
C9orf72 mRNA. At the transcriptional level, transcript variant 2 of C9orf72, which 
encodes the long isoform and is the main C9orf72 transcript, appears to undergo reduced 
transcription in C9ALS patients’ tissue (DeJesus-Hernandez et al., 2011, Gijselinck et al., 
2012, van Blitterswijk et al., 2015, Donnelly et al., 2013, Haeusler et al., 2014, Ciura et 
al., 2013, Tran et al., 2015, Belzil et al., 2013, Waite et al., 2014, Fratta et al., 2013). This 
was also observed for human iPSC-derived motor neurones (Donnelly et al., 2013). 
Whether a reduction in C9orf72 protein levels is the primary cause of C9ALS has been 
tested using knock-out and knock-down models. In c. elegans, ablation of the C9orf72 
ortholog, alfa-1 resulted in the specific degeneration of GABAergic motor neurones, 
which led to age-dependent motor defects (Therrien et al., 2013). However, drawing 
conclusions about possible haploinsufficiency in human C9ALS from this model seems 
unreliable since its ortholog shares limited homology with that of humans (23%). In 
zebrafish, the zgc:100846 gene is the ortholog for C9orf72, sharing a 76% homology. 
Knockdown of zgc:100846 which targeted the ATG initiation codons, resulted in a 
reduced motility and axonopathy (Ciura et al., 2013). Zebrafish knockdown, however, 
requires confirmation with genetic mutants due to possible off-target effects (Robu et al., 
2007). Some other groups have studied the effects of C9orf72 ablation both ubiquitously 
and in neuronal and glial cells specifically using mouse models, whose C9orf72 ortholog 
(henceforth C9orf72) is 98% similar to humans. The studies which targeted only brain 
cells show that a depletion of C9orf72 in the brain is not sufficient to cause ALS 
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phenotypes or pathology (Lagier-Tourenne et al., 2013, Koppers et al., 2015). Total 
ablation of C9orf72 in mice resulted in immune dysregulation, but the mice did not 
develop motor neurone disease phenotypes or pathology (O'Rourke et al., 2016, Sullivan 
et al., 2016, Sudria-Lopez et al., 2016, Burberry et al., 2016). One study showed mild 
neuronal deficits and multiple anomalies in the immune system in knock-out mice, but 
not a motor neurone disease phenotype (Atanasio et al., 2016). Amongst the immune 
system anomalies, they detected a generalised increase in the amount of immune cells 
and a rise in the levels of some cytokines and chemokines such as interleukins, tumour 
necrosis factor alpha, and monocyte chemoattractant protein 1. Interestingly, they also 
found that knock-out mice produce a significantly higher amount of autoantibodies for 
the rheumatoid factor protein. Therefore, the current consensus appears to be that 
haploinsufficiency contributes to the development of the C9ALS, but it is not the primary 
cause of the disease. 
1.4.5 Toxic accumulation of RAN-translated polypeptides  
Repeat-associated non-ATG initiated (RAN) translation is a form of polypeptide 
synthesis which does not depend on an AUG codon. RAN-translation has been 
demonstrated in other repeat-associated diseases such as fragile X-associated tremor 
ataxia syndrome (FXTAS) and fragile X syndrome (FXS): A CGG repeat expansion in the 
5’ UTR of the fragile X mental retardation gene (FMR1) causes the translation of poly-
Gly or poly-Ala, depending on the reading frame used by the ribosome. The size of this 
expansion determines whether the carrier will be more prone to develop FXTAS or FXS. 
FXS is associated with what is known as a full mutation, meaning that the expansion 
contains over 200 repeats (Yu et al., 1991, Oberle et al., 1991). However, carriers of the 
premutation, consisting of 55-200 repeats, are more prone to develop FXTAS, and the 
penetrance will be dependent on age and repeat size (Jacquemont et al., 2004). Initiation 
of RAN translation of the FMR1 expansion seems to occur at a near-cognate ACG codon 
upstream the CGG repeats (Sellier et al., 2017). RAN-translation of the C9ALS-associated 
GGGGCC expansion also causes the synthesis of sense and antisense insoluble dipeptide 
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repeats (DPR) which aggregate in neurones and glia in the brain of both C9ALS and 
C9FTD patients (Mori et al., 2013a, Mori et al., 2013c, Ash et al., 2013, Zu et al., 2013). 
The protein sequence of the DPR depends on the reading frame from which it is 
translated, which gives rise to a total of 5 different DPR (figure 1.3). These are –in 
descending order of the frequency in which they are found aggregated in the brain- poly-
GA, poly-GP, poly-GR, poly-PA and poly-PR. From those, arginine-containing DPR 
(poly-GR and poly-PR) have been shown to be the most neurotoxic when aggregated 
after overexpression in cultured neurones, yeast, and drosophila. Arg-rich DPR have 
been mainly found to localise within the nucleolus. They interact with nuclear and 
nucleolar proteins, inducing nucleolar stress, which causes impairment of normal gene 
expression, including the dysregulation and silencing of mRNAs (Tao et al., 2015). 
Nucleolar stress is usually denoted by the cytoplasmic translocation of B23 (Yao et al., 
2010), which is responsible for ribosome biogenesis, promotes cell survival and regulates 
cell cycle progression (Lee et al., 2008, Lindstrom, 2011). Arg-rich DPR aggregation in 
the nucleus also causes the enlargement and dysfunction of the nucleolus in neurones 
(Mizielinska et al., 2017). The relevance of poly-GR aggregation seems more relevant 
than that of poly-PR because while poly-GR is found frequently in post mortem 
ALS/FTD brains, poly-PR is rarely found (Mackenzie et al., 2015, Schludi et al., 2015). 
 Surprisingly, poly-GA, the most commonly found form of DPR, appears to reduce the 
toxicity caused by arginine-rich DPR in human induced-pluripotent stem cell-derived 
neurones and drosophila. Poly-GA (15 and 50 repeats) was also found to form toxic 
fibrils in solution and to cause motor deficits in mice when expressed using an adeno 
associated virus (AAV) viral system injected in the cerebral ventricles. It remains to be 
ascertained whether the level of expression reached using viral vectors is similar to that 
of human C9ALS and whether it produces neurotoxicity at normal pathological levels (as 
opposed to overexpression levels) in the human brain. 
It would be expected to find correlations between neuronal death or disease severity and 
the degree of DPR accumulation if DPR were indeed the main cause of C9ALS/FTD 
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pathogenesis. However, even with DPR being prevalent in some key areas of these 
patients’ brains (Mackenzie et al., 2013), the relative infrequency of the most toxic, Arg-
rich DPR species, suggests that they could merely be pathological hallmarks in some 
regions of the brain, but be of no neurotoxic consequence. Opposing this view, there is 
also the possibility that most of the neurones and glial cells containing these aggregates 
die before the patient does, causing ALS/FTD phenotypes and rendering 
neuropathologists unable to detect them post mortem. 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Dipeptide repeat (DPR) sequences translated from C9orf72 
expansions. GGGGCC repeats are RAN-translated into toxic polypeptides consisting in 
the repetition of two amino acid residues. The translated DPR depends on which DNA 
strand is used as the template and on the reading frame. Two of these sequences are 
redundant (poly-GP), so only five different DPR can result from this form of translation.  
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1.4.6 Nucleocytoplasmic transport and the C9orf72 expansion 
Common ground for the mRNA and DPR toxic gain of function hypotheses seems to be 
the impairment of nucleocytoplasmic transport. As stated above, the most commonly 
aggregated protein in ALS cytoplasmic inclusions, TDP-43, is constantly shuttled 
between the nucleus and the cytoplasm, and so do other proteins and molecules. This 
transport requires GTP-bound RAs-related nuclear protein (RanGTP) to hydrolyse its 
bound GTP to GDP, forming RanGDP. Otherwise, importins would be inhibited in the 
cytoplasm, disabling cytoplasm-to-nucleus transport. Ran GTPase-activating protein 
(RanGAP) is essential to activate the catalytic function of RanGTP. The cytoplasmic 
accumulation and dysfunction of RanGAP and RanGTP, and their co-localisation with 
expanded C9orf72 mRNA foci have been demonstrated in C9ALS brain tissue as well as 
in patient iPSC-derived neurones and Drosophila models harbouring expanded C9orf72 
(Zhang et al., 2015). Also, the severity of RanGTP mislocalisation correlates with the 
severity of TDP-43 nuclear depletion (Winton et al., 2008), meaning that TDP-43 keeps 
being transported out of the nucleus without making its way back in. Also, nuclear 
depletion of TDP-43 aggregation seems to accumulate in cells with expanded C9orf72 
mRNA foci (Cooper-Knock et al., 2015). This all seems to indicate that expanded C9orf72 
mRNA binds and sequesters some essential factors for the active transport of 
macromolecules between the nucleus and the cytoplasm. However, there is also evidence 
that RAN-translated poly-GA DPR can cause mislocalisation of RanGAP and nuclear 
envelope proteins just by itself (Zhang et al., 2016b). Cytoplasmic poly-GA also inhibits 
the nuclear import of transcription factor p65 and promotes the cytoplasmic aggregation 
of TDP-43 in neurones (Khosravi et al., 2017). This phenotype can be rescued by inducing 
the overexpression of importin-alpha and nuclear pore components. Furthermore, 
directing poly-PA to the nucleus avoids TDP-43 mislocalisation to the cytoplasm 
(Khosravi et al., 2017). Another study showed a lower import rate in the nucleus caused 
by poly-PR and poly-GR (arginine-rich) using NSC-34 cells (Shani et al., 2017). Therefore, 
cytoplasmic aggregation of poly-GA and expanded C9orf72 mRNA both contribute to 
ALS pathogenesis by disrupting nucleocytoplasmic transport. 
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1.4.7 Pathology in C9orf72 expansion-carrying patients 
Surprisingly, ALS cases harbouring C9orf72 mutations show a pathological pattern 
which seems qualitatively very similar (but quantitatively greater) from patients not 
harbouring the expansion. Additionally, as described above, RAN-translated DPR also 
aggregate in C9ALS to form cytoplasmic and intranuclear neuronal inclusions which are 
negative for TDP-43, but positive for proteins related to the proteasome such as p62 and 
ubiquitin (Mackenzie et al., 2013, Zu et al., 2013, Mori et al., 2013c, Gendron et al., 2013, 
Ash et al., 2013). This neuronal aggregation accompanied by dystrophic neurites is 
extended in the cortex from the prefrontal cortex all the way to the visual cortex in the 
occipital lobe. The hippocampus is an extramotor area where TDP-43 and OPTN are 
usually good markers for protein inclusion pathology at stage 4, showing little 
involvement in the rest of the stages. However, neither of them can pick up all the 
abundant intra- and extra-nuclear neuronal inclusions which are labelled for p62 and 
DPR in granular and Purkinje cells of the cerebellum and the pyramidal neurones of the 
hippocampus found in C9ALS (Cooper-Knock et al., 2012, Mackenzie et al., 2014, Ash et 
al., 2013).  
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1.5 Oligodendrocytes and their dysfunction in ALS 
There are four main types of glial cell in the adult CNS: microglia, astrocytes, ependymal 
cells, and oligodendrocytes. The latter are responsible for forming the myelin sheaths 
which wrap the neuronal axons and make them deliver the nerve impulse considerably 
faster than unsheathed axons. It has been shown that many ALS cases and SOD1 (G93A) 
mice show demyelination of motor fibres (Verstraete et al., 2014, Ahdab et al., 2013, Kang 
et al., 2013, Borisow et al., 2013, Nishijima et al., 2012). Furthermore, myelin 
degeneration has been seen in higher mammal models of ALS. For example, canine 
degenerative myelopathy (CDM) is a condition that affects dogs with a naturally—
occurring mutation in their SOD1 homologue gene (Awano et al., 2009). CMD is 
considered a model of human ALS because affected dogs show the same type of spinal 
lesions and the adult-onset progressive loss of motor function (Nardone et al., 2016). 
One of the main pathological features of CDM is the evidence of demyelination in the 
spinal cord funiculi, especially in the dorsal area of the lateral funiculi, where the lateral 
motor tracts are located (Griffiths and Duncan, 1975). Additionally, a transgenic line of 
pigs expressing ALS-causing mutant human G93A SOD1 has been made (Yang et al., 
2014). These pigs showed myelin sheath degeneration in the spinal cord along with all 
the other common features of ALS -e.g. muscle wasting, motor disfunction and SOD1 
neuronal and glial inclusions. Demyelination in these models and in human ALS patients 
can be caused by a number of factors, including a lack of myelin production, a lack of the 
appropriate receptors which allow oligodendrocyte processes to attach to the axon or 
other layers, or an inefficacy of the oligodendrocytes to produce competent processes to 
wrap the axons. 
1.5.1 The role of MBP in myelin formation 
Oligodendrocytes develop multiple processes which project from the oligodendrocyte 
cell body to axons which they wrap in a process known as myelination: this is where 
multiple membrane layers containing myelin stack around the axon to isolate the axon 
from the external medium. This membrane assembly has recently been shown to be 
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triggered by a phase transition of myelin basic protein (MBP), from a soluble form to a 
form which makes the cytoplasm extremely viscous (Aggarwal et al., 2013). 
MBP is the main protein responsible for compaction and biogenesis of myelin. This was 
established in the shiverer mouse which lacks myelin due to Mbp mutations and 
accordingly, shows hypomyelination and incorrect compaction of myelin were present in 
the central, but not the peripheral nervous system. This results in the mouse showing the 
characteristic shivering gait. Axonal remyelination was restored following the expression 
of the MBP protein using an MBP-containing cosmid plasmid that was injected into 
fertilised eggs (Readhead et al., 1987, Allinquant et al., 1991). Consisting mostly of polar 
and charged amino acids which exert self-repulsive forces, MBP has almost no secondary 
structure in aqueous solution, appearing as a flexible coil, (a so-called ‘intrinsically 
unstructured protein’; Tompa, 2002). Once it binds to the cell membrane, the charges 
are neutralised and MBP polymerises into a meshwork, with non-polar phenylalanine 
groups playing a crucial role in this polymerisation. When polymerised, MBP shows 
typical alpha-helix and beta-sheet folding patterns. 
1.5.2 The role of MOBP in myelin formation 
A protein very similar to MBP, myelin-associated oligodendrocytic basic protein (MOBP), 
regulates the radial growth of axons and the radial component of the myelin sheath, a 
network of interlamellar tight junctions that is present in the central nervous system only 
(Sadahiro et al., 2000). MOBP is not necessary for the compaction of the myelin sheath, 
unlike MBP, but mice lacking MOBP have more sheath damage than wild-type mice after 
treatment with hexachlorophene, a myelin sheath disruptor (Yoshikawa, 2001). As a 
regulator of the tight junction distance between the myelin layers, MOBP probably 
confers the membrane protection against external agents by keeping the lamellae 
attached to each other. Interestingly, three single nucleotide polymorphisms in MOBP, 
the gene encoding MOBP, have been recently denoted as ALS risk loci by a GWAS study 
(van Rheenen et al., 2016). The same polymorphisms had previously been linked to FTD 
and progressive supranuclear palsy (PSP). FTD patients harbouring the MOBP SNPs 
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presented with an increased white matter atrophy which shortened the duration of the 
disease compared to noncarriers (Irwin et al., 2014). However, in PSP patients, the 
MOBP SNPs impaired the expression of the neighbouring gene SLC25A38 (Hoglinger et 
al., 2011), a mitochondrial carrier for glycine (Lunetti et al., 2016). This is not an issue 
for FTD because this SLC25A38 knock-down effect affects mainly the cerebellum and not 
so much the frontal cortex.  
1.5.3 Oligodendrocytes support axons metabolically, and this 
function is impaired in ALS 
In addition to being electrical insulators of axons, oligodendrocytes have also been 
shown to support axon upkeep and metabolic support. This is done by releasing 
neurotrophic factors and maintaining the energetic balance inside the axon, thus 
performing some roles classically attributed only to astrocytes in the CNS (Funfschilling 
et al., 2012, Lee et al., 2012). Indeed, the lack of metabolic support of axons has been 
proposed to be more important than the lack of electric insulation in some diseases such 
as hereditary spastic paraplegia and multiple sclerosis (reviewed by Soderblom et al., 
2006). 
Monocarboxylate transporter 1 (MCT1) is a myelin sheath-localised protein which helps 
oligodendrocytes perform their axonal metabolic support functions via export/import of 
lactate. In a study using cell culture, human tissue, and ALS rat tissue, Lee et al. (2012) 
showed that ALS patients generally show a reduction of more than 50% of MCT1 in the 
motor cortex, compared to healthy controls. They also revealed that a loss of MCT1 leads 
to a deficiency in axonal function and neuronal degeneration, making it crucial to 
maintain the energetic requirements of axons. Furthermore, Kang et al. (2013) found 
oligodendroglial degeneration and protein aggregates in human ALS motor cortex and 
determined that specific demyelination of the motor cortex is a feature of ALS. 
There are very few studies which have investigated the mechanism underlying 
dysfunction of oligodendrocytes and myelin in ALS pathogenesis compared to the vast 
39 
 
literature dedicated to ALS pathogenic mechanisms involving neurones, astrocytes and 
microglia. This makes it an unexplored field yet to be investigated, but the current 
evidence points towards oligodendrocytes playing a role in the pathogenesis of ALS.  
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1.6 Modelling ALS and demyelination using Zebrafish 
Monitoring the development of the brain pathology along the life of a patient with a 
neurodegenerative disease such as ALS raises ethical concerns due to the risk of 
significantly altering the life of the patient upon the extraction of brain tissue samples. 
Nonetheless, in vitro models using cultured brain cells differentiated from patients’ 
fibroblasts have been trying to circumvent this limitation in the last decade, allowing us 
to study the impact of these diseases in patients’ neurones and glia while the patients are 
still alive. These patient-derived cells also provide a good balance between the level of 
throughput and the translatability to patients. However, these in vitro models lack the 
complexity that a full organism has, and that is one of the reasons why in vivo models 
are still used today. Regarding ALS, numerous models have been created to help 
understand the different aspects of the disease since 1993, when the first ALS-causing 
mutations were identified in the SOD1 gene (Rosen et al., 1993). In particular, distinct 
features of familial ALS have been modelled in yeast, small invertebrates, such as C. 
elegans or D. melanogaster; and vertebrates with a high degree of genetic homology, 
such as zebrafish and mice (Van Damme et al., 2017). In this project, zebrafish was used 
as a model species, and the relevant characteristics why this organism was chosen are 
described in this section. 
1.6.1 Zebrafish as a model species 
Zebrafish (Danio rerio) is a small teleost fish which has proven advantageous as a model 
species for the human central and peripheral nervous system. Zebrafish go through rapid 
embryonic growth, generating a nervous system that is of experimental utility in a less 
than a week in contrast to the mouse, which takes a few weeks to reach such a stage. 
Moreover, the zebrafish embryo is transparent during embryonic stages, which allows 
for a clear visualisation of internal organs and cells at early stages of growth. Hundreds 
to thousands of embryos are easily harvested from a few mating couples in one day, 
thanks to the external fertilisation. This is really useful when a large number of 
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individuals are needed in high-throughput experiments such as drug screening 
(McGown et al., 2016) or large-scale mutational studies (Pichler et al., 2003).  
Regarding genetic manipulation, zebrafish can be subject to a variety of techniques 
including CRISPR/Cas9, TALENS and Zinc fingers for site-specific mutations; or tools 
such as the modular Gateway system (Kwan et al., 2007) or bacterial artificial 
chromosomes (BACs) (Ramesh et al., 2010) for transgenesis. In this aspect, they can 
serve as models of human mutations due to the high degree of homology many zebrafish 
genes share with mammals. 
 Overall, zebrafish represents an excellent option to investigate the effects of disease-
causing mutations in vivo in a way that allows a diversity of manipulating techniques to 
be used, especially when in vitro models are not an option due to the complexity of the 
whole organism. For example, this includes the instances when signalling cascades, 
molecular gradients, and interaction with different types of cells are involved in the fate 
of the investigated cells. This is particularly relevant in the context of myelination, where 
all of those are relevant –as  explained in the next section. 
1.6.2 Zebrafish as a model of myelination 
Zebrafish oligodendrocytes are developed within the first days of embryonic life from 
oligodendrocyte precursor cells (OPCs) while the embryo is still transparent. Due to the 
quick growth of the central nervous system, it is crucial that axonal myelination occurs 
promptly, and it can be observed from 4 dpf with the expression of mbp, the zebrafish 
ortholog of MBP (Jung et al., 2010). There are many aspects of zebrafish myelination 
which replicate those of human myelination. Firstly, zebrafish myelin contains 
homologous proteins to those of human myelin, namely mbp, Plp/DM20, and Mpz 
corresponding to human MBP, PLP, and myelin protein zero respectively (Nawaz et al., 
2013, Schweitzer et al., 2006, Bai et al., 2011, Avila et al., 2007). In addition, the 
properties of myelin sheaths are very similar across both species, including lipid 
composition, sheath thickness, periodicity and membrane packing (Avila et al., 2007, 
Kirschner et al., 1989). The relationship between axonal diameter and the radial 
42 
 
component of myelin sheaths are positively correlated across multiple vertebrate species, 
including mammals and fish (Hildebrand and Hahn, 1978). 
Regarding myelination signalling pathways, zebrafish share with humans the Notch 
regulatory signal which allows for the maintenance of radial glia and the formation of 
oligodendrocytes and primary motor neurones (Kim et al., 2008). Additionally, the Wnt 
pathway has been shown to drive the expression of myelinating genes and to be essential 
for myelination (Tawk et al., 2011), and is conserved in zebrafish (Azim and Butt, 2011). 
The same can be said for the hedgehog pathway: Inhibition of sonic hedgehog signalling 
leads to a decrease in the levels of OLIG2, which is essential for the early differentiation 
of motor neurones and OPCs (Park et al., 2004, Chung et al., 2013). Inhibition of the 
hedgehog pathway also results in a reduction in the expression of proteins which are 
crucial for myelination in both the central and peripheral nervous system –such as MBP 
and MAG (Yoshimura and Takeda, 2012, Wang and Almazan, 2016). This pathway is 
conserved between humans and zebrafish (Schebesta and Serluca, 2009) and has been 
thoroughly studied in zebrafish. Another well-studied pathway that regulates 
myelination is the ErBb pathway. The different members of the ErBb family collaborate 
towards the differentiation of oligodendrocytes from OPCs. For example, EGFR plays a 
role in the asymmetrical polarisation of neural precursor cells into different classes of 
neural cells (Sun et al., 2005), and plays a major role in remyelination in mammals 
(Aguirre et al., 2007, Brinkmann et al., 2008). The ErBb signalling pathway is also 
shared by zebrafish (Lyons et al., 2005, Pruvot et al., 2014) and the effect of 
overexpression and inhibition of the different ErBb proteins in vivo is an area of ongoing 
research in this model animal. 
1.6.3 Zebrafish as a model of ALS 
The genetic homology to humans that zebrafish have and the relatively high throughput 
they offer compared to other vertebrates have allowed multiple mutations that cause ALS 
to be modelled in zebrafish to investigate their pathogenic mechanisms. Most of the 
genes found mutated in fALS and sALS have known zebrafish orthologs with usually high 
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degrees of genetic homology and protein residue conservation. Therefore, this allows for 
the genetic manipulation of the endogenous zebrafish orthologs to investigate the effect 
of ALS-causing mutations. For example, the use of antisense morpholino 
oligonucleotides (AMOs) to knock down the expression of the FUS, TARDBP, SOD1, and 
C9orf72 orthologs (fus, tardbp, sod1, and C13H9orf72) has been useful to confirm that 
their loss of function leads to motor deficits and axonopathy (Kabashi et al., 2011, 
Armstrong and Drapeau, 2013, Ciura et al., 2013). Random mutagenesis and gene 
mutation screening have also been used to identify a tardbp allele that contains an early 
stop codon (Hewamadduma et al., 2013). This strain was used to demonstrate that 
Tardbp depletion in zebrafish leads to the alternative splicing of the mRNA of another 
TARDBP ortholog, tardbpl, which replaces tardbp when the latter is not expressed. For 
that strain, a tardbpl-targeted AMO in a high concentration produced defects in axonal 
guidance and motor function, also reducing zebrafish survival. Similar results were 
found in a study where zinc finger nucleases were used to knock out tardbp and tardbpl 
(Schmid et al., 2013). Additionally, CRISPR/Cas9 (Clustered Regularly Interspaced 
Short Palindromic Repeats/CRISPR associated system 9) technology have been used to 
knock-in human ALS-causing mutations in conserved amino acids of the endogenous 
Tardbp and Fus zebrafish proteins (Armstrong et al., 2016). However, these strains still 
remain to be fully characterised regarding any ALS-related pathology. Regarding SOD1, 
transgenesis of wild type human SOD1 and of SOD1 containing an ALS-causing mutation 
in zebrafish was detrimental to motor neurones, causing motor deficits, abnormal 
neuromuscular junctions and premature death (Ramesh et al., 2010). A similar approach 
also showed that mutant SOD1 can provoke a heat shock response in zebrafish without 
the need of a heat shock, affecting mainly the inhibitory input of the glycinergic 
interneurons in the spinal cord (McGown et al., 2013). Transient expression of human 
SOD1 harbouring ALS-causing mutations has also been used to show that it causes the 
deficiency of motor neurone axons in zebrafish embryos (Sakowski et al., 2012). 
Concerning C9orf72, the injection DNA constructs containing 38 and 72 GGGGCC 
repeats in zebrafish embryos increased the number of apoptotic cells in zebrafish 
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compared to constructs containing 8 repeats and controls (Lee et al., 2013). Embryos 
injected with the 72× GGGGCC construct also displayed GGGGCC-positive RNA foci in 
the majority of the apoptotic cells. 
In summary, using zebrafish as a model to investigate human CNS myelination and ALS 
has proven to be a successful approach regarding the proteins and differentiating and 
specialising regulatory pathways involved. 
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1.7 Myelin and MBP production 
This section is focused on how the CNS myelination is controlled. It covers diverse 
aspects of myelination which are relevant to eventually understand the mechanisms that 
can be susceptible to be dysregulated or impaired by ALS-causing mutations. 
1.7.1 The different models of CNS myelination 
The insulating and metabolic functions performed by oligodendrocytes are dependent 
on the integrity of the myelin sheath and its physical contact with the axonal membrane. 
Since 1954, when glial cells were associated with the production of myelin (Geren and 
Schmitt, 1954), the mechanisms of myelination have been mostly in the dark due to the 
lack of the necessary technology to visualise the wrapping of the oligodendroglial 
processes around axons. A first model –the “carpet crawler” model- proposed that upon 
contact with the axon, oligodendrocytes and Schwann cells extend the myelin 
compartment all along the internode prior to wrapping the axon (Bunge et al., 1961, 
Bunge et al., 1989). This was observed using light microscopy to observe the 
remyelinating axons of cats upon which a myelin injury had been caused. However, this 
contradicted the nonuniformity in sheath thickness during early ensheathment (Knobler 
et al., 1976) and would imply that the leading membrane would have to use a large 
amount of force to displace the layers in contact with the axon. With the development of 
new visualisation techniques, the “liquid croissant” model was proposed (Sobottka et al., 
2011) using confocal and electron microscopy. In this model, the axon guides the 
oligodendrocyte’s process laterally along the internode as new layers “pour” on top of 
each other, resembling the layered structure of a croissant. However, the observations 
made by Snaidero et al. (2014) using a reporter of membrane trafficking to visualise 
membrane growth suggest that the myelin growth cone does follow the “carpet crawler” 
type of spiralling around the axon. Nonetheless, as new layers are formed, they begin 
growing laterally along the axonal internode from the oligodendrocyte-axon contact 
point. Thus, the shorter inner layers grow under the longer outer layers until they all 
cover the whole of the internode. This explains the observation that the sheath is not 
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uniform during its development, but it is later on after it is fully compacted. They also 
observed 2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNP) regulates the MBP-
mediated compaction of the layers. The mRNA encoding MBP is transported in protein 
granules to the myelin sheath (Colman et al., 1982), where MBP is synthesised to produce 
compact myelin. However, if this compaction occurred at all times during the growth of 
the sheath, the leading edge would not be able to continue growing due to the constraints 
caused by myelin compaction. While MBP is indeed synthesised along the sheath during 
its development, CNP concentration modulates the compaction rate so that the leading 
edge can grow while the outer layers are compacted as they deposit along the axon 
(Gravel et al., 1996, Snaidero et al., 2014). Therefore, compaction seems to happen from 
the outside in. 
1.7.2 Relevant characteristics of the MBP mRNA 
As noted above, MBP is not synthesised in the cell body, where it would cause a fatal 
compaction of the cellular organelle membranes. Instead, its mRNA is silenced by the 
action of some proteins and small RNA molecules (described below), and another 
number of proteins bind to its 3’ untranslated region (UTR) in order to facilitate its 
transport to the myelin compartment, where it is translated (Muller et al., 2013). This 
protein complex is known as the transport granule, whose current model is depicted in 
figure 1.4. There are a number of features of MBP mRNA which have been shown to be 
essential for the assembly of the transport granule, and for its transport along 
microtubules towards the myelin compartment. 
Lack of exon II: MBP has a number of isoforms. Of all these, only those lacking exon 
II seem to be localized in the oligodendrocyte distal cell membrane in adults, while all 
other isoforms, which include exon II, account for only about 5% of MBP in adults and 
are located in the cell body (de Vries et al., 1997). Transcripts that retain exon II are 
probably predominantly present in a subset of OPCs which are ready for remyelination 
in the event of a loss of myelin: Allinquant et al. (1991) transfected cultured 
oligodendrocytes from shiverer mice with pRSV viral vectors containing the sequence 
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for each of the MBP isoforms, and their transcription was stimulated using sodium 
butyrate. They showed that OPCs in shiverer mice expressed almost exclusively exon II-
containing MBP isoforms which were located in the cell soma. However mature 
oligodendrocytes only show exon II-lacking MBP isoforms, and these were located in the 
distal processes.  
Cis-acting elements are specific sequences located in RNA to which trans-acting 
elements bind and act upon. In the context of mRNA expression, a trans-acting element 
is a molecule, usually a protein, which regulates certain aspects of mRNA biology by 
interacting with the cis-acting elements in the mRNA. In the case of MBP mRNA, there 
are two essential cis-acting elements in the 3’untranslated region (3’UTR) relevant to 
transport: the RNA trafficking sequence (RTS) in which a sequence referred to as the A2 
response element (A2RE) is located, and the RNA localization signal (RLS). A2REs are 
found in many mRNAs which are transported in granules to distal compartments of 
different cells for local translation (Kindler et al., 1996, Carson et al., 2008). The RLS is 
a region of the MBP mRNA which adopts a specific secondary structure that has been 
shown to be required for its location in the myelin compartment (Barbarese et al., 1999). 
Regarding MBP, the RTS is a 21-nucleotide sequence in the 3’UTR of MBP mRNA which 
binds hnRNP-A2 via the 11-nucleotide A2RE. The RTS has been shown to be sufficient 
for RNA transport (Ainger et al., 1997). Binding of hnRNP-A2 to the A2RE seems to 
trigger the assembly of an mRNA-transport granule and the recruitment of translation 
repressors which will prevent ectopic translation of the MBP mRNA. The recruited 
molecules are shown in figure 1.4 and will be discussed in the next section. 
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Figure 1.4: Simplified current model of the transport granule. A2RE: A2 
response element; RLS: RNA localisation signal; A2, E1, F, K, A3, U: heterogeneous 
ribonucleoprotein A2, E1, F, K, A3 and U; 40S, 60S: ribosomal subunits 40S and 60S; 
CBF-A: CArG box-binding factor A; TOG: tumor overexpressed gene protein; EF1A: 
elongation factor 1a; ATS: arginyl-tRNA synthetase; TDP-43: transactive response-DNA 
binding protein of 43 kDa; FUS: fused in sarcoma/translocated in liposarcoma; sncRNA 
715: small non-coding RNA 715; Arg2: Argonaute 2; UTR: untranslated region; START: 
initiation codon; STOP: stop codon; AAAAAAAA: polyadenine tail; 5’CAP: 5’ 7-
methylguanylate CAP. *hnRNPs E1 and K compete for two RNA binding sites and only 
bind at certain stages of the transport. 
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1.7.3 The transport granule: Interactions between the components 
and their function during MBP mRNA transport 
As shown in figure 1.4, the MBP mRNA transport granule is formed by the association 
of multiple proteins and RNA molecules, where some of them bind indirectly to the 
transported mRNA through those molecules that directly interact with it. This section 
describes the known roles for the molecules involved in the MBP mRNA transport 
granule and how they interact with each other to assemble and guide it towards the 
myelin compartment through the cytoplasmic microtubular network. This information 
can provide an idea of how the sequestration and mislocalisation of the different 
components of the granule, as sometimes observed in ALS, can affect the granule’s 
transport. 
hnRNP-A2 is the main molecule required for the coordinated assembly of the transport 
granule. It is likely that this function is performed by binding hnRNPs E1 and F, CBF-A 
and TOG. Knock-down of hnRNP-A2 in oligodendrocytes resulted in the confinement of 
MBP mRNA to the cell body, suggesting that hnRNP-A2 is essential for the initiation of 
transport (Laursen et al., 2011). A mutation in the G-rich C-terminus of hnRNP-A2 has 
been linked to multisystem proteinopathy (MSP) (Kim et al., 2013), which involves ALS-
like pathology amongst other neurological problems (Benatar et al., 2013). hnRNP-A2 
also has the intrinsic property of forming fibrils via the G-rich terminus, and this is 
exacerbated when the MSP-causing mutation is present (Kim et al., 2013). Additionally, 
the CGG repeat sequence that causes FXTAS binds hnRNP-A2 causing neurotoxicity, 
splicing dysregulation, and transport granule mislocalisation (He et al., 2014, Muslimov 
et al., 2011), and this protein is also part of the pathological protein inclusions present in 
that disease (Iwahashi et al., 2006). Therefore, there is the possibility that the ALS-
causing C9orf72 GGGGCC-repeat expansion causes hnRNP-A2 sequestration in ALS 
cases that harbour it. As explained above, C9orf72 mRNA containing the GGGGCC 
expansion does sequester a number of RNA-binding proteins of the hnRNP family. 
Additionally, C9orf72 binds hnRNP-A2 and mediates its shuttling between the nucleus 
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and the cytoplasm (Farg et al., 2014), so reduced levels of C9orf72 could potentially 
impair the function of hnRNP-A2 in the cytoplasm. 
CBF-A: Raju et al. (2008) showed by protein-RNA interaction assays that CBF-A binds 
the RTS in MBP mRNA along with hnRNPs A2, U, and A3. They then demonstrated that 
the wild-type RTS, but not a scrambled RTS, binds hnRNP-A2 and CBF-A. In addition, 
RNAase treatment prevented the co-precipitation of hnRNP-A2 and CBF-A, meaning 
that they form part of the same complex but do not interact directly. Silencing the CBF-
A gene resulted in fewer granules being transported. Instead, these remained in the cell 
body. They concluded that CBF-A plays a role in at least the initial steps of carriage of 
the granule. 
hnRNP-F: White et al. (2008 and 2012) showed that hnRNP-F co-precipitates with 
hnRNP-A2 in an RNA-independent manner. They found that hnRNP-F is necessary for 
MBP synthesis upon arrival of the granule to the translation site, but whether or not 
hnRNP-F has any function during trafficking of the granule is yet to be discovered. 
hnRNP-E1 co-precipitates with hnRNP A2, even in the absence of RNA (suggesting that 
the interaction is direct with hnRNP A2 and not RNA-dependent) and inhibits the 
translation of A2RE-containing mRNA in a manner that is dependent on binding of 
hnRNP-A2 to A2RE (Kosturko et al., 2006). Furthermore, Torvund-Jensen et al. (2014) 
showed that overexpression of hnRNP-E1 leads to a delay in the translation of MBP 
mRNA, while its silencing causes premature translation of MBP and results in 
oligodendrocytes showing fewer and less extended processes, possibly due to the 
premature translation of MBP mRNA. This premature translation was previously 
demonstrated by Staugaitis et al. (1990), who showed that the inhibition hnRNP-E1 
exerts upon MBP mRNA translation is crucial during transport. 
hnRNP-K co-precipitates with hnRNP-A2 even in the absence of MBP mRNA (Laursen 
et al., 2011, Torvund-Jensen et al., 2014). hnRNP-K binds to three sites in the MBP 
mRNA, two of which are also binding sites for hnRNP-E1. hnRNP-K also co-localises 
with transport granules, but only in sections of the oligodendrocyte processes which are 
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proximal to the cell body but not in the distal parts. Furthermore, knockdown of hnRNP-
K prevents the granules from being transported further than the first oligodendroglial 
branches, suggesting that its function has to do with the last part of the transfer rather 
than with the initiation (Laursen et al., 2011). Recent findings of Torvund-Jensen et al. 
(2014) propose that hnRNP-K replaces hnRNP-E1 to promote the transport of MBP 
mRNA from the oligodendrocyte branching points to the most distal part of the processes. 
They also showed that these two hnRNPs do not co-localise in differentiated 
oligodendrocytes, and that hnRNP-K is found co-localised with MBP mRNA transport 
granules only when differentiated oligodendrocytes begin producing myelin. 
Oligodendrocytes with more abundant and larger branches were observed upon 
silencing of hnRNP-K, which may be caused by the delayed translation of MBP mRNA 
that silencing causes. 
TOG: Kosturko et al. (2005), using a two-hybrid system, demonstrated an interaction 
between the N-terminal of TOG and hnRNP-A2. Furthermore, Francone et al. (2007) 
have shown an association of TOG with MBP mRNA transport and translation. Ohkura 
et al. (2001) revealed that TOG promotes the elongation of microtubules in animal and 
cellular systems and that TOG interacts with kinesin-like and dynein-like proteins in 
RNA transport granules harbouring the A2RE sequence, to regulate the direction of 
transport. Therefore, they proposed that TOG might have a function in directing the 
granule along microtubules towards the distal processes. This was contradicted by 
Francone et al. (2007) in a rat oligodendrocyte culture system: They found that the 
number of granules in the myelin compartments did not change upon silencing of the 
TOG gene, although the silenced oligodendrocytes showed no myelin formation. This 
could mean that in humans this protein is essential for MBP mRNA translation in the 
myelin compartment but may not be as important for the regulation of granule transport 
as stated by Ohkura et al. (2001). Very recently, a study involving TOG-knockout mice 
showed that the absence of TOG leads to hypomyelination/dysmyelination and to motor 
deficits (Maggipinto et al., 2017). In the same study, they showed that MBP mRNA 
transport is impaired by TOG knockout in cultured spinal cord oligodendrocytes. 
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Small non-coding RNA 715 (sncRNA-715) precipitates with hnRNP-A2 and with MBP 
mRNA and probably acts as a trans-acting element by binding to a sequence of 21 
nucleotides located in the 3’UTR of MBP mRNA and thereby silencing it (Bauer et al., 
2012). Rat oligodendrocytes transfected with synthetic sncRNA-715 showed an abnormal 
morphology and lower levels of MBP compared to controls. Interestingly, multiple 
sclerosis lesions had much higher levels of sncRNA-715 compared to controls, this being 
one of the possible reasons why these lesions may fail to remyelinate in some 
circumstances. This direct inhibition of MBP expression by sncRNA-715 has also been 
observed in Schwann cells (Muller et al., 2015a). 
Ago2 is a protein of the Argonaute family. Argonaute proteins have an important role in 
RNA silencing via RNA interference: They bind to small, non-coding RNA molecules that 
silence a target RNAs (such as sncRNA-715). Ago2 co-localises and co-precipitates with 
hnRNP-A2, sncRNA-715, and MBP mRNA, suggesting thatAgo2 is involved in silencing 
MBP mRNA during transport (Muller et al., 2015b), especially as Ago2 is a target of Fyn 
kinase, a known MBP translation regulator in the myelin compartment. This means that 
Ago2 silencing effect could potentially be dependent on its phosphorylation state. 
Other molecules which show no direct interaction with hnRNP-A2 but have been related 
to the MBP mRNA transport granule include kinesin motor protein kif1b, which has 
been demonstrated to be necessary for RNA granule trafficking along the microtubules, 
probably by interaction with TOG (Lyons et al., 2009). In order for MBP mRNA to be 
translated, the necessary translating proteins and RNA need to be transported too. Both 
fragments of the ribosomal machinery (40s and 60s), elongation factor 1a (EF1a) 
and arginyl-tRNA synthetase (ATS) (i.e. the necessary translation machinery) have been 
found to form part of MBP mRNA-containing granules by fluorescent in situ 
hybridisation (Barbarese et al., 1995). The way they are attached to the granule, however, 
remains uncertain. 
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1.7.4 The relationship of TDP-43 and FUS with mRNA transport 
granules 
A number of other molecules have been found to be part of mRNA transport granules. 
Among these molecules are the proteins FUS and TDP-43. As above stated, both of 
them are RNA-binding proteins of the heterogeneous nuclear ribonucleoproteins 
(hnRNP) family and are usually found in cytoplasmic inclusion bodies in ALS cases. In 
the nucleus, TDP-43 and FUS regulate gene transcription, control the splicing of specific 
mRNAs in the nucleus in conjunction with other hnRNPs, and are involved in the 
processing of micro RNA and long, non-coding RNA (Ederle and Dormann, 2017). TDP-
43 and FUS are most abundant in the nucleus, where they perform those functions. 
However, they are also found in small concentrations in the cytoplasm, especially 
clustered with other proteins and RNA molecules. Apart from being involved in mRNA 
stability there, TDP-43 and FUS are also necessary for mRNA trafficking as parts of 
kinesin-bound transport granules, and they co-localise with such structures in the 
dendrites and axons of neurones (Wang et al., 2008, Schoen et al., 2015, Belly et al., 
2005). One key study revealed that ALS-causing mutations in TDP-43 caused TDP-43-
granules to not reach the distal part of the axons and show a net retrograde movement 
along the microtubules in Drosophila and human iPSC-derived neurones (Alami et al., 
2014). Later, (Ishiguro et al., 2016) demonstrated that TDP-43 binds guanine-rich G-
quadruplexes in vitro, and that this is essential for the TDP-43-dependent dendritic 
transport of mRNA in murine cultured neurones. This is very relevant for the 30% of 
dendritic mRNAs which share this pattern in their 3’UTR, which is sufficient for the 
localisation of mRNA in dendrites (Subramanian et al., 2011). Interestingly, C9orf72 
mRNA GGGGCC expansions, as described above, form G-quadruplexes which can bind 
and sequester important RNA-binding proteins (Lee et al., 2013). Ishiguro et al. (2016) 
also showed that 8 GGGGCC repetitions are sufficient for TDP-43 to bind the expansion 
and that 60 repetitions, closer to the hundreds of repetitions found in C9ALS patients, 
are enough to impair mRNA dendritic transport, confining TDP-43 to the cell body.  
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In the light of the importance of TDP-43 and FUS as mRNA trafficking regulators, it 
would be relevant to ascertain whether TDP-43 and FUS are involved in the transport of 
MBP mRNA transport granules in oligodendrocytes. It has been shown that TDP-43 
binds hnRNP-A2 when the latter is not bound to hnRNP-A1’s target sequence, which 
happens when there is a shortage of hnRNP-A1, and hnRNP-A2 needs to assume its 
function (Buratti et al., 2005). The interaction between TDP-43 and hnRNP-A2 is also 
necessary for the splicing of particular mRNAs in the nucleus. Additionally, both TDP-
43 and hnRNP-A2 are part of transport granules, but this does not mean that they 
necessarily work together while doing so. However, this remains to be ascertained. 
Therefore, it is likely that the pathological aggregation of TDP-43 in oligodendroglia and 
neurons seen in ALS patients and ALS models, could impair the transport of mRNA. This 
mRNA shortage could affect the myelin compartment of oligodendrocytes, but also the 
dendrites and spines or the distal part of the neuronal axons and dendrites (Fallini et al., 
2012, Wang et al., 2008). 
Thus, a shortage of TDP-43 and FUS caused by ALS-causing mutations or, in the case of 
TDP-43, by cytoplasmic aggregation in most cases of ALS, could result in an incorrect 
transport of the MBP mRNA in oligodendrocytes, which could cause the incorrect 
myelination seen in ALS. This is a key hypothesis for this thesis. Due to time limitations, 
this study was limited to the study of the effect of TDP-43, whose pathological 
aggregation is the most commonly seen in ALS –not only cases harbouring TDP-43 
mutations-, while FUS aggregation is almost restricted to ALS caused by FUS mutations.  
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1.7.5 The transport granule: granule disassembly and MBP mRNA 
translation 
Upon arrival to the myelin compartment, MBP mRNA must be released from the granule, 
especially from the translation inhibitors hnRNP-E1 and sncRNA-715 so localised 
translation can be initiated. It has been shown that proto-oncogene tyrosine-protein 
kinase (Fyn kinase) is crucial at this step because it phosphorylates hnRNP-F and 
hnRNP-A2, facilitating their release from the granule (White et al., 2008; see below, 
White et al., 2012). The current model for activation of Fyn kinase and initiation of MBP 
mRNA translation is explained in the next sections and can be seen in figure 1.5. 
1.7.6 Axonal signalling 
White et al. (2008) and Wake et al. (2011) found that electrical stimulation of the axon 
leads to increased axonal expression of the transmembrane cell adhesion molecule L1 
and glutamate release from the axonal membrane. This activated Fyn kinase and MBP 
synthesis in the processes of nearby oligodendrocytes, most probably by inducing an 
accumulation of cholesterol-rich domains on the oligodendrocyte areas which responded 
to glutamate. The results suggest that myelination occurs preferentially on electrically 
active axons. This is also strongly supported by recent zebrafish studies (Mensch et al., 
2015, Hines et al., 2015). They found that most of the myelin wrappings initially formed 
by oligodendrocytes do not fully wrap around their axons: Only those sheaths stimulated 
by neuronal activity –measured by synaptic vesicle release- extended the sheath 
completely, and axons with a decreased activity showed a significant loss of myelin 
sheaths. In other experiments, Laursen et al. (2009, 2011) found that oligodendrocyte 
expression of contactin F3 is essential for L1 signalling. They also showed that axonal 
laminin must interact with integrins α6 and β1 to achieve oligodendroglial Fyn 
phosphorylation of hnRNPs F and A2. 
Laminin, L1 and glutamate signalling is induced by electrical stimulation of the axon. 
Therefore, both series of experiments suggest that Fyn activation is dependent on 
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electrical stimulation of the axon, which provides multiple coordinated signals (laminin, 
L1, and glutamate) to lead the oligodendroglial protrusion around the axon during 
myelination and to release MBP mRNA from the transport granule, as will be discussed 
below. 
1.7.7 Granule breakdown and MBP synthesis 
As previously stated, hnRNPs F and A2 are tyrosine-phosphorylated when Fyn is 
activated. hnRNP-K also seems to be tyrosine-phosphorylated, but whether or not this is 
due to the action of activated Fyn is still to be addressed. These phosphorylation events 
appear to lead to the disassembly of the transport granule and the lack of local inhibition 
of the translational machinery (White et al., 2008). The translation inhibitor sncRNA-
715 is detached from MBP mRNA thanks to the action of Fyn kinase upon Ago2, as 
described above (Muller et al., 2015b). 
Animal models have also been used to demonstrate the importance of Fyn during 
myelination. Czopka et al. (2013) showed that overexpression and depletion of Fyn 
upregulates or downregulates the number of myelin sheaths produced by 
oligodendrocytes in zebrafish. Sperber and McMorris (2001) showed that mice suffered 
hypomyelination that was not uniform in the CNS upon Fyn knockdown. This 
demonstrates the essential need of Fyn for MBP synthesis and myelination, and how this 
process is conserved between species. 
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Figure 1.5: Current model in the initiation of MBP mRNA translation upon 
arrival to the myelin compartment. 1) The granule arrives at the distal end of the 
microtubule and hnRNPs A2 and F are tyrosine-phosphorylated by Fyn kinase once it is 
activated by a coordinated action of laminin-activated integrins α6 and β1, and glutamate 
receptors which are activated by glutamate released by the axon after stimulation by the 
nerve impulse. Phosphorylation of hnRNP-K might trigger its binding to its mRNA 
binding site, displacing hnRNP-E1 from it. 2) Phosphorylation of hnRNP-A2, hnRNP-F 
and Ago2 promotes their removal from the transport granule, which makes the 
translation inhibitory elements detach from MBP mRNA and allows 3) the translating 
machinery begins MBP synthesis. α6, β1: integrins α6 and β1; F3: contactin F3; L1: 
contactin L1; NMDAR: glutamate NMDA receptor; mGluR: metabotropic glutamate 
receptor; Fyn kinase: proto-oncogene tyrosine-protein kinase.  
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1.8 Conclusion and aims of the project 
Key aspects of ALS pathophysiology and MBP production have been discussed in this 
section. It is now hypothesised that impaired transport of MBP mRNA toward the end of 
the oligodendroglial processes is one of the main contributing factors to disease in ALS, 
with an increased relevance in cases bearing GGGGCC expansions in C9orf72 (C9ALS). 
Zebrafish have also been discussed as an appropriate model organism to study myelin 
and ALS in vertebrates. Therefore, the aims this project pursued are the following: 
• As stated in previous sections, cytoplasmic aggregation of ubiquitylated proteins 
in neurones and glia is a pathological hallmark of ALS. It was aimed to 
characterise the glial pathology of our cohort of ALS cases by quantifying the 
protein aggregates using IHC for p62, a ubiquitin-binding protein, in motor and 
extra-motor regions of the CNS. In most cases, phosphorylated TDP-43 (pTDP-
43) is one of the main proteins aggregated in those p62-positive inclusions. 
Therefore, it was sought to quantify the pTDP-43 inclusion pathology using IHC 
to compare it to that found using p62 as the marker. In order to elucidate whether 
those glial p62/pTDP-43-positive inclusions were composed by dipeptide repeat 
(DPR) protein in C9ALS, IHC for the 5 different types of DPR would be performed 
as well. 
• Moreover, TDP-43 is necessary for the splicing and transport of a number of 
mRNA molecules to neuronal dendrites whose transport depend on the binding 
of hnRNP-A2, so there is also the possibility that TDP-43 plays a role in the MBP 
mRNA transport granule, which also depends on hnRNP-A2. This would make 
TDP-43 aggregation directly detrimental to MBP production in ALS. It was, thus, 
hypothesised that ALS cases suffer a reduction in the quantity of produced MBP 
compared to other myelin proteins whose synthesis do not depend on mRNA 
transport, such as PLP. PLP transport to the myelin compartment does not follow 
the same mechanism as mRNA transport. It was also hypothesised that this 
selective reduction in MBP is not caused by a depletion of its mRNA.  Thus, it was 
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aimed to compare the levels of MBP and PLP and their mRNAs in the lateral 
corticospinal tracts of C9ALS, sALS, and controls using Western blot and qPCR 
in extracts from human post-mortem tissue. To provide visual evidence of the 
trafficking impairment of MBP mRNA transport granules, it was also aimed to 
use in situ hybridisation to visualise the cellular localisation of MBP mRNA in 
human post mortem tissue. This would allow investigating whether MBP mRNA 
is mislocalised in oligodendrocytes pertaining to ALS cases. 
• Additionally, TDP-43 binds hnRNP-A2, which is necessary for the transport of 
MBP mRNA. It is, therefore, possible that sequestration of TDP-43 into protein 
inclusions causes the mislocalisation of cytoplasmic hnRNP-A2 to these 
inclusions. hnRNP-A2 is mainly nuclear, but constantly shuttles between the 
nucleus and the cytoplasm. Sequestration of hnRNP-A2 in the cytoplasm might 
eventually cause its depletion in the nucleus. Therefore, it was aimed to quantify 
the number of nuclei which are positive for hnRNP-A2 using IHC in relevant 
areas of the CNS. Western blot and qPCR would also be used to test whether 
protein and mRNA levels were normal for hnRNP-A2. 
• hnRNP-A2 sequestration by aggregated TDP-43 could be detrimental to the 
transport of MBP mRNA, but equally relevant is the known binding of hnRNP-
A2 and other hnRNPs to the G-quadruplexes formed by C9orf72 mRNA 
containing GGGGCC expansions. This could also impair MBP production and 
demyelination even further in C9ALS. It was then hypothesised that C9ALS cases 
suffer a greater lack of MBP in their myelin than sALS cases, presenting as well a 
greater oligodendroglial pathology and that this increased pathology is related to 
a decrease in myelin production. Part of this hypothesis would be tested using the 
Western blot for MBP and PLP mentioned above. Additionally, it was aimed to 
characterise and quantify the microscopic p62-positive and pTDP-43-positive 
pathology in our bank of C9ALS cases and contrast the findings to sALS cases and 
healthy controls. This includes the analysis of IHC for p62 and pTDP-43 
mentioned above, and the quantification of oligodendrocyte precursor cells. 
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• It is yet unknown what first triggers motor neurone and glial degeneration in 
ALS. Neuronal failure and the degeneration of axons could cause the observed 
pathology of the related glia. However, oligodendroglial disfunction in the white 
matter would cause a shortage of trophic factors in the axons that could cause 
axonal degeneration. To test the hypothesis that oligodendrocyte dysfunction 
occurs before the degeneration of primary motor neurone axons in ALS, it was 
aimed to use IHC for axonal markers (SMI31) to quantify the axonal density of 
the dorsolateral motor tracts of spinal cord sections to compare it across the 
patient cohorts and to the glial pathology in the same region.  
• As stated above, GGGGCC expansions in C9orf72 have a deleterious effect in 
motor neurones through RNA-binding protein sequestration and the production 
of toxic RAN-translated dipeptide repeats. This has led to the production of an 
increasing amount of animal models expressing GGGGCC expansions in the CNS. 
In order to test whether C9orf72 expansions are enough to cause ALS just 
through oligodendroglial dysfunction in vivo, it was aimed to generate and 
characterise a zebrafish model which expresses GGGGCC interrupted expansions 
exclusively in oligodendrocytes. In principle, the interruptions in the expansions 
should disable their propensity to give rise to dipeptide repeats and should only 
cause the sequestration of RNA-binding proteins. This could be detrimental to 
the synthesis of mbp, and therefore, this model would be useful to analyse how 
the production of mbp and the transport of its mRNA might be impaired in 
C9ALS. 
• As stated before, TDP-43 ALS-causing mutations have the potential to cause ALS 
by the loss of function of the protein in the nucleus and the cytoplasm. This could 
impair MBP mRNA transport if TDP-43 were part of the transport granule. 
However, it is also known that mutant TDP-43 can sequester RNA-binding 
proteins and mRNA molecules into protein aggregates, and this could mislocalise 
other hnRNPs necessary for MBP mRNA transport. To elucidate whether any of 
these mechanisms can explain the oligodendroglial dysfunction observed in ALS, 
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it was aimed to characterise the development of the oligodendroglial cell line fate 
in two different zebrafish models. This would be done by using a whole-mount in 
situ hybridisation approach for markers of oligodendroglial fate at different 
stages of the zebrafish embryo development. 
Initially, this would be analysed in an already generated zebrafish strain which 
does not express the tardbp gene. This way, it would be possible to test the 
hypothesis that TDP-43 loss of function impairs MBP mRNA transport and the 
full differentiation of oligodendrocytes. Additionally, it was planned to devise and 
test strategies using CRISPR/Cas9 technology to generate a zebrafish strain 
carrying tardbp point mutations. Those would be mutations that cause familial 
ALS when they occur in the same amino acids of the human TARDBP gene. This 
model could help explore the role that TDP-43 exerts in the transport of MBP 
mRNA and how ALS-causing mutations in this gene affect myelination in the 
adult individual.
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CHAPTER 2 
Materials and methods 
2.1 Studies using human post-mortem tissue 
2.1.1 Patients 
We had access to formalin-fixed, paraffin-embedded, and frozen CNS tissue 
blocks from 100 ALS patients who were selected following El Escorial revised 
criteria (Brooks et al., 2000) whose brains were donated at autopsy to the 
Sheffield MND Brain Tissue Bank with the consent of the next of kin. Of those 
100 cases, 16 were neurologically healthy control cases, 67 did not carry any 
known ALS-causing mutation, and 17 carried a hexanucleotide-repeat expansion 
in C9orf72. All samples were anonymised. The Sheffield Brain Tissue Bank 
Management Board gave ethical approval for the use of tissue in this study under 
the provision to act as a Research Tissue Bank as approved by the Scotland A 
Research Ethics Committee (ref 08/MRE00/103). The analysed blocks include 
motor cortex, prefrontal cortex and spinal cord, although there was not available 
tissue from all three areas of all cases. 
Immunohistochemistry 
The antisera and variable conditions for immunohistochemistry used are 
detailed in table 2. 
2.1.1.1 p62 and pTDP43 immunohistochemistry 
Formalin-fixed, paraffin-embedded (FFPE) CNS sections had been previously 
stained using the anti-p62 Ick ligand antibody (BD Transduction Laboratories). 
This antibody labels p62: a small protein which binds to ubiquitin, and which is 
widely used as a marker for pathological ubiquitylated inclusions. Motor cortex 
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and spinal cord sections from a sub-cohort of the cases stained for p62 were 
immunostained using an anti-pTDP43 antibody (BD Transduction Laboratories). 
This antibody labels specifically the pathological cytoplasmic 
hyperphosphorylated form of the TDP43 protein. This is the form of TDP43 that 
forms cytoplasmic inclusion bodies in the CNS tissue of most ALS cases. Our 
laboratory counted with optimised protocols for these two markers and, therefore, 
we decided to use them. 
For both p62 and pTDP43 antibodies, antigen retrieval was performed in a 
pressure cooker (125°C for 30 s, A.Menarini Antigen Access Unit, A.Menarini 
Diagnostics, Berkshire, UK) at pH6. The MenaPath X-Cell-Plus HRP Detection 
Kit (A.Menarini Diagnostics, Berkshire, UK) was used to stain the CNS sections, 
applying the mouse anti-p62 antibody at a dilution of 1:200, or the anti-pTDP43 
at a dilution of 1:4000. The detailed times for each step were:  
1. Endogenous peroxidase block, 5 minutes. 
2. Protein block, 5 minutes. 
3. Primary antibody incubation, 60 minutes. 
4. Universal probe, 10 minutes. 
5. HRP polymer, 15 minutes. 
6. DAB chromogen, 5 minutes. 
7. Haematoxylin counterstain, 1 minute. 
8. HCM (Harry’s haematoxylin, 2 min; Scott’s tap water, until blue colour; 
rapid dehydration and clear through 70%/95%/2x100% ethanol-2x 
xylene; mount in DPX –i.e. Distyrene/ Plasticizer/Xylene). 
All the staining steps were done at room temperature (RT). 
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Myelin basic protein immunohistochemistry (IHC) 
An anti-MBP antibody (Chemicon) was used to immunostain fixed motor cortex 
and spinal cord sections. MBP is the myelin-forming protein whose mRNA has to 
be transported in the hnRNP-A2-dependent transport granules. 
Antigen retrieval was done in a microwave oven, soaking the samples in trisodium 
citrate (TSC) pH6.5 and heating them at 800 W for 10 minutes. The Vector ABC 
Elite kit was used afterwards, following these steps: 
1. 3% H2O2 in methanol, 20 min. 
2. Serum, 30 min. 
3. 1º antibody (1:500 dilution), 1h. 
4. 2º biotinylated antibody, 30 min. 
5. ABC reagent, 30 min. 
6. Vector DAB reagent, 30 min. 
7. HCM. 
All the staining steps were done at RT. 
2.1.1.2 Myelin proteolipid protein 1 IHC 
PLP is the major component of myelin. It is translated in the oligodendrocyte cell 
body and then transported to the myelin compartment. This contrasts with MBP, 
whose mRNA is transported in the cytoplasm before translation. Fixed motor 
cortex and spinal cord sections were stained with an anti-PLP antibody (Bio-Rad). 
Apart from incubation time and antibody dilution (see table 2), the antigen 
retrieval and staining methods were otherwise identical to those used to stain p62. 
2.1.1.3 hnRNP-A2 IHC 
66 
 
hnRNP-A2 is the essential protein for the correct assembly and transport of the 
MBP mRNA transport granule. Most hnRNP-A2 is located in the nucleus. 
Expanded C9orf72 mRNA and TDP-43 both bind hnRNP-A2 and can potentially 
sequester it, bringing its concentration below the detectable limits. Therefore, the 
aim was to quantify the number of oligodendroglial nuclei stained for hnRNP-A2 
in the white matter below the motor cortex and in the dorsolateral motor tracts 
of the spinal cord. An available anti-hnRNP-A2 antibody (Abcam) whose working 
conditions had been previously optimised was used to stain fixed motor cortex 
and spinal cord sections.  
Except for the antigen retrieval method –carried out at pH9- and the primary 
antibody dilution –see table 2-, the antigen retrieval and staining methods were 
otherwise identical to those used for p62. 
2.1.1.4 Oligodendrocyte precursor cell (OPC) IHC 
OPCs were stained in fixed motor cortex and spinal cord sections using the 
MAP2+13 antibody. This antibody was donated to us by Shafit-Zagardo et al. 
(1999 and, as they show, it labels OPCs which are ready to differentiate into 
myelinating oligodendrocytes. In the case of myelin loss, those OPCs normally 
take the place of the oligodendrocytes that have stopped myelinating. Our 
laboratory counted with an optimised method for this antibody and, thus, it was 
the one that was chosen for this study. 
With the exception of the primary antibody incubation -1:100 incubation, 2h RT-, 
the antigen retrieval and staining methods were otherwise identical to those used 
for MBP. 
2.1.1.5 Neurofilament IHC 
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Mature, phosphorylated neurofilaments were stained in fixed spinal cord sections 
using an SMI31 antibody (Biolegend). Neurofilament protein is an important part 
of the neuronal cytoskeleton, especially in the axon. It becomes phosphorylated 
as a sign of maturation, and the SMI31 antibody recognises that form. There are 
three main types of neurofilament (i.e. light, medium and heavy).  This antibody 
labels all three. 
With the exception of the primary antibody incubation –see table 2.1-, the 
protocols for antigen retrieval and staining were otherwise identical to those used 
for p62. 
2.1.1.6 Dipeptide repeat (DPR) IHC 
The five different forms of DPR (poly-AG, poly-AP, poly-GP, poly-GR, and poly-
PR) that can be RAN-translated from the expanded C9orf72 mRNA were 
immunostained in fixed motor cortex tissue. The five antibodies used 
(Proteintech) are specific to each of the DPR types and had been previously tested 
and optimised by other groups in our laboratories. 
Apart from the primary antibody incubation –see table 2-, the antigen retrieval 
and staining methods for poly-AG and poly-PR were otherwise identical to those 
used for MBP.  
For poly-AP. poly-GP and poly-GR, the Immpress HRP polymer detection kit was 
used as follows:  
1. BLOXALLTM blocking solution 10 min. 
2. RTU 2.5% blocking serum 20 min.  
3. 1º antibody (time and temperature in table 2.1),  
4. ImmPRESSTM reagent 30 min.  
5. Brown peroxidase substrate solution 10 min. 
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6. HCM. 
All the staining steps were done at RT.  
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Antibody Source 
Antigen 
retrieval 
IHC kit 
Primary 
antibody 
incubation 
p62 Ick ligand 
BD Transduction 
Laboratories 
PC pH6 
A.Menarini 
Intellipath 
1:200 – 1h RT 
Phosphorylated TDP-43 
BD Transduction 
Laboratories 
PC pH6 
A.Menarini 
Intellipath 
1:4000 – 1h RT 
Myelin basic protein Chemicon TSC pH6.5 M/W Vector ABC 1:500 – 1h RT 
Nogo-A Abcam PC pH9 
A.Menarini 
Intellipath 1:50 – 1h RT 
Proteolipid protein Bio-Rad PC pH6 
A.Menarini 
Intellipath 
1:800 - 30min RT 
SMI31 Biolegend PC pH6 
A.Menarini 
Intellipath 
1:200 - 30min RT 
hnRNPA2B1 Abcam PC pH9 
A.Menarini 
Intellipath 
1:1000 – 1h RT 
MAP2+13 
Donation by 
Shafit-Zagardo 
et al. (1999) 
TSC pH6.5 M/W Vector ABC 1:100 - 2h RT 
Poly-AG Proteintech PC pH6 Vector ABC 1:200 - O/N 4ºC 
Poly-AP Proteintech PC pH6 Vector Impress 1:500 - O/N 4ºC 
Poly-GP Proteintech PC pH6 Vector Impress 1:500 - O/N 4ºC 
Poly-GR Proteintech PC pH6 Vector Impress 1:200 - O/N 4ºC 
Poly-PR Proteintech PC pH6 Vector ABC 1:200 - O/N 4ºC 
Table 2.1: Sources and conditions used for the antibodies used in IHC. TSC: Trisodium 
citrate. M/W: Microwave PC: Pressure cooker. RT: Room temperature. O/N: Overnight. 
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2.1.1.7 Oligodendrocyte-specific protein (OSP) immunohistochemistry 
The clear labelling of oligodendrocytes cell bodies is a challenging task that 
different researchers approach differently. OSP is a protein which is primarily 
expressed by oligodendrocytes in the CNS (Bronstein et al., 1997). Initially, FFPE 
CNS sections, as well as frozen sections, were immunostained using rabbit anti-
OSP antibodies ab7474 and ab53041 (Abcam, Cambridge, UK). Other classic 
oligodendroglial markers such as Olig2 had been unsuccessfully trialled in both 
frozen and FFPE tissue in our laboratories in the past. However, our laboratories 
counted with a working protocol for anti-OSP (ab7474) in frozen tissue and, thus, 
we decided to try it first for the co-staining of oligodendrocyte cell bodies and 
p62-positive inclusions. It was first attempted to optimise the ab7474 antibody 
for PPFE tissue. This antibody recognises the OSP C-terminus as it was raised 
against the 15 amino acids that compose it. The ab53041 antibody was optimised 
and used later, when ab7474 did not give the expected staining pattern when used 
along the anti-p62 antibody. The ab53041 antibody recognises the full human 
OSP protein rather than just the C-terminus, as it was raised against human OSP. 
2.1.1.8 Fixed tissue 
The protocol was similar to that used with the poly-GA antibody. The kit used was 
the VECTASTAIN ABC-AP KIT (Rabbit IgG; Vector Laboratories), and the 
coloured substrate was the VECTOR Red alkaline phosphatase (AP) substrate. 
The sections were not treated with hydrogen peroxide because the AP substrate 
does not detect endogenous peroxidase. Levamisole was instead used after the 1º 
antibody incubation to block endogenous phosphatase. After the antigen retrieval 
step and having been treated with the antibodies, they were incubated for 30 min 
with the avidin-biotin-AP complex (ABC), and 25 minutes with the AP red 
substrate, before HCM. 
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2.1.1.9 Frozen tissue (standard protocol) 
The sections were thawed at room temperature for 5 minutes and fixed in acetone 
at 4oC for 5 minutes, before proceeding to stain them following the same protocol 
as with the fixed tissue, omitting the antigen retrieval step. 
2.1.1.10 Frozen tissue (rapid protocol) 
The reagents were the same as used in the frozen tissue standard protocol. The 
incubation times were as follows:  
1. Thawing, 5 minutes;  
2. Fixation in chilled acetone at 5ºC, 5 minutes. 
3. Serum block, 3 minutes. 
4. Primary antibody, 5 minutes. 
5. Biotinylated secondary antibody, 10 minutes. 
6. Avidin-biotin-AP complex, 5 minutes. 
7. AP red substrate, 25 minutes. 
8. HCM. 
With the exception of the fixation in acetone, all the staining steps were done at 
RT. 
2.1.1.11 Double IHC of OSP and p62 
Multiple strategies were trialled to double stain sections with OSP and p62 in an 
attempt to co-stain oligodendrocytes and p62-positive inclusions, as motor cortex 
and spinal cord sections showing co-staining of both p62 and GFAP (a marker for 
astrocytes) or IBA1 (a marker for microglia) had already been counted. The first 
attempt was to use OSP and p62 antibodies, which became extremely challenging. 
The different strategies followed to optimise this double staining can be seen in 
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table 2.2. In our laboratories, DAB brown and VECTOR Red have become the 
gold standard for co-staining because they usually provide a good contrast 
between the two antigen locations when using brightfield microscopy. After this 
pair did not work as expected for the co-staining of OSP and p-62, different 
chromogens that usually provide good contrast were trialled. The aim of trialling 
all these different markers was to obtain a pair of chromogens that would provide 
enough contrast to distinguish the p62-positive inclusions from the 
oligodendroglial cell bodies. These are the protocols that were followed for each 
attempt, all in frozen motor cortex: 
OSP: NovaRED and DAB 
Brown (DAB) and alternative red staining (Nova Red) of OSP was performed 
following the same protocols as with the phosphatase Vector Red staining, using 
the VECTASTAIN Elite ABC Kit (Vector Laboratories, Peterborough, UK). The 
chromogens VECTOR DAB Peroxidase (HRP) Substrate and the VECTOR 
NovaRED Peroxidase (HRP) Substrate were used instead. The protocol was 
identical, but the peroxidase substrate incubation was only 10 minutes. 
OSP: BCIP/NBT 
Blue staining of OSP was achieved using the same protocol as with Vector Red, 
only changing the chromogen to BCIP/NBT, included as part of the VECTOR Blue 
Alkaline Phosphatase (AP) Substrate Kit (Vector Laboratories). 
p62: Ni-DAB 
Black staining of p62 inclusions was done using a modified version of the DAB 
protocol, adding a nickel solution (included in the DAB kit) to the chromogen 
reaction mix, which turns the normal brown DAB colour into black. The 
incubation time was identical. 
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OSP and p62: FITC and TRITC 
The rapid protocol was applied up to and including the incubation with the 
biotinylated secondary antibody, to visualise fluorescent oligodendrocytes and 
p62-positive inclusions. Then, the sections were incubated with a 1:100 dilution 
of either streptavidin conjugated to fluorescein isothiocyanate 
(Streptavidin:FITC, AbD Serotec) for OSP, or rhodamine conjugated to 
isothiocyanate (TRITC) for p62, for 60 minutes. The sections were then mounted 
with VECTASHIELD HardSet Mounting Medium with DAPI (Vector 
Laboratories), which stains the nuclei. 
Methyl Green counterstaining 
For the protocols in which OSP was stained in blue, the counterstaining protocol 
was modified to show the nuclei in green rather than the usual haematoxylin blue. 
The counterstaining protocol was as follows:  
1. Rinse slides in tap water. 
2. Submerge slides in preheated Vector Methyl Green solution (Vector 
Laboratories) at 60ºC, 5min. 
3. Wash in deionised water, 1min RT. 
4. Dip in acetone containing 0.05% (v/v) acetic acid, 10 times RT. 
5. Dehydrate through 95% and 100% ethanol, clear in xylene, and mount in 
VectaMount Permanent Mounting Medium (Vector Laboratories). 
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First primary 
antibody-Chromogen 
Second primary 
antibody-Chromogen 
Counterstain method 
p62-DAB (rapid) OSP-Vector Red (rapid) Haematoxylin 
OSP-Vector Red (rapid) p62-DAB (rapid) Haematoxylin 
p62-DAB OSP-Vector Red (rapid) Haematoxylin 
p62-DAB + double time 
avidin/biotin block 
OSP-Vector Red (rapid) Haematoxylin 
OSP-Vector Red (rapid) + 
double time avidin/biotin 
block 
p62-DAB Haematoxylin 
OSP-DAB p62-Ni-DAB Haematoxylin 
OSP-NovaRED p62-DAB Haematoxylin 
OSP-NovaRED p62-Ni-DAB Haematoxylin 
OSP-Vector Blue AP p62-DAB Vector methyl green 
OSP-Vector Blue AP p62-Ni-DAB Vector methyl green 
 
Table 2.2: Attempts at the double staining of p62 and OSP. Unless indicated 
(rapid), the protocols used standard IHC as described above. 
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2.1.1.12 Nogo-A IHC 
We first tried to optimise this antibody using the same method used for MBP in 
fixed motor cortex, at primary antibody dilutions of 1:50/200/500/1500/5000. 
Then, we changed the method to that used for p62, trying antigen retrieval at both 
pH6 and pH9, and primary antibody dilutions of 1:50/100/150/200/500. 
Antigen retrieval at pH9, and 1:50 dilution were chosen as the option that 
provided the best balance of specificity and sensitivity. This will be later discussed 
in chapter 3. 
2.1.1.13 Double IHC of Nogo-A and p62 
We tried to optimise double immunostaining of Nogo-A and p62. To achieve this, 
the first step was to optimise staining of p62 using the pH9 antigen retrieval 
method, which works best for Nogo-A. We used p62 antibody dilutions of 
1:20/100/200. The dilution we preferred was 1:200 using this antigen retrieval 
method. 
For this double IHC, Nogo-A was stained using Vector Red as a chromogen 
instead of DAB, and p62 was stained using DAB to have a good contrast between 
the two. Two different protocols were used: In one, p62 was stained first, and in 
the second, Nogo-A was stained first. 
 
2.1.2 IHC scoring 
The areas where the different markers were quantified were the following: 
Layer V of frontal and motor cortices: Layer V contains large pyramidal neurones 
that project to other brain areas. In the frontal cortex, layer V neurones synapse with the 
striatum and the thalamus. In the motor cortex, however, layer V neurones are the 
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primary motor neurones that synapse with the lower motor neurones of the spinal cord. 
Investigating the pathology of the upper motor neurones and the surrounding glia in ALS 
could help explain any axonopathy found in the descending motor tracts of the spinal 
cord. Also, quantifying glial pathology in the motor cortex would be useful to discern 
whether it correlates with the glial and neuronal pathology of the spinal cord. 
White matter underlying the frontal and motor cortices: the levels of glial 
pathology were quantified in the white matter directly beneath the cortices. Subcortical 
oligodendroglial pathology could be related to the above neuronal cortical pathology or, 
in the case of the precentral gyrus, even to that of the spinal cord descending motor tracts. 
Dorsolateral motor tracts of the spinal cord: As mentioned above, upper motor 
neurones send their projections down the spinal cord to synapse with the lower motor 
neurones of the spinal cord. Most of those axons form the dorsolateral motor tracts of 
the spinal cord, in the most dorsal region of the lateral funiculi. Comparing the levels of 
glial pathology found in this area in ALS cases to those found in the primary motor cortex 
and underlying white matter could help elucidate whether they are correlated or 
independent events. Additionally, it was of interest to know whether the glial pathology 
in this region correlates with axonal counts for the same area. 
Ventral horns of the spinal cord: This region harbours the large lower motor 
neurones that synapse with the muscles. These neurones degenerate in ALS and their 
pathology could be related to the surrounding glial pathology, or even that of the 
oligodendrocytes supporting the axons of the descending dorsolateral motor tracts, 
whose axons synapse onto the lower motor neurones. 
2.1.2.1 p62-positive, pTDP43-positive and DPR inclusions 
The total number of p62-positive and pTDP43-positive inclusions were counted 
in the ventral horn and the lateral motor tracts of spinal cord sections. 
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 In sections of the motor and frontal cortices, inclusions were counted in 10 fields 
at 25x magnification in layer V, and ten fields at 25x magnification in the 
underlying white matter.  
In all types of tissue, for p62/pTDP43-positive inclusions, a distinction was made 
between inclusions present in neuronal cell bodies in the grey matter, those in 
glial cells in grey matter, and those present in glial cells in WM. DPR were only 
counted in the glia of the white matter under the motor cortex. 
 
2.1.2.2 Percentage of MBP and PLP stained area 
The proportion of area labelled for MBP and PLP in the white matter under the 
motor cortex, and the spinal cord dorsolateral motor tract was quantified by 
analysing 4 pictures from each section with ImageJ applying the following 
method: 
1. The images were taken using a Nikon DS Ri1 Eclipse microscope using a 
20× objective. 
2. Each image was subjected to colour deconvolution (Ruifrok and Johnston, 
2001) to separate DAB staining (brown) from hematoxylin staining (blue) 
(figure 2.1). 
3. A Shanbhag threshold (Shanbhag, 1994) was applied to the DAB-only 
images, and the stained area fraction was measured in the pictures 
submitted to a threshold. 
4. The mean of the four values was used in the statistical analysis for each 
case.  
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Figure 2.1: Processing of images to quantify the area labelled for MBP 
and PLP. A and B are the original photographs. These example pictures are from 
fixed white matter under the motor cortex. C and D are the DAB images after 
using the colour deconvolution plug-in in ImageJ. E and F show the DAB images 
after subjecting them to a Shanbhag threshold, after which labelled area appears 
in white (quantified by ImageJ), and the unlabelled area appears in brown (not 
quantified by ImageJ).  
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2.1.2.3 Axonal density using SMI31 
After staining neurofilaments in spinal cord with the SMI31 antibody in coronal 
sections of the spinal cord at the cervical level, axonal density was measured in 
the dorsolateral motor tracts using a protocol similar to that used by Highley et 
al. (1999) with some modifications: 
1. For each case, a total of four pictures at a 1280x1024 pixel resolution were 
taken from both tracts (two of each side) using a Nikon DS Ri1 Eclipse 
microscope with  ×100 oil immersion objective. 
2. An 8x7 grid of identical rectangular counting frames  (figure 2.3) of 
160x146.18 pixels was placed on top of each image using the macro shown 
in figure 2.2. 
3. Five counting frames were chosen from each image using the 
www.random.org random integer generator. Twenty frames were counted 
in total from each patient. 
4. Section-spanning axons were counted according to standard stereology 
rules (Gundersen et al., 1988) in each chosen counting frame, discarding 
those axons touching the top and left sides and including the axons 
touching the bottom and right sides. 
5. The approximate “axons per image” was calculated using the formula 
56
5
rec
total
Axons
Axons =   
where totalAxons  is the total number of axons in the picture, and 
recAxons  is the total number of axons counted in the five rectangles. The 
average number of axons per counting frame was multiplied by 56 because 
each image was divided into 56 rectangles. 
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6. The value for axonal density in each dorsolateral motor tract was 
calculated dividing totalAxons  by the total area represented in the picture 
(AREA): 
total
density
Axons
Axon
AREA
=  
 
 
 
 
  
Figure 2.2: Macro to create a grid of rectangles. This macro was used to 
overlay a grid of rectangles on an image. The variables width and height refer to 
the dimensions of each rectangle; spacing sets the space left between rectangles; 
numRow and numCol indicate the number of rows and columns in the grid 
respectively. 
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Figure 2.3: Grid of rectangles. This picture shows the result of applying the 
macro described in the previous figure. It was designed for the grid to cover the 
totality of the image. The numbers were assigned to select random rectangles 
from each image. This is a photography of a lateral corticospinal tract in a fixed 
spinal cord section.  
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2.1.2.4 Quantification of oligodendrocyte precursor cells (OPCs) 
The number of OPCs labelled with the MAP2+13 antibody were counted in 20 
fields at 20× magnification in the motor cortex grey matter (layer 5) and white 
matter. Regarding the spinal cord, total numbers of OPCs were counted in the 
ventral horn and the lateral motor tract of 4 sections. This number was divided 
by the number of half sections counted, to obtain the number of OPC per ventral 
horns or dorsolateral motor tracts. 
2.1.2.5 Percentage of cells labelled for hnRNP-A2 
hnRNP-A2 is mainly located in the nucleus. The relative number of nuclei 
labelled for hnRNP-A2 in the white matter under the motor cortex and the spinal 
cord lateral tracts was obtained by counting labelled and unlabelled nuclei in 4 
images of these areas taken using the 20x objective in a Nikon DS Ri1 Eclipse 
microscope. 
 
2.1.3 Quantitation of protein in human post-mortem tissue 
In order to ascertain whether oligodendroglial mRNA transport is impaired in the 
motor tracts of ALS patients, MBP, whose translation is dependent on mRNA 
transport, was quantified in the dorsolateral motor tracts. A lack of MBP could be 
caused by a general malfunction of oligodendrocytes rather than a specific mRNA 
transport impairment. Therefore, PLP, a myelin protein that is translated in the 
cell body, whose translation does not depend on mRNA transport, was measured 
as well in the same area. This study also measured the same proteins in the dorsal 
column, an extra-motor area that would serve as an internal control. These and 
other proteins of interest and the reasons why we quantified them are as follows: 
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- MBP: The protein whose mRNA transport (and therefore, its translation) we 
hypothesised is impaired in C9ALS. If the hypothesis is correct, we would expect 
to see an acute reduction in the amount of MBP in C9ALS. 
- PLP1: The most common protein found in myelin, which is translated in the cell 
body and transported to the myelin compartment as a protein. If there is a general 
myelin loss rather than specific MBP loss, PLP levels should be affected. Equally, 
if mRNA transport is affected specifically, PLP should be affected to a lesser 
degree than MBP. Thus, the MBP/PLP ratio will decrease. 
- hnRNP-A2: The protein that is necessary for the correct transport of the MBP 
mRNA in oligodendrocytes. We need to know whether a hypothetical reduction 
in MBP is caused by depletion of this protein. 
- Neurofilament heavy chain: This is an axonal marker, labelled by the SMI31 
antibody. Whether axonal loss causes oligodendroglial degeneration or vice versa 
was still unclear. This marker would give some guidance on this issue: If MBP 
was affected disproportionately compared to neurofilament, it would provide 
evidence that degeneration of oligodendrocytes precedes axonal degeneration.  
- β-tubulin: This is the control “housekeeping” protein of our choice to be used 
for normalisation, and it is not thought to be affected by the mechanisms under 
investigation. 
2.1.3.1 Spinal cord tissue dissection for protein and RNA extraction  
Tissue from frozen dorsolateral motor tract and dorsal column was dissected 
from thoracic spinal cord blocks to measure their protein and RNA contents by a 
neuropathologist (JRH). Dorsolateral-motor-tract-enriched tissue pieces were 
excised from the dorsolateral area of the lateral funiculi, located in the immediate 
ventrolateral area from the grey matter posterior columns. Dorsal column tissue 
pieces were excised from the area between both grey matter posterior columns. 
Both the dissection surface inside the cryostat and the scalpel were sterilised 
between samples using 70% IMS in water. 
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2.1.3.2 Protein extraction 
Tissue samples were homogenised in RIPA buffer, using an electric pellet pestle 
(Fisherbrand). The composition of the RIPA buffer was as follows: 50 mM Tris-
HCl pH8, 5 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 
150 mM NaCl. Immediately before proceeding to homogenise the tissue, one 
tablet of Protease Inhibitor Cocktail (Roche) and 1 mM 4-benzenesulfonyl 
fluoride hydrochloride (AEBSF) were added to 50 ml of RIPA buffer. All the 
homogenisation steps were done with the samples on ice. 
To homogenise the tissue, it was first weighed. Three times the weight in 
milligrams of the tissue was added of RIPA buffer volume in microliters. The 
tissue was then homogenised with the pellet pestle and centrifuged for 5 min at 
4oC at 21000 g. The supernatant containing soluble protein was removed and 
kept in a separate tube. Both tubes containing soluble and insoluble proteins were 
kept at -80oC. 
2.1.3.3 Bicinchoninic acid (BCA) protein assay 
Due to the presence of EDTA in the RIPA buffer, the concentration of the 
extracted protein was measured using the Pierce BCA Protein Assay Kit (Thermo 
Fisher). The protocol followed was the one indicated in the manual of the kit. A 
standard BSA curve was made using duplicate samples for the following serial 
concentrations of BSA (mg/ml): 1, 
1
2
, 
1
4
, 
1
8
, 
1
16
, 
1
32
, 
1
64
, 
1
128
. The absorbance 
of the solutions was measured using the PHERAstar FS plate reader (BMG 
Labtech). 
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2.1.3.4 Western blot 
Western blotting was used to quantify the relative amounts of MBP, PLP, hnRNP-
A2, neurofilament heavy chain, and β-tubulin in the protein extracts. To denature 
the protein, the necessary volume for 40 µg of protein, 3 µl of 6× denaturing 
protein loading buffer (0.375 M Tris pH 6.8, 12% sodium dodecyl sulfate, 60% 
glycerol, 0.6 M dithiothreitol, 0.06% bromophenol blue), and distilled water to 
18 µl, were mixed and incubated at 95oC for 10min. 
Polyacrylamide gels in which the samples were resolved were made as follows: 
10% RESOLVING GEL: 7.9 ml distilled H2O; 6.7 ml 30% Acrylamide/Bis 37.5:1 
Solution (Bio-Rad); 5 ml 1.5M Tris pH 8.8; 200 µl 10% SDS; 200 µl 10% APS; 8µl 
TEMED. STACKING GEL: 2.7 ml distilled H2O; 670 µl 30% Acrylamide/Bis 
Solution; 500 µl 1M Tris pH 6.8; 40 µl 10% SDS; 40 µl 10% APS; 4 µl TEMED. 
The samples were loaded on the gel along with the Precision Plus Protein Dual 
Color Standards (Bio-Rad) and were electrophoresed in electrophoresis buffer at 
100v for approximately two hours until the blue dye reached the bottom of the 
gel. 
ELECTROPHORESIS BUFFER: 3.5 mM SDS, 25 mM Tris, 0.192 M glycine, 2.5 
mM Tris, 19.2 mM glycine, 2 mM Tris pH 7.5, 15 mM NaCl. 
The protein from the gel was then transferred to a PVDF membrane which had 
been previously activated in 100% methanol. The transfer was performed in ice-
cold transfer buffer, for 1h at 300mA. 
TRANSFER BUFFER: 25 mM Tris, 190 mM glycine, 20% methanol. 
Protein transfer was confirmed by staining the membrane with Ponceau S 
solution (0.1 % in 5% acetic acid in distilled water). The membrane was then 
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washed with distilled water and blocked for 1h in 5% reconstituted cow’s 
milk/TBST. It was then washed 3x10min in TBST. 
TBST: 20 mM Tris, 150 mM NaCl, 0.1% Tween 20. 
All antibodies were diluted in TBST, and three 10min washes in TBST were done 
after each incubation. Image acquisition of the protein bands was performed with 
a G-Box (Syngene) after subjecting the membranes to treatment with an enhance 
chemiluminescence solution (Biological Industries). The image acquisition 
method is explained below. The antibody incubations were as follows: the whole 
membrane was incubated with 1:1500 anti-HNRNPA2B1 mouse antibody for 1h 
at RT, then 1:10000 anti-mouse IgG-HRP for 1h at RT. After obtaining an image, 
the membrane was incubated with 1:3000 anti-MBP rabbit antibody/0.02% 
sodium azide for 1h at RT, followed by 1:10000 anti-rabbit IgG-HRP for 1h at RT. 
After an image was acquired, the membrane was incubated with 1:10000 anti-β-
tubulin mouse antibody/0.02% sodium azide for 1h RT, followed by 1:10000 anti-
mouse IgG-HRP for 1h RT. This time, after the image was acquired, the 
membrane was cut to isolate the parts where neurofilament protein chains and 
PLP should be. Each of these sections of the membrane was incubated with either 
1:1000 SMI31 mouse antibody (for neurofilament labelling) or 1:5000 anti-PLP 
mouse antibody for 1h at RT, followed by 1:10000 anti-mouse IgG-HRP for 1h at 
RT. Images were then acquired. 
2.1.3.5 Image acquisition of Western blots using the G-Box 
After treatment with a chemiluminescent reagent and incubation for 1 min, the 
blotted membrane was introduced in a transparent plastic bag to avoid 
evaporation of the liquid and dryness of the membrane. This bag was introduced 
in the G-Box chamber, and chemiluminescence was measured using GeneSnap 
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software (Syngene). The program includes an algorithm called “Intelli-chemi”, 
which determines the time the camera should be exposed to the 
chemiluminescent signal to avoid light saturation. This mode was used to acquire 
the images shown in the results. 
2.1.3.6 Analysis of Western blots 
Relative protein levels in gel bands were quantified using the GeneTools software 
(Syngene). Whole bands were selected as regions of interest (ROIs), and the 
optical density was measured for each ROI. This measured density is directly 
proportional to the amount of protein when the image is sub-saturated. All results 
were normalised to the average of the loading control to obtain a percentage 
related to the loading control. 
 
2.1.4 Quantitation of RNA in human post-mortem tissue 
mRNA encoding for the same proteins measured in the spinal cord was quantified 
in the same areas. This was done to confirm that any loss of a protein found in 
the Western blot had not been caused by a depletion of its corresponding mRNA. 
2.1.4.1 RNA extraction from human post-mortem tissue 
Tissue samples were homogenised in Trizol buffer using the Direct-zol MiniPrep 
Plus kit (Zymo Research). The RNA was prepared according to the 
manufacturer’s instructions. It works similarly to a DNA miniprep kit, and the 
membrane-bound RNA was eluted in 50µl of nuclease-free water and stored at -
80oC.  
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2.1.4.2 cDNA synthesis from total RNA 
cDNA was synthesised using a SuperScript II Reverse Transcriptase kit. Due to 
the multiple ways in which this kit can be used, the protocol used in our 
experiments is detailed here: On ice, 10 µl of extracted total RNA was mixed with 
1 µl of random primer mix (3 µg/µL in 3 mM Tris-HCl pH 7.0, 0.2 mM EDTA), 
and 1µl of dNTPs mix (each at a final concentration of 10 mM, in 10 mM Tris-HCl 
pH 7.5). The mixture was incubated for 5min at 65oC and put back on ice 
afterwards. After a rapid centrifugation step, 4µl of 5xFS Buffer and 2µl of 0.1M 
DTT were added. The mixture was incubated at 25oC for 2min. Then, 1µl of 
SuperScript II Reverse Transcriptase was added, and the mixture was incubated 
sequentially for 10min at 25oC, 50min at 42oC, and 15min at 70oC. The 
synthesised cDNA was stored at -20oC. 
2.1.4.3 Quantitative PCR 
Previously RT-synthesised cDNA was quantified using qPCR. A 5’ nuclease-
quencher assay was used to generate fluorescence. In this type of assay, a probe 
specific to the region being amplified is attached to a fluorophore (6-FAM) and 
two quencher molecules (ZEN & Iowa Black FQ) which stop 6-FAM from 
producing fluorescence. When the polymerase starts synthesising a new DNA 
strand, it will reach the probe, and the 5’ nuclease activity of the enzyme will 
cleave 6-FAM off the probe. This cleavage releases 6-FAM from the quenchers, 
allowing it to produce fluorescence, which is then measured by a detector. This 
fluorescence increases every PCR cycle as more probe molecules are cleaved, 
enabling us to measure the relative amounts of a certain cDNA. Predesigned 
assays were acquired from IDT (Integrated DNA Technologies). These include 
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specific primers and probes to gauge the amount of certain mRNA isoforms. The 
assays used are described below. 
MBP: Assay number Hs.PT.58.2684380 measures the amount of the isoform 
MBP-001 (RefSeq NM_002385-2). This is the predominant isoform of MBP 
mRNA which is transported to the myelin compartment. 
PLP1: Assay number Hs.PT.58.39005119 measures the amount of the different 
isoforms of PLP1 mRNA. No specific assays for different isoforms were available 
at the time of ordering. 
HNRNPA2B1: Assay number Hs.PT.58.20218961 measures the amount of the 
different isoforms of the HNRNPA2B1 gene. No specific assays for isoforms 
specific for hnRNP-A2 were available at the time of ordering. 
RNA18S5: This was the control gene of choice. Assay number 
Hs.PT.39a.22214856.g measures the amount of 18s ribosomal RNA (rRNA) 
present in the sample. 
The PCR protocol used was a standard 2-step protocol with the following steps 
(figure 2.4): 
1. 10min initial denaturation step at 95oC. 
2. 40 cycles (30 s at 95oC, 1min at 60oC, measuring fluorescence at 520nm). 
3. 1min at 95oC. 
4. Dissociation curve starting at 55oC and ending at 95oC with 0.5oC steps 
(the dissociation curve is not necessary for a 5’-nuclease-based protocol, 
but it was pre-set in the program because it is a protocol used for SYBR 
Green intercalating dye qPCR, which emits light at the same wavelength 
as 6-FAM, the dye we used).  
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Figure 2.4: qPCR program. Two-step programme for qPCR. END indicates 
the step after which a measurement is taken. Segment 3 generates a dissociation 
curve, usually used when DNA-intercalating dyes are used. We used a 5’ nuclease-
quencher assay which does not require this step, but it did not change our results, 
which were obtained during segment 2. 
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2.1.4.4 qPCR setup 
Because the qPCR was done in triplicate for each sample and gene, all samples 
would not fit in a single 96-well plate. To be able to compare results from different 
runs, one of the samples was included in every run. This allowed for cross-
comparison between runs. In figure 2.5, triplicates 1 to 4 are the ones done for 
our cross-referenced sample, while the four individually numbered ones (29-32) 
are non-template controls (NTC) to account for any DNA contamination in our 
samples. Contamination is particularly relevant when using ribosomal RNA as 
the reference gene, due to its ubiquitousness in all species. If our NTC presented 
a Ct value, and it was anywhere near or below the Ct values obtained for our 
samples, then the results obtained for those samples would not be reliable, since 
the contribution to the RNA measurement due to contamination would be 
indistinguishable from that due to our sample’s RNA. If any of the samples did 
not reach a Ct value for one of the genes, then the protocol was repeated for that 
sample. If it did not reach a Ct value this second time, it was not included in the 
analysis for that gene. 
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Figure 2.5: qPCR set-up. Same numbers represent triplicates. Triplicates 1 to 4 are 
from the sample which was used as the inter-plate reference. Each colour represents one 
cDNA sample. Wells 29 to 32 are non-template controls.  
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2.1.4.5 Calculations for relative amounts of mRNA 
The amount of mRNA in the original tissue homogenates is assumed to be directly 
proportional to the amount of cDNA synthesised during the reverse transcription 
reaction. Thus, measuring the relative quantities of a specific cDNA in the 
samples subjected to qPCR gives a direct correlation to the relative amount of 
specific mRNA in the homogenised tissue. 
The following steps were followed to obtain a semi-quantitative result for the 
cDNA concentration of each gene from the Ct values provided by qPCR: 
1. The Ct value for each triplicate was averaged. 
2. The averaged Ct values were firstly normalised to the reference sample, present 
in all experiments. The obtained value is termed
geneCt . 
3. The Ct values obtained in step 2 for each gene different from RNA18S5 were 
normalised to the RNA18S5 Ct value obtained for the same sample ( 18 5RNA SCt ). 
This value is termed
geneCt . 
18 5gene gene RNA SCt Ct Ct = −  
4. The average was calculated for the 
geneCt  values of the healthy control samples 
obtained in step 3, for both dorsolateral motor tracts and DSSC samples. This 
average is called controlCt . 
5. For each spinal cord region, the 
geneCt  values obtained in step 3 were used to 
calculate the concentration of cDNA relative to the control group ([ ]rcDNA ), using 
the following formula: 
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( )[ ] 2 100control geneCt CtgenecDNA  −=     
The 100 factor was added to get more intuitive numbers. It does not change the 
proportionality across the data so that the results will be the same. 
The numbers obtained using this formula are the comparable mRNA copy 
numbers found in our samples, normalised to the average of the control group. 
2.1.5 Statistical analyses 
All statistical analyses for significance were done using R (R Foundation for 
Statistical Computing, Vienna, Austria) and the α-value was set at 0.05 for all 
tests. The normality of the data distribution was tested using the Shapiro-Wilk 
normality test. Due to the lack of normality presented by the data, and to the 
limited amount of cases, homoscedasticity was tested using the Brown-Forsythe 
Levene-type test. Stochastic dominance amongst the difference groups was tested 
with the Kruskal-Wallis test. Where a Kruskal-Wallis test showed significance, 
posthoc Mann-Whitney tests were performed. One-tailed Mann-Whitney tests 
were used when the hypothesis predicted change in a single direction and change 
in the other direction would be irrelevant to the study. Otherwise, 2-tailed tests 
were used. Statistical significance of correlations between variables was 
measured calculating the Kendall tau rank correlation coefficient. Post hoc 
statistical power analyses were performed with G-Power (version 3.1.9.2). 
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2.2 Generation of zebrafish transgenic and mutant models 
2.2.1 General reagents 
2.2.1.1 LB agar solid medium 
Antibiotic-selective plates for growth of transformed bacteria were made using 
LB agar solid medium. LB agar powder (Fischer Bioreagents) was reconstituted 
with water at a concentration of 40 g/l, which was then sterilised by autoclaving. 
Antibiotics (carbenicillin 50 mg/ml, kanamycin 50 mg/ml, spectinomycin 50 
mg/ml, and chloramphenicol 25 mg/ml) were added to the sterile agar for a final 
concentration of 50 µg/ml, and the mixture was poured into sterile plastic Petri 
dishes near a flame and allowed to cool. Plates were stored inverted at 4oC if not 
used on that day. 
2.2.1.2 LB broth liquid medium 
This medium was used to grow bacteria for plasmid preparation. LB broth was 
dissolved in water at a concentration of 20 g/l, which was then sterilised by 
autoclaving, and hermetically closed for later use. It was stored at room 
temperature. 
2.2.1.3 TAE buffer 
Agarose gels were made using this buffer, and then electrophoresed immersed in 
it in a tank. A 1x TAE working solution contains 40 mM Tris, 20 mM acetic acid, 
and 1 mM EDTA. 
2.2.1.4 TE buffer 
This buffer was used to extract plasmid DNA from pieces of filter paper. A 1x TE 
solution contains 10mM Tris, and 1mM EDTA, pH 8 (adjusted with HCl). 
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2.2.2 Methods for the generation of the Gateway construct 
2.2.2.1 Polymerase chain reaction (PCR) 
To amplify the mbpa promoter from the zebrafish (Danio rerio) genome, PCR was 
performed using primers. 
Forward primer: 5’-GTCGACCAGATGCTGAGATGTGACTACTGCAAATGA-3’ 
Reverse primer: 5’-GGATCCGTTGATCTGTTCAGTGGTCTACAGTCTGGA-3’ 
Each PCR reaction contained the following: 1 μl of diluted DNA, 1.25 μl of forward 
primer (10 μM), 1.25 μl of reverse primer (10 μM), 0.25 μl of Q5 High-Fidelity 
DNA Polymerase (New England Biolabs), 5.0 μl of 5x Q5 reaction buffer (New 
England Biolabs), 0.5 μl of dNTPs solution (10 mM, 2.5 mM of each dNTP) 
(Bioline), and 15.75 μl of sterile, nuclease-free water. 
Two different thermal cycling programmes were utilised: 
-Standard PCR: 5 minutes at 95oC followed by 35 cycles (10 seconds at 95oC, 
30 seconds at 72oC, 90 seconds at 72oC) and 10 minutes at 72oC. 
-Touchdown PCR: 5 minutes at 95oC followed by 15 touchdown cycles (1 
minute at 95oC, 1 minute at 65→50oC decreasing 1 degree per cycle, 1 minute at 
72oC), 25 standard cycles (1 minute at 95ºC, 1 minute at 58ºC, 1 minute at 72ºC), 
and 10 minutes at 72ºC. 
2.2.2.2 Plasmid extraction from filter paper 
We obtained a small sample of a plasmid containing the mbpa promoter from 
Kim Lab (Jung et al., 2010). The plasmid was embedded in a piece of filter paper, 
so it needed to be extracted from it. To achieve this, the piece of paper was soaked 
in enough TE buffer to cover it and left overnight at room temperature to allow 
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the extraction. The extracted plasmid was stored at 4oC for subsequent 
transformation. 
2.2.2.3 Plasmid DNA transformation 
Three different commercially available strains of E. coli were used to grow up 
stock plasmids. Each of these required an independent protocol, both provided 
by the manufacturer: 
Subcloning Efficiency DH5α Competent Cells (Invitrogen) 
This strain was transformed with the plasmid containing the zebrafish mbpa 
promoter, obtained from Jung et al. (2010) and plasmids containing probe 
templates for in situ hybridisation. This strain was used so that the concentration 
of plasmid obtained would be enough for the subcloning of the mbpa promoter. 
One Shot Mach1 T1 Phage-Resistant Chemically Competent E. coli 
(Invitrogen) 
This strain was transformed with the plasmids necessary to construct zebrafish 
expression vectors. These plasmids are listed in table 2.3. Initially, this strained 
was selected for its high efficiency. However, knowing how unstable the C9orf72 
hexanucleotide repeats are, it would have been wiser to choose a strain that is 
better suited for cloning unstable sequences retrospectively. An example from the 
same brand would be the One Shot Stbl3 strain. 
One Shot ccdB Survival™ 2 T1R Competent Cells (Invitrogen) 
The Gateway destination vectors contain a ccdB gene, whose product is toxic to 
bacteria (Bernard and Couturier, 1992, Bernard et al., 1993). This strain is 
resistant to the ccdB product, making it useful to grow these vectors. 
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Transformed bacteria were spread on pre-warmed (30 min, 37oC) selective LB-
agar plates, and grown overnight at 37oC. The plates containing colonies of 
transformants were stored at 4oC. 
2.2.2.4 Plasmid DNA minipreparation  
Competent bacteria which had been transformed previously were picked into 3 
ml of sterile liquid LB medium containing 50 µg/ml of the appropriate antibiotic 
and grown at 37oC overnight on a rotating platform at 220 rpm. Plasmid DNA 
was then harvested using the NucleoSpin Plasmid kit (Macherey-Nagel) or the 
FastGene Plasmid Mini Kit (Nippon Genetics), following the manufacturer’s 
protocol. 
2.2.2.5 Plasmid DNA midipreparation 
A colony from each of the plates containing One Shot Mach1 transformants was 
picked into 3 ml of sterile liquid LB medium containing 50 µg/ml of the 
appropriate antibiotic and grown at 37oC for 6-8 h on a rotating platform at 220 
rpm. One hundred millilitres of autoclaved, fresh liquid LB medium containing 
50 µg/ml of the appropriate antibiotic, was then inoculated with the starter 
culture, and incubated overnight at 37oC as before. Plasmid DNA was then 
harvested using the Plasmid Midi Kit (Qiagen), according to the manufacturer’s 
protocol.  
2.2.2.6 Restriction endonuclease digestion of plasmid DNA 
Single digestion: The reaction mix was composed of the following components: 
10 µg of diluted DNA (15-30 µl), 5µl of either 10× B Buffer (Thermo Scientific) or 
10× FastDigest Universal Buffer (Thermo Scientific) (according to the restriction 
enzyme requirements), 2.5 µl of restriction enzyme (Thermo Scientific), and 
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deionised water to a final reaction volume of 50 µl. The mix was incubated at 37oC 
for 1 h.  
Double digestion: The components were mixed in the following proportions: 
10 µg of DNA (15-30 µl), 5 µl of 10× FastDigest Universal Buffer (Thermo 
Scientific), 2.5 µl of each enzyme (Thermo Scientific), and water to a final reaction 
volume of 50 µl. The mix was incubated at 37oC for 1h. 
2.2.2.7 Phenol:chloroform:isoamyl alcohol extraction of DNA 
DNA was purified from digestion mixtures using a standard 
phenol:chloroform:isoamyl alcohol extraction: First, an approximately equal 
volume of 25:24:1 phenol:chloroform:isoamyl alcohol was added to the digestion 
mix, and it was mixed briefly using a vortex to form an emulsion. The emulsion 
was centrifuged, and the upper aqueous phase pipetted into a fresh tube. The 
organic phase was back-extracted by repeating the previous steps and the 
aqueous phases pooled. 
2.2.2.8 Ethanol precipitation of DNA 
To precipitate DNA, 10% of the volume was added of 3 M sodium acetate pH 5.2. 
Two and a half volumes of that total volume was added of 100% ethanol to 
precipitate DNA. The mixture was incubated at -20oC for 1 h and then centrifuged 
at 4oC for 20min at a centrifugal force of 21000 g. The supernatant was removed 
carefully, and then the DNA pellet resuspended in 200µl of 70% ethanol. It was 
centrifuged at 4oC for 10 min at 21000g, and the supernatant was again removed. 
The DNA pellet was air-dried at room temperature until no visible traces of 
ethanol were present in the tube. The purified DNA was resuspended in an 
appropriate amount of deionised water. Half a microlitre of the resuspended DNA 
was analysed on an agarose gel to check the size and concentration. 
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2.2.2.9 Agarose gel electrophoresis  
DNA was electrophoresed on an agarose gel containing an appropriate 
concentration of agarose and 100 ng/ml ethidium bromide, at 120 or 80 V for 
enough time to allow clear resolution of the DNA bands.  An appropriate DNA 
ladder was included in each run. DNA was visualised using a Geni Gel 
Documentation System (Syngene). 
2.2.2.10 Purification of DNA from agarose gel slices 
Bands were excised with a clean scalpel on a UV light transilluminator, weighed 
in a microcentrifuge tube, and then the DNA purified with the QIAEX II Gel 
Extraction kit (Qiagen) following the manufacturer’s instructions. 
2.2.2.11 5’ dephosphorylation of digested DNA 
Dephosphorylation of the 5’ ends of linearised plasmid DNA was performed to 
minimise vector recircularization during the ligation step. The reaction 
components were mixed in these proportions: 1 µg of digested DNA (volume 
dependent on DNA concentration), 2 µl of 10× CutSmart Buffer (New England 
Biolabs), 1 unit of Shrimp Alkaline Phosphatase (rSAP, New England Biolabs), 
and deionised water to a final reaction volume of 20 µl (these volumes were scaled 
proportionally if a larger amount of DNA was to be dephosphorylated). The mix 
was incubated at 37oC for 30 min, and the reaction was then stopped by heat-
inactivation at 65oC for 5 min.  
2.2.2.12 DNA ligation 
T4 DNA ligase was used to clone purified inserts into their respective Gateway 
entry plasmids. The ligation components were mixed in the following 
proportions: 50 ng of vector (1-4 µl), insert DNA giving a 1:3 vector:insert ratio 
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(1-4 µl), 1 µl of 10× T4 DNA ligase buffer (New England Biolabs), 1 µl (400 units) 
of T4 DNA ligase (New England Biolabs), and deionised water to a final volume 
of 10 µl. Ligation reactions were incubated overnight at room temperature. 
2.2.2.13 Gateway recombination reaction 
To recombine the inserts in the 5’E-[mbpa prom] (5’ Entry-mbpa promoter), ME-
10×/51xHNR (Middle entry-interrupted GGGGCC hexanucleotide repeats), and 
the 3’E-GFP (3’ entry-Green fluorescent protein) plasmids with the pDestPA2 
(Destination vector including a poly-adenine tail), 10fmol of each entry plasmid 
was added to 20 fmol of the pDestPA2 vector, to obtain a final volume of 8 µl. To 
this mixture, 2µl of the Gateway LR Clonase II Plus (Thermo Fisher) was added, 
and the reaction was left at 25oC overnight. 
2.2.2.14 In vitro transcription of the Tol2 transposase mRNA 
The pCS2FA-transposase plasmid contains the transposon which encodes the 
Tol2 transposase, necessary for the Gateway construct to incorporate the desired 
genes in the chromosomal DNA of zebrafish embryos. The mRNA for this 
transposase needs to be co-injected with the DNA construct. To obtain this RNA, 
the pCS2FA-transposase plasmid was linearised with NotI, making it possible to 
obtain mRNA molecules for the transposase using the SP6 RNA polymerase. We 
used the mMESSAGE mMACHINE SP6 Transcription Kit (Thermo Fisher) to 
obtain this mRNA from 1µg of template DNA, according to the protocol provided 
in the kit. The template DNA was degraded using TURBO DNAse as indicated in 
the kit. 
2.2.2.15 Alcohol precipitation of Tol2 transposase mRNA 
To purify the generated mRNA, this is the protocol that was followed using the 
reagents included in the mMESSAGE mMACHINE SP6 Transcription Kit: 
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Nuclease-free water was added to the transcription reaction to a total volume of 
135 µl, then 15 µl of Ammonium acetate solution and 300 µl of 100% ethanol 
added, the mixture chilled for 15 min at -20oC, then centrifuged for 15 min at 4oC 
at 21000 g. The supernatant was removed, the pellet air-dried and resuspended 
in 10-20 µl of nuclease-free water. RNA was stored at -80oC. 
2.2.2.16 Sequencing of DNA 
The University of Sheffield Genomics Core Facility service uses the Applied 
Biosystems' 3730 DNA Analyser and BigDye v3.1 chemistry to analyse DNA 
sequences on demand. We sent 10 µl of each purified DNA (about 100 ng/µl) to 
the UoS Genomics Core Facility for sequencing using the appropriate primers, 
which depend on the plasmid. When sequencing plasmids containing the HNR 
expansions, a sequencing reaction including betaine was requested. Betaine helps 
with the sequencing of GC-rich sequences. 
2.2.2.17 Injection of zebrafish embryos with the Gateway vectors 
The cell of one-cell stage zebrafish (Danio rerio) embryos was injected with a total 
of 30 pg of one of the generated [mbpa prom]:10×/51xHNR:GFP:pDestPA2 
constructs, 25 pg of Tol2 transposase mRNA, and phenol red to confirm the 
injection. The injection needed to be done directly in the cell for rapid integration 
of the constructed gene in the genome. Injected and uninjected (control) embryos 
were raised for five days in E3 medium containing methylene blue. The GFP 
reporter, which should hypothetically be expressed only by differentiating Mbp-
producing oligodendrocytes in the CNS, should be visible by day 5. 
2.2.2.18 Visualisation of GFP-fluorescent embryos 
The embryos were anesthetised by adding 1 ml of 4 mg/ml tricaine 
methanesulfonate to each petri dish containing embryos to check for GFP 
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fluorescence in the developing CNS. After cessation of movement, the embryos 
were visualised using a set of binocular lenses connected to a fluorescent light 
source, using filters to visualise GFP fluorescence.   
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Table 2.3: Plasmids used to construct the Gateway zebrafish expression 
vectors, their integrated resistance gene, the restriction enzyme used 
linearise prior to electrophoresis, and the restriction enzymes used for 
cloning. 
  
Plasmid Description Resistance 
Linearising 
enzyme 
Double 
digestion 
enzymes 
p5E-MCS 
5’entry-Multiple-
cloning site 
Kanamycin SalI SacII/SalI 
pME-MCS 
Middle entry-
Multiple-cloning 
site 
Kanamycin SalI SmaI/SalI 
p3E-EGFPpA 
3’entry – 
Enhanced green 
fluorescent 
protein – Poly-
adenine 
Kanamycin EcoRV --- 
pDestTol2pA 
Destination 
vector – Poly-
adenine 
Ampicillin/Carbenicillin EcoRI --- 
pGEM-T 
Easy-mbpa 
promoter 
Plasmid 
containing the 
mbpa promoter, 
obtained from 
Jung et al. (2010) 
Ampicillin/Carbenicillin  SacII/SalI 
pcDNA 6.2 
GW/emGFP-
miR- HNRx10 
Plasmid 
containing 10 
interrupted 
hexanucleotide 
repeats 
(GGGGCC) 
Spectinomycin EcoRV EcoRV/SalI 
pcDNA 6.2 
GW/emGFP-
miR- HNRx51 
Plasmid 
containing 51 
interrupted 
hexanucleotide 
repeats 
(GGGGCC) 
Spectinomycin EcoRV EcoRV/SalI 
pcDNA 6.2 
GW/emGFP-
miR- 
HNRx102 
Plasmid 
containing 102 
interrupted 
hexanucleotide 
repeats 
(GGGGCC) 
Spectinomycin EcoRV EcoRV/SalI 
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2.2.3 CRISPR/Cas9 experiment design 
The aim of this part of the project was to use CRISPR/Cas9 technology to direct 
the mutagenesis of specific nucleotides in the zebrafish tardbp gene, the human 
TARDBP orthologue. The point mutations were planned to occur in conserved 
protein residues which are mutated in human fALS cases. A zebrafish tardbp 
point mutant model of ALS would be different from other zebrafish models 
involving the tardbp gene. For example, the tardbp knock-out strain generated 
by Hewamadduma et al. (2013) is useful to investigate the effects of a depletion 
of the tardbp protein product. This is different from investigating the effects 
produced by a defective protein, which includes a mutation found in humans in 
the same protein residue. 
The CRISPR/Cas9 system, is based on a prokaryotic immune system which 
provides resistance against foreign segments of DNA, such as the ones contained 
in bacteriophage viruses. Cas9 nuclease recognises a small single-stranded RNA 
sequence called “guide RNA” (gRNA). This gRNA consists of a trans-activating 
scaffold region containing CRISPRs (tracrRNA) attached to a ~20-nucleotide-
long sequence that is complementary to a genomic target sequence (spacer). Cas9 
binds to the tracrRNA region of the gRNA, which brings Cas9 towards the target 
sequence (protospacer) of the genomic DNA, complementary to the spacer 
(figure 2.6). When the gRNA/Cas9 complex binds to the target sequence via the 
complementary region, Cas9 cleaves the DNA strand near the end of the target 
sequence. This cleavage only occurs if the protospacer is adjacent to a 3-5 
nucleotide sequence named protospacer adjacent motif (PAM), which usually 
follows the sequence NGG (figure 2.6). 
By designing a gRNA that matches a genomic sequence in which a missense 
mutation is desirable to be introduced, the CRISPR/Cas9 system could be used 
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to nick the genomic DNA strand close to the point in which the mutation should 
be introduced. This can trigger three different types of DNA repair mechanism: 
non-homologous end joining (NHEJ), microhomology-mediated end joining 
(MMEJ), and homologous recombination (HR). NHEJ is prone to cause indels at 
the break point, where MMEJ causes deletions. HR recombines the cut DNA with 
an identical template for repair of both strands and causes no mutations in 
normal conditions. 
A single-stranded oligodeoxynucleotide donor template (ssODN) is a DNA strand 
which is identical to the upstream and downstream sequence from the cleavage 
point except for the mutation we would like to introduce. Once the target 
sequence has been cleaved, the ssODN will serve as a template for the HR 
machinery in some events, thus introducing the desired mutation in the genomic 
DNA (figure 2.6). 
The reason for selecting certain mutations amongst all the known ALS-causing 
TARDBP mutations, is because in the event of a successful mutagenesis, a 
restriction site would be lost, while a new restriction site would be generated. This 
would make screening for mutant zebrafish easier by using PCR and digesting the 
amplified DNA using specific restriction enzymes. There were two mutations that 
we selected to try and introduce in the zebrafish TARDBP protein: p.G347→V and 
p.A379→T. These mutations have been reported by (Budini et al., 2012) and 
(Orru et al., 2012) to cause ALS in humans. Figure 2.7 shows that the targeted 
amino acids are conserved amongst the TARDBP orthologues of other species. To 
produce these mutants, the donor DNA strands needed to contain a mutation that 
changed the codons which encode those amino acids. In the case of the 
p.G347→V mutation, the change would be GGT→GTC. For the p.A379→T 
mutation, the change would be GCT→ACC. The DNA mutation to produce the 
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p.G347→V protein mutation would remove a CviQI restriction site and create a 
Tsp45I site in its place, whereas the mutation to obtain the p.A379→T protein 
change would eliminate a PvuII site, generating a BsaJI site instead.  
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Figure 2.6: CRISPR/Cas9-directed mutagenesis. First, a single-stranded gRNA 
binds to both Cas9 and to the genomic DNA region that is homologous to its spacer 
region, thus guiding Cas9 towards the desired cutting point. Then, Cas9 causes a 
double-strand break in the genomic DNA a few bases behind the PAM site. In some 
instances, the homology-directed repair machinery uses the donor DNA strand as the 
template to repair the DNA. This donor DNA includes the desired mutation, thus 
causing the repaired DNA to include it.  
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Figure 2.7: Interspecies alignment of orthologous TDP-43 proteins. 
The amino acids which were chosen for CRISPR/Cas9 mutagenesis in zebrafish 
are marked with a black arrow. The amino acid number indicates the position in 
the zebrafish sequence.  
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The spacer sequence needs to be designed so that it is complementary to the 
genomic strand and targets the gRNAs to the target sequence. Additionally, the 5’ 
end of the target sequence needs to contain a PAM site (NGG) for the Cas9 protein 
to effectively cleave both DNA strands three bases before the PAM site (figure 
2.8). In general, there are five requisites for the choice of target sequences: 
- It needs to be 20bp long. 
- It must span the codon we intend to mutate. 
- It needs to be adjacent to a PAM sequence which does not contain single 
nucleotide polymorphisms (SNPs) in the G nucleotides. 
- It should not have a high degree of homology with other sequences in the 
genome of the target organism. 
- The distance between the PAM sequence and the target codon has to be at 
least two bases, but they should not be too far from each other. This is the 
safe distance, so Cas9 does not cleave the site where our codon of interest 
is. 
There are electronic tools to help choose target sequences that fulfil these 
requirements. We used the tool available at http://crispr.mit.edu/ which scores 
multiple possible target sequences as a function of the degree of homology with 
other sequences in the genome of the organism of interest. The following 
sequence from tardbp exon 6 was introduced on the above website as a query (the 
red bases indicate the codons we aimed to mutate): 
TTTGGGAATGGGTTCGGAGGTCAGGGTTTTGCAGGCAGCCGAAGCAACATGGGTGGT
GGTGGTGGGGGTAGCTCCAGCAGCTTGGGAAATTTTGGCAATTTCAATCTAAACCCG
GCCATGATGGCTGCCGCCCAGGCTGCCTTGCAGAGTAGTTGGGGTATGATGGGAATG
CTAGCTCAGCAGAATCAGTCGGGTACTTCAGGCACAAGCACAAGTGGCACCAGTTCC
TCTCGAGACCAAGCCCAAACATATAGCTCGGCTAACAGCAATTACGGCAGCAGCTCAG
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CTGCTCTCGGCTGGGGCACCGGCTCTAACTCGGGCGCTGCCAGTGCTGGCTTTAACT
CCAGTTTTGGCTCTAGTATGGAGTCCAAGTCATCGGGGTG 
 
The website proposed a significant number of plausible target sequences within 
the query sequence, and we selected the ones with the best scores that had all the 
requirements stated above. These are given below. The highlighted sequence is 
the PAM sequence, which is present in the genome, but which should not be 
included in the gRNA, and the red sequence is the codon of interest. 
 
p.G347→V 
GAATCAGTCGGGTACTTC AGG 
p.A379→T 
GGCAGCAGCTCAGCTGCTCT CGG 
Blue = Target sequence; Red = codon to be mutated; Yellow = PAM 
site. 
Thus, the full sequences for the gRNAs, including the scaffold sequence (common 
to all CRISPR gRNA) are as follows: 
p.G347→V 
GAAUCAGUCGGGUACUUCGUUUUAGAGCUAGAAAUAGCAAGUUAA
AAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCG
GUGCUUU 
p.A379→T 
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GGCAGCAGCUCAGCUGCUCUGUUUUAGAGCUAGAAAUAGCAAGUU
AAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGU
CGGUGCUUU 
Blue = Target sequence; Red = codon to be mutated; Black = scaffold 
 
To obtain these RNA sequences by in vitro transcription, a DNA template which 
included a T7 promoter was added at the end of the DNA reverse complement of 
the above sequences: 
 
p.G347→V 
AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCC
TTATTTTAACTTGCTATTTCTAGCTCTAAAACGAAGTACCCGACTGAT
TCCTATAGTGAGTCGTATTACGC 
p.A379→T 
AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCC
TTATTTTAACTTGCTATTTCTAGCTCTAAAACAGAGCAGCTGAGCTGC
TGCCCTATAGTGAGTCGTATTACGC 
Blue = Target sequence; Red = codon to be mutated; Black = scaffold; 
Gold = T7 promoter  
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p.G347→V 
GTTGCCGCCGCTTTGTGTGGAGAAGATCTGATCATCAAGGGCGTCAG
TGTGCATATCTCAAACGCTGAGCCCAAACACAATAACACTAGGCAGA
TGATGGAGCGGGCAGGGCGCTTTGGGAATGGGTTCGGAGGTCAGGG
TTTTGCAGGCAGCCGAAGCAACATGGGTGGTGGTGGTGGGGGTAGC
TCCAGCAGCTTGGGAAATTTTGGCAATTTCAATCTAAACCCGGCCATG
ATGGCTGCCGCCCAGGCTGCCTTGCAGAGTAGTTGGGGTATGATGGG
AATGCTAGCTCAGCAGAATCAGTCGGGTACTTCAGGCACAAGCACAA
GTGGCACCAGTTCCTCTCGAGACCAAGCCCAAACATATAGCTCGGCT
AACAGCAATTACGGCAGCAGCTCAGCTGCTCTCGGCTGGGGCACCGG
CTCTAACTCGGGCGCTGCCAGTGCTGGCTTTAACTCCAGTTTTGGCTC
TAGTATGGAGTCCAAGTCATCGGGGTGGGGTATGTAA 
 
p.A379→T 
GTTGCCGCCGCTTTGTGTGGAGAAGATCTGATCATCAAGGGCGTCAG
TGTGCATATCTCAAACGCTGAGCCCAAACACAATAACACTAGGCAGA
TGATGGAGCGGGCAGGGCGCTTTGGGAATGGGTTCGGAGGTCAGGG
TTTTGCAGGCAGCCGAAGCAACATGGGTGGTGGTGGTGGGGGTAGC
TCCAGCAGCTTGGGAAATTTTGGCAATTTCAATCTAAACCCGGCCATG
ATGGCTGCCGCCCAGGCTGCCTTGCAGAGTAGTTGGGGTATGATGGG
AATGCTAGCTCAGCAGAATCAGTCGGGTACTTCAGGCACAAGCACAA
GTGGCACCAGTTCCTCTCGAGACCAAGCCCAAACATATAGCTCGGCT
AACAGCAATTACGGCAGCAGCTCAGCTGCTCTCGGCTGGGGCACCGG
CTCTAACTCGGGCGCTGCCAGTGCTGGCTTTAACTCCAGTTTTGGCTC
TAGTATGGAGTCCAAGTCATCGGGGTGGGGTATGTAA 
 
Figure 2.8: CRISPR design for the exon 6 coding sequence. Blue = 
Target sequence; Red = codon to be mutated; Yellow = PAM site; Grey = CviQI 
(p.G347→V) or PvuII (p.A379→T) restriction site, which disappears after 
successful mutagenesis, leaving a Tsp54I and a BsaJI site respectively; Green = 
sequence to be added to donor DNA; Black = Primer target sequences  
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2.2.3.1 Testing for possible single nucleotide polymorphisms on the PAM sites 
If the PAM sites contained common SNPs in any of the two compulsory G 
nucleotide residues, this technique would prove inefficient since Cas9 would be 
unable to cause the double strand break in the target sequence in the embryos 
where these SNPs were present. 
A group of 2 days post-fertilisation (dpf) wild type zebrafish embryos were 
anesthetised to test for SNPs in exon 6, by adding 1 ml of 4 mg/ml tricaine 
methanesulfonate to each petri dish containing embryos, to extract their genomic 
DNA. 
2.2.3.2 DNA extraction of zebrafish embryos 
To extract the genomic DNA of 2 dpf zebrafish embryos, each one was submerged 
in 30 µl of DNA extraction solution containing 10 mM Tris pH 8, 2 mM EDTA, 
0.2% Triton X-100, and 200 µg/ml Proteinase K. The suspended embryos were 
incubated at 65oC for 2 h, followed by 98oC for 2 min. 
The zebrafish lysate was subjected to PCR using a set of primers designed to 
amplify both target sequences (figure 2.8): 
 
Exon6 forward primer: TTTGGGAATGGGTTTGGAGG 
Exon6 reverse primer: CACCCCGATGACTTGGACTC 
 
These primers will be called Exon6 primers henceforth. The following reagents 
were mixed for PCR: 13 µl dH2O, 1 µl extracted DNA, 1 µl 10 µM forward primer, 
1 µl 10 µM reverse primer, 4 µl 5x FIREPol Master Mix. The temperature settings 
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were the following: 94oC for 3 min, 30 cycles (94oC for 30 s, 58oC for 45 s, 72oC 
for 90 s), 72oC for 2 min, store at 10oC. 
2.2.3.3 ExoSAP treatment of PCR-amplified DNA 
Primers and dNTPs, which would be a contaminant for sequencing, were 
degraded using an ExoSAP protocol, which includes the following reagents: 5 µl 
PCR mix, 3.95 µl dH2O, 1 µl Shrimp Alkaline Phosphatase (New England Biolabs), 
0.05 µl Exonuclease I (New England Biolabs). This mixture was left at 37oC for 
45 min, followed by 80oC for 15 min, and was performed in a thermocycler. 
2.2.3.4 Sequencing of the tardbp exon 6 amplicon 
The sequencing technique was as described in section 2.2.2.16, using the Exon6 
primers described above. 
2.2.3.5 Amplification of CRISPR templates 
Template ultramers were obtained from IDT (Integrated DNA Technologies) in 
lyophilised form and were diluted to 0.01 mM. The ultramers were then amplified 
via PCR using these primers: 
Forward primer: AAAGCACCGACTCGGTGCCA (targets the beginning of the 
scaffold sequence). 
Reverse primer: GCGTAATACGACTCACTATA (targets the T7 promoter). 
The PCR reaction was assembled mixing 73 µl dH2O, 2 µl template ultramer, 2.5 
µl forward primer, 2.5 µl reverse primer, 20 µl 5x FIREPol Master Mix (Solis 
Biodyne). The reactions and a negative control without template DNA were done 
in a thermocycler using the following PCR protocol: 1 min at 95oC, 40 cycles (15 s 
at 95oC, 30 s at 60oC, 20 s at 72oC), 5 min at 72oC, store at 4oC. The completed 
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reactions were analysed using a 3% agarose gel along with Hyperladder V 
(Bioline) to check for a band at 120 bp. The band was excised and purified using 
the PureLink Quick Gel Extraction Kit (Invitrogen). 
2.2.3.6 Synthesis of the gRNA 
A T7 reaction was assembled to synthesise the gRNA from the DNA templates, 
using these volumes: 4 µl template DNA, 1 µl 10× T7 reaction buffer, 1 µl ATP 10 
mM, 1 µl CTP 10 mM, 1 µl 10 mM UTP, 1 µl 10 mM GTP, 1 µl T7 enzyme mix. The 
mixture was incubated at 37oC for 4 h. One microliter of Turbo DNAse was added 
to degrade the DNA template, and the reaction was incubated at 37oC for 15 min. 
2.2.3.7 Purification of the gRNA 
Ethanol precipitation was used to purify the gRNA following these steps: 125 µl 
of nuclease free water and 15 µl ammonium acetate were added to the previous 
T7/Turbo DNAse reaction, then 302 µl of ethanol added to precipitate the RNA, 
leaving it to chill at -20oC for 15 min. The RNA was centrifuged for 15 min at 4oC 
at 20000 g; the supernatant was discarded, and the RNA pellet was left to air dry, 
resuspended in 10 µl of nuclease free water, and stored at -80oC. Half a microlitre 
of the purified gRNA was visualised in a 3% agarose gel, using the DNA 
Hyperladder V to give a rough approximate reference of the size (since single-
stranded RNA migrates differently than double-stranded DNA in a gel). 
2.2.3.8 Injection of zebrafish using the gRNA and Cas9 
Prior to injecting the gRNAs, they were individually mixed on ice with the 
following reagents: 1 µl 0.5% phenol red (for visualisation of the injection), 0.5 µl 
Cas9 protein (New England BioLabs) 2.5 µl gRNA. Zebrafish embryos were 
harvested from pair matings, and 2 nl of the CRISPR mixture was injected into 
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the yolk mass of each zebrafish embryo at the 1-cell stage using a microinjector 
and pulled fine glass needles. Non-injected embryos were used as negative 
controls. 
2.2.3.9 Genotyping of injected zebrafish 
When Cas9 cleaves genomic DNA, the DNA repair machinery will try to repair it 
using the error-prone non-homologous end joining pathway, typically 
introducing an insertion or a deletion. This makes it straightforward to test 
whether the injection has been successful using PCR primers flanking the target 
site and sequencing the amplified DNA. 
 
2.2.4 Studying oligodendrocyte development in tardbp-deficient 
zebrafish 
To investigate whether knocking out the tardbp gene causes defects in or delays 
the early myelination stages of zebrafish oligodendrocytes, heterozygous and 
homozygous mutants containing a nonsense mutation in tardbp (tardbp+/- and 
tardbp-/- respectively) were assessed for correct early oligodendrocyte 
differentiation and myelination. These mutants are described in detail by 
Hewamadduma et al. (2013). To assess them, OPCs were stained at different 
stages using different probes targeting mRNA molecules which are specifically 
expressed in these cells at various stages of development. Three dpf embryos were 
stained for the sox10 transcription factor (Dutton et al., 2001), and 5 dpf for mbpa 
(Brosamle and Halpern, 2002) found in myelinating oligodendrocytes.  
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2.2.4.1 Synthesis of the mbpa probe 
A λ-ZipLox plasmid (Invitrogen) containing the template for the mbpa cDNA was 
available. It was amplified in OneShot chemically competent E. coli (using 
carbenicillin-selective LB plates and broth) and purified using a midiprep kit as 
described in section 2.2.2.5 to obtain a concentration which allows for enough 
template to synthesise the probe efficiently. Ten micrograms of plasmid DNA was 
digested using SalI by assembling the following reaction: 20 µl plasmid DNA (500 
ng/µl), 5 µl 10× FastDigest digestion buffer, 20 µl nuclease free water (all water 
used for the synthesis and use of the probe was nuclease free, and will be referred 
as H2O henceforth), 5 µl FastDigest SalI. The digestion was left at 37oC for 1.5 h, 
and the linearisation of the DNA was confirmed using a 1% agarose gel and 
Hyperladder 1Kb size standards. 
The digested DNA was extracted from the reaction mix via phenol/ 
chloroform/isoamyl alcohol extraction and ethanol-precipitated as described in 
section 2.2.2.7. The concentration of the digested DNA was assessed using a 
Nanodrop spectrophotometer. 
A transcription reaction was assembled to synthesise the desired antisense mbpa 
probe from 1 µg template as follows: 2.2 µl DNA (485 ng/µl), 2 µl 10× SP6 
transcription buffer, 2 µl 10× DIG labelling mix, 1 µl RNAse inhibitor (murine), 
10.8 µl H2O, 2 µl SP6 RNA polymerase. The transcription mix was incubated at 
37oC for 2 h. 
To degrade the template DNA, 2.5 µl of 10× DNAse I buffer and 2.5 µl of 1 U/µl 
DNAse I were added to the previous transcription reaction and incubated at 37oC 
for 30 min. The probe was then precipitated by adding 2.5 µl of LiCl (4 M) and 75 
µl of ethanol and incubation at -80oC overnight. The pellet was then centrifuged 
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at 20000 g and 4oC for 20 min. The supernatant was discarded, and the pellet 
was washed with 75% ethanol and centrifuged at 20000 g and 4oC for 15 min. The 
supernatant was discarded, and the pellet was allowed to air dry until no traces 
of ethanol were visible. The pellet was then resuspended in 50 µl H2O and allowed 
to rehydrate on ice for 15 min before resuspension and addition of 50 µl of 
formamide prior to storage at -20oC. 
2.2.4.2 Production of zebrafish embryos 
Adult tardbp-/- and wild type (tardbp+/+) zebrafish were either inbred or bred 
with each other to provide embryos with distinct genotypes: tardbp-/-, tardbp+/-, 
and tardbp+/+. Different groups of each phenotype were raised to either 2, 3 or 5 
dpf in E3 medium with methylene blue. 
2.2.4.3 Fixation of zebrafish embryos 
When necessary, the embryos were dechorionated before fixation. When the 
embryos reached the desired stage, they were anaesthetised by adding 1 ml of 4 
mg/ml tricaine methanesulfonate to each petri dish containing embryos. They 
were transferred to 1.5 ml microfuge tubes (60 per tube) and were incubated in 1 
ml PBS containing 0.15 mg/ml tricaine methanesulfonate for 5 min at room 
temperature on a rocker (all incubations were done on a rocker). Then, they were 
incubated in 1 ml Fish Fix solution (4% paraformaldehyde in PBS) overnight at 
4oC. The following day, the embryos were washed with 1ml PBS twice, then 1 ml 
50% methanol in PBS, for 5 min each at room temperature. The embryos were 
then submerged in 100% methanol and stored at -20oC. 
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2.2.5 Whole-mount in situ hybridisation of zebrafish embryos 
2.2.5.1 General reagents 
PBS (Phosphate Buffer Saline) 
Commercially available PBS tablets were dissolved to a final concentration of 137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4 in distilled water. 
The solution was autoclaved. 
PTW (PBS-Tween) 
A volume of 0.5 ml of 10% Tween-20 detergent was added to 50 ml PBS to a final 
concentration of 0.1%. Tween is a surfactant which prevents the embryos from 
sticking to pipette tips and other surfaces. 
PBT (PBS-BSA-Tween) 
PBT is a PTW solution to which it has been added sheep serum to 2% and BSA 
(Bovine Serum Albumin) to 0.2%. It needs to be made just before use to prevent 
microbial growth. 
20x SSC (Salt-Sodium Citrate) 
A water solution containing 3 M NaCl and 0.34 M sodium citrate, whose pH has 
been set at 7.0 with NaOH. 
2x/0.2x SSC 
1:10/1:100 dilution in distilled water of 20x SSC. 
Full hybridisation solution (HYB+) 
A milli-Q H2O solution made in batches of 50 ml by mixing 25 ml formamide, 
12.5 ml 20x SSC, 2.5 ml tRNA (from 10 mg/ml stock), 50 µl heparin (from 50 
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mg/ml stock), 0.5 ml 10% Tween-20, 0.46 ml 1M citric acid, and 8.99 ml milli-Q 
H2O. 
Incomplete hybridisation solution (HYB-) 
A milli-Q H2O solution made in batches of 50 ml by mixing 25 ml formamide, 
12.5 ml 20x SSC, 0.5 ml 10% Tween-20, 0.46 ml 1M citric acid, and 11.54 ml milli-
Q H2O. 
Staining buffer 
This solution was made by mixing 5 ml 1M Tris pH 9.5, 2.5 ml 1M MgCl2, 1 ml 5M 
NaCl, 0.5 ml 10% Tween-20, and 41 ml milli-Q H2O. 
0.1M PO buffer (Phosphate buffer) 
This solution was made by mixing 20 ml 0.2M NaH2PO4, 80 ml 0.2M Na2HPO4, 
and 100 ml milli-Q H2O. 
1x Fish fix 
This solution is used to fix zebrafish embryos. It was made by mixing 25 ml 0.1M 
PO buffer, 3 µl 1M CaCl2, 1 g PFA (paraformaldehyde) powder, and 1 g sucrose. 
The mixture is brought to 70oC, aliquoted, and stored at -20oC. 
Bleaching solution 
This solution was used to clear the superficial pigments of zebrafish embryos and 
make the interior easier to visualise. It was made by mixing 8.9 ml distilled water, 
0.25 ml 20x SSC, 0.5 ml formamide (5% final), and 0.33 ml 30% H2O2. 
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2.2.5.2 Whole mount RNA in situ hybridisation 
Day 1 
All solutions were prepared using nuclease-free water. Fixed embryos from 
various stages (2, 3, and 5 dpf) and genotype (tardbp+/+, tardbp+/-, and tardbp-
/-) were washed once with 1 ml 50% methanol in PBS at RT and 4 times with 1 ml 
PTW at RT. The embryos were incubated with 1 ml 10 µg/ml proteinase K at RT 
to permeabilise them. The permeabilisation time depended on the embryonic 
stage due to the different sizes: 3 dpf for 30 min, and 5 dpf for 50 min. The 
embryos were then fixed in 1 ml Fish Fix for 20 min at RT and washed in 1 ml 
PTW 5 times for 5 min each at RT. After that, they were rinsed in 0.25 ml HYB- 
solution and were pre-hybridised in 300 µl HYB+ for 2.5 h at 65oC. To hybridise 
the embryos, they were incubated overnight at 65oC with 0.3 ml preheated HYB+ 
containing the DIG labelled probe at a 1:200 dilution. As mentioned above, the 
probes targeted sox10 for 3 dpf and mbpa for 5 dpf. 
Day 2 
The probe was removed, and the embryos were washed in 0.5 ml 50% HYB- in 1x 
SSC for 20 min at 65oC, followed by another wash in 1 ml 2x SSC for 20 min at 
65oC, and 2 washes in 1 ml 0.2x SSC for 60 min each at 65oC. The embryos were 
then washed in 1 ml 50% PBT in 0.1x SSC for 10 min at RT, followed by a wash in 
1 ml PBT for 10 min at RT, and a blocking incubation in 1 ml PBT for 2.5 h at RT. 
The embryos were incubated overnight at 4oC with 1 ml of PBT including Anti-
Digoxigenin-AP, Fab fragments (Sigma-Aldrich) in a 1:2000 dilution to label the 
previously hybridised RNA. 
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Day 3 
The embryos were washed 6 times with 1 ml PTW for 20 min each time at RT. 
They were then equilibrated by washing them 3 times with 1 ml staining buffer 
without NBT and BCIP for 10 min at RT. The embryos were transferred to a 12-
well plate with 1 ml staining buffer containing 3.5 µl/ml BCIP and 4.5 µl/ml NBT 
per well. The embryos were stained in the dark for about 4 h at RT until the colour 
was fully developed. The staining reaction was stopped by washing the embryos 
3 times with 1 ml PTW for 5 min at RT, and then they were fixed overnight in Fish 
Fix at 4oC. 
Day 4 
The embryos were rinsed in 1 ml PTW twice for 5 min at RT and bleached with a 
bleaching solution for about 2 h at RT until the endogenous pigment faded. This 
step was followed by four washes in PTW for 5 min at RT. To store the embryos, 
they were transferred to 75% glycerol through a series of glycerol dilutions in PBS: 
10% → 25% → 50% → 75%. 
2.2.5.3 Visualisation of stained embryos 
Six embryos of each embryonic stage and tardbp genotype were decapitated using 
two sharp syringes, and their heads mounted on glass slides which had a small 
receptacle loaded with 75% glycerol in PBS, and covered with a glass coverslip. 
The dorsal side was placed uppermost for easier inspection of the OPCs. 
These mounted heads were photographed at different z-layers using an FV1000 
confocal microscope using its associated software. 
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2.2.5.4 Quantification of OPCs and oligodendrocytes 
For mbp (5 dpf), images where the myelinated axons were sharply in focus were 
used as a reference. One example can be seen in figure 2.9 (bottom). On these, 
we counted the number of labelled myelinating oligodendrocytes and the number 
of myelinated axons. 
For sox10 (3 dpf), images where the midline of the hindbrain was sharply in focus 
were used as a reference. Figure 2.9 (top) shows an example of these. We 
counted the number of labelled OPCs in a fixed area of these pictures.  
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Figure 2.9: Whole-mount in situ hybridisation. Examples of reference 
pictures for 3 dpf sox10 (top), and 5 dpf mbp (bottom).
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RESULTS: Part I 
 
Study of oligodendroglial pathology and myelin loss in ALS  
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CHAPTER 3 
Protein aggregation in ALS 
3.1 Introduction 
The first objective was to characterise the glial and neuronal pathologies in our cohorts 
of ALS cases which are positive for hexanucleotide expansions in C9orf72 (C9ALS), 
sporadic ALS cases (sALS) with no known mutations of ALS, and neurologically healthy 
controls. The hypotheses underlying this characterisation were the following: 
• C9ALS cases bear a higher degree of oligodendroglial pathology than sALS cases 
because aggregated expanded C9orf72 mRNA can bind and sequester proteins 
relevant to mRNA transport, which adds to ALS protein aggregate pathology. To 
test this, p62 and TDP-43 stained and protein inclusions positive for these 
proteins were counted in the precentral gyrus, the prefrontal cortex and the 
spinal cord. Co-localisation with oligodendrocytes was aimed to be tested using 
double staining for p62 and oligodendroglial markers. 
• Dipeptide repeat protein (DPR) caused by the RAN-translation of C9orf72 mRNA 
hexanucleotide repeats is a component of those oligodendroglial p62-positive 
inclusions. Initially, this was tested using IHC for each of the five possible DPRs 
and quantifying the DPR-positive oligodendroglial inclusions in precentral gyrus 
sections. 
• Aggregated cytoplasmic TDP-43 can trap hnRNP-A2 and will, therefore, cause its 
depletion from the cytoplasm and eventually from the nucleus in the 
oligodendrocytes supporting the primary motor neurones of ALS patients. To test 
this, hnRNP-A2-positive nuclei were counted in the white matter under the 
motor cortex and in the dorsolateral motor tracts of spinal cord sections. Total 
protein and mRNA amounts were also quantified for this protein. 
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• MBP synthesis is decreased in motor pathways of ALS patients, but PLP synthesis 
is not because MBP requires its mRNA to be transported to the myelin 
compartment to be translated, and mRNA transport is impaired in ALS, 
especially in C9ALS. To test this, MBP and PLP, and their respective mRNAs, 
were quantified in the dorsolateral motor tracts of the spinal cord. 
• Oligodendroglial dysfunction is part of the etiology of ALS and leads to defects in 
the myelination of motor pathways, causing motor neurone axonopathy. This was 
tested by staining and calculating the density of axons panning the dorsolateral 
tracts of spinal cord sections, and the number of oligodendrocyte precursor cells 
available for re-myelination in both the spinal cord and the precentral gyrus. 
The results presented in this and the next chapters provide evidence supporting a 
prevalence of glial pathology in relevant motor areas in C9ALS cases compared to sALS. 
Additionally, those levels of pathology and the C9orf72 mutation were correlated with 
the loss of both myelin and oligodendroglial precursor cells. 
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3.2 Subjects 
Immunohistochemistry (IHC) was performed on a cohort of post mortem 
samples. The average demographic details of these cases can be found in table 
3.1 and the anonymised individual details are in table 3.2. The unbalanced 
female/male ratio for the control group is due to those tissue blocks being the 
only ones available to us at the time of the study. The samples used for each 
analysis depend on whether enough tissue was available and whether that cohort 
was relevant to the study -e.g. only the C9ALS group was relevant for the DPR 
analysis. The samples used for each analysis in this and the next chapters are 
detailed in table 3.3. 
 
Group 
N 
(female/male) 
Post 
mortem 
delay* 
(h ± SD) 
Age at 
death* 
(years ± 
SD) 
Age at 
onset* 
(years ± 
SD) 
Disease 
duration* 
(months 
± SD) 
C9ALS 17 (8/9) 35 ± 31 60 ± 8 58 ± 8 27 ± 14 
sALS 67 (30/37) 22 ± 10 64 ± 10 62 ± 11 36 ± 13 
Controls 17 (4/12)* 23 ± 15 58 ± 19 N/A N/A 
Table 3.1: Demographic data of the studied population. *Calculated using 
data from the patients for which that information was available at the time of the study. 
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Patient ID C9ORF72 genotype Sex Age at onset Duration of disease Age at death PM delay 
1 C9ORF72 Female 58 7 58 2 
2 C9ORF72 Female 59 40 62 63 
3 C9ORF72 Female 50 28 52 
 
4 C9ORF72 Female 63 43 66 24 
5 C9ORF72 Female 61 40 64 7 
6 C9ORF72 Female 67 26 69 55 
7 C9ORF72 Female 56 43 59 32 
8 C9ORF72 Female 61 42 64 
 
9 C9ORF72 Male 56 13 57 
 
10 C9ORF72 Male 64 31 66 96 
11 C9ORF72 Male 67 14 68 31 
12 C9ORF72 Male 63 11 63 6 
13 C9ORF72 Male 70 26 72 96 
14 C9ORF72 Male 62 20 63 48 
15 C9ORF72 Male 45 14 46 4 
16 C9ORF72 Male 47 19 48 23 
17 C9ORF72 Male 42 50 46 15 
18 Control Female N/A N/A 59 
 
19 Control Female N/A N/A 69 
 
20 Control  N/A N/A 
  
22 Control Male N/A N/A 70 
 
23 Control Male N/A N/A 27 
 
25 Control Female N/A N/A 
 
36 
27 Control Female N/A N/A 59 5 
28 Control Male N/A N/A 46 20 
29 Control Male N/A N/A 46 20 
30 Control Male N/A N/A 55 24 
32 Control Male N/A N/A 67 20 
33 Control Male N/A N/A 82 36 
34 Control Male N/A N/A 87 18 
35 Control Male N/A N/A 64 12 
36 Control Male N/A N/A 51 25 
37 Control Male N/A N/A 72 31 
38 Control Male N/A N/A 67 63 
39 Sporadic Female 55 56 59 
 
40 Sporadic Female 81 24 83 44 
41 Sporadic Female 58 16 59 60 
42 Sporadic Female 73 31 75 48 
43 Sporadic Female 66 20 67 15 
44 Sporadic Female 45 20 46 20 
45 Sporadic Female 78 33 80 24 
46 Sporadic Female 67 33 69 
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Patient ID C9ORF72 genotype Sex Age at onset Duration of disease Age at death PM delay 
47 Sporadic Female 39 28 41 10 
48 Sporadic Female 59 57 63 34 
49 Sporadic Female 59 46 62 36 
50 Sporadic Female 63 31 65 
 
51 Sporadic Female 76 25 78 19 
52 Sporadic Female 66 44 69 24 
53 Sporadic Female 65 14 66 50 
54 Sporadic Female 57 48 61 36 
55 Sporadic Female 64 66 69 12 
56 Sporadic Female 57 38 60 18 
57 Sporadic Female 65 38 68 
 
58 Sporadic Female 61 42 64 27 
59 Sporadic Female 68 26 70 35 
60 Sporadic Female 77 8 77 34 
61 Sporadic Female 72 104 80 50 
62 Sporadic Female 58 25 60 70 
63 Sporadic Female 58 121 68 40 
64 Sporadic Female 55 82 61 
 
65 Sporadic Female 62 23 63 40 
66 Sporadic Female 49 23 50 24 
67 Sporadic Female 67 21 68 40 
68 Sporadic Female 71 50 75 24 
69 Sporadic Male 62 25 64 9 
70 Sporadic Male 63 26 65 
 
71 Sporadic Male 47 13 48 8 
72 Sporadic Male 66 22 67 62 
73 Sporadic Male 49 29 51 
 
74 Sporadic Male 63 53 67 6 
75 Sporadic Male 49 28 51 
 
76 Sporadic Male 36 59 40 25 
77 Sporadic Male 56 38 59 
 
78 Sporadic Male 69 47 72 18 
79 Sporadic Male 43 47 46 10 
80 Sporadic Male 75 6 75 28 
81 Sporadic Male 75 19 76 10 
82 Sporadic Male 60 40 63 32 
83 Sporadic Male 49 29 51 
 
84 Sporadic Male 60 38 63 16 
85 Sporadic Male 68 17 69 11 
86 Sporadic Male 60 57 64 9 
87 Sporadic Male 31 66 36 35 
88 Sporadic Male 83 97 91 44 
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Patient ID C9ORF72 genotype Sex Age at onset Duration of disease Age at death PM delay 
89 Sporadic Male 38 32 40 96 
90 Sporadic Male 64 25 66 96 
91 Sporadic Male 63 43 66 30 
92 Sporadic Male 76 24 78 30 
93 Sporadic Male 48 22 49 48 
94 Sporadic Male 73 14 74 12 
95 Sporadic Male 66 36 69 34 
96 Sporadic Male 65 46 68 48 
97 Sporadic Male 67 12 68 
 
98 Sporadic Male 56 27 59 60 
99 Sporadic Male 57 24 59 16 
100 Sporadic Male 64 21 65 46 
101 Sporadic Male 50 44 53 16 
102 Sporadic Male 71 9 71 53 
103 Sporadic Male 62 14 63 48 
104 Sporadic Male 49 29 51 22 
105 Sporadic Male 78 10 78 
 
106 Sporadic Male 74 63 79 24 
Table 3.2: Anonymised individual demographic details for the post mortem 
study cases. A blank cell indicates missing data at the time of the study. Control cases 
21, 24, 26 and 31 are missing from the table due to their exclusion at the time of the study.  
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Study Technique Tissue 
C9ALS 
cases 
sALS cases Control cases 
p62-positive 
inclusions 
IHC 
Spinal 
cord 
1-8, 10-17 
39, 44, 45, 47-49, 
51, 52, 54-56, 58, 
59, 61-68, 70, 73, 
76, 78-82, 85, 90, 
91, 95, 96, 98-103, 
105, 106 
25, 29, 30, 32, 
33 
Motor 
cortex 
1-7, 10-17 
39-42, 44, 45, 47-49, 
51-59, 61-64, 66-73, 
75, 76, 78, 80, 83, 
84, 86-93, 95, 96, 
98, 100-104, 106 
27, 28, 34, 35, 
38 
Frontal 
cortex 
1-7, 9-17 
39-46, 48-52, 55-57, 
59-77, 79, 80, 82-85, 
88, 89, 91-94, 96, 
97, 99-106 
22, 27, 28, 35, 
37, 38 
pTDP43 
inclusions 
IHC 
Spinal 
cord 
1-4, 6, 10, 
12-16 
56, 73, 90, 95, 105, 
106 
27, 30, 32,33, 
36, 38 
Motor 
cortex 
1, 2, 4-7, 
10, 12-14, 
16, 17  
44, 55, 75, 78, 86, 96 
18, 19, 22, 23, 
35, 38 
DPR inclusions IHC 
Motor 
cortex 
4, 5, 13, 14, 
16, 17 
N/A N/A 
PLP vs. MBP 
(and other 
proteins) 
Western 
blot 
Spinal 
cord 
4, 13, 14, 
16 
44, 55, 58, 96 20, 27, 35, 38 
PLP vs. MBP 
(and other 
mRNAs) 
qPCR 
Spinal 
cord 
6, 13, 14, 
16, 17 
44, 55, 58, 61, 64, 
91, 96 
20, 35, 38 
PLP vs. MBP IHC 
Spinal 
cord 
1-4, 6, 10-
16 
56, 73, 90, 95, 105, 
106 
27, 30, 33, 35, 
36, 38 
Motor 
cortex 
1, 2, 4-7, 
10-17 
44, 55, 58, 86, 90, 96 
19, 22, 23, 27, 
35, 38 
Axonal density 
(SMI31) 
IHC 
Spinal 
cord 
1-4, 6, 10-
12, 14-16 
56, 73, 90, 105, 106 
27, 30, 33, 35, 
36, 38 
hnRNP-A2 IHC 
Spinal 
cord 
1-4, 6, 10-
16 
44, 56, 58, 73, 81, 
90, 95, 99, 101, 106 
27, 30, 33, 35, 
36, 38 
Motor 
cortex 
2, 4-7, 10-
17 
44, 55, 56, 58, 86, 
88-90, 96 
19, 22, 27, 30, 
35, 38 
OPC (MAP2-13) IHC 
Spinal 
cord 
1-4, 6, 10-
16 
44, 56, 58, 73, 81, 
95, 101, 105, 106 
27, 30, 33, 35, 
36, 38 
Motor 
cortex 
2, 4-7, 10-
17 
44, 55, 56, 58, 86, 
88-90, 96 
19, 22, 27, 35, 
38 
Table 3.3: List of post mortem cases used for each experiment. Case numbers 
correspond to the patients on table 2.2. 
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3.3 Quantification of the p62-positive cytoplasmic inclusions 
Immunohistochemistry was performed for p62 for a large number of slides of 
human spinal cord, and motor and frontal cortices prior to this study. p62 is a 
well-characterised constituent of the ubiquitylated inclusion bodies which are a 
pathological feature of ALS (Neumann et al., 2006). Anterior frontal cortex 
sections were also quantified, as a representative extra-motor region which often 
shows pathological involvement in ALS (Brettschneider et al., 2013). 
The total number of glial (figure 3.1.2A) and neuronal (figure 3.1.2B) p62-
positive inclusions were counted in the ventral horns and lateral corticospinal 
tracts of cervical spinal cord sections. Inclusions were also counted in 10 fields 
with a ×20 objective in layer V of the motor cortex –the neurones in this layer 
project their axons to the corticospinal tracts- and in white matter underlying the 
frontal and motor cortices. No difference was found between the density of 
inclusions counted in males and females (p ≥ 0.1506), so both sexes were pooled 
for subsequent analyses. 
None of the data was normally distributed (Shapiro-Wilk normality test all 
p<0.05). Thus, differences between the three experimental groups were analysed 
using the Kruskal-Wallis (Kruskal-Wallis) test followed by post hoc Mann-
Whitney U tests with a Bonferroni-Holm correction (only corrected p-values are 
shown henceforth). Kruskal-Wallis tests always have 2 degrees of freedom in 
these analyses. 
3.3.1 C9ALS presents with a distinct glial p62-positive cytoplasmic 
protein inclusions pathology in the cortex, but not in the spinal cord 
There were significant intergroup differences for glial inclusion counts in the grey 
matter and underlying white matter of both motor cortex (grey matter: 2=29.42, 
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p= 4.08 × 10-7, figure 3.1.1E; white matter: 2= 15.17, figure 3.1.1F) and 
prefrontal cortex (grey matter: 2= 37.56, p= 6.96 × 10-9, figure 3.1.1H; white 
matter: 2= 16.88, p=2.16 × 10-4, figure 3.1.1I),  in the lateral corticospinal tracts 
of the spinal cord (2= 12.31, p=0.00213, figure 3.1.1C), and in the spinal cord 
ventral horns (2= 8.749, p= 0.0125, figure 3.1.1B).  
Post hoc tests for both the precentral gyrus revealed a greater number of glial 
inclusions in both ALS cohorts compared to controls, and increased pathology in 
C9ALS cases compared to sALS cases. This was found for both the grey matter 
(C9ALS vs controls: W=0, p= 0.00474; C9ALS vs sALS: W=54.5, p=9.02 × 10-07; 
sALS vs controls: W=222, p=0.00481, figure 3.1.1E) and white matter (C9ALS 
vs controls: W=5, p=0.0201; C9ALS vs sALS: W=180.5, p=0.00235; sALS vs 
controls: W=221.5, p=0.00465, figure 3.1.1F). 
Post hoc tests for the anterior frontal cortex gave the same pattern to the motor 
cortex in the grey matter (C9ALS vs controls W=96, p=0.00121; C9ALS vs sALS 
W=869.5, p=6.894 × 10-8; sALS vs controls: W=66, p=0.0310, figure 3.1.1H) 
and the underlying white matter (C9ALS vs controls W=92.5, p=0.00307; C9ALS 
vs sALS W=692, p=0.00403; sALS vs controls: W=310, p= 0.00652, figure 
3.1.1I). 
Post hoc Mann-Whitney U tests for the spinal cord revealed greater numbers of 
glial inclusions in both C9ALS and sALS cases compared to controls in both the 
ventral horns (controls vs C9ALS: W=101.5, p=0.00394; controls vs sALS: 
W=222.5, 
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Figure 3.1.1: Quantification of the p62-positive inclusion pathology in 
C9ALS, sALS, and controls. Neuronal inclusion pathology is consistently 
greater in C9ALS in the spinal cord ventral horns (A), motor cortex (D) and 
frontal cortex (G). The amount of glial pathology is larger in ALS than in controls 
in the motor and frontal cortices (E, H), and the associated subcortical white 
matter (F, I), but C9ALS cases bear greater pathology in the same areas. In the 
spinal cord, both ALS cohorts show more inclusions than controls, but no 
differences can be seen between them (B, C).  *p<0.05, **p<0.01, ***p<0.001 by 
Mann-Whitney U test. 
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Figure 3.1.2: Representative images of p62-positive cytoplasmic 
inclusions. On the top image (A), a glial p62-positive cytoplasmic inclusion 
(arrow) is shown in the dorsolateral motor tract of a C9ALS patient’s FFPE spinal 
cord section. The bottom image (B) is a photograph of the motor cortex (layer V 
in a FFPE section) showing two neuronal p62-positive cytoplasmic inclusions 
(arrows). 
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p=0.0319, figure 3.1.1B) and the corticospinal tracts (controls vs. C9ALS: W=0, 
p=0.00369; controls vs. sALS: W=18, p=0.00904, figure 3.1.1C). 
 
3.3.2 C9ALS cases show increased counts for neuronal p62-positive 
cytoplasmic inclusions in both the motor cortex and the spinal cord 
Neuronal inclusion pathology was assessed to investigate how this related to the 
glial pathology seen. For neuronal inclusion counts, there were significant 
intergroup differences in all three CNS regions (spinal cord: 2= 26.31, p= 1.937 
× 10-6, figure 3.1.1A; motor cortex: 2= 29.67, p= 3.60 × 10-7, figure 3.1.1D; 
frontal cortex: 2= 51.0, p= 8.25 × 10-12, figure 3.1.1G).   
Post hoc Mann-Whitney U tests for the spinal cord revealed greater numbers of 
neuronal inclusions in the ventral horns in both C9ALS and sALS cases compared 
to controls (C9ALS vs controls: W=77.5, p= 1.92 × 10-4; sALS vs controls: W=195, 
p=2.81 × 10-4, figure 3.1.1A) and significantly greater numbers of neuronal 
inclusions in C9ALS compared to sALS (W=579.5, p= 3.34 × 10-5, figure 3.1.1A).  
Post hoc Mann-Whitney U tests for the motor cortex showed that the number of 
neuronal inclusions in the C9ALS group was significantly higher than in the 
controls (W=0.5, p=0.00137, figure 3.1.1D) and sALS groups (W=49, p=2.45 × 
10-07, figure 3.1.1D).  There was no difference between controls and sALS cases 
(p=0.0902). The prefrontal cortex showed the same pattern as the motor cortex: 
the number of neuronal inclusions in the C9ALS group was significantly higher 
than in the controls (W=96, p=0.000168, figure 3.1.1G) and sALS groups 
(W=905.5, p=1.16 × 10-11, figure 3.1.1G). There was no difference between 
controls and sALS cases (p=0.0949). 
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3.3.3 Summary of glial and neuronal inclusion counts 
In summary, p62-positive glial pathology was greater in both C9ALS and sALS 
than controls in the lateral corticospinal tracts and the ventral horns of the spinal 
cord, and both cortical areas and the subjacent white matter. C9ALS cases had 
significantly more glial pathology than sALS cases in the cortical and subcortical 
regions. 
The C9ALS cases had a greater burden of neuronal p62-positive inclusion 
pathology than both controls and sALS cases in all three regions. As expected, 
sALS cases also had more neuronal pathology than controls in the spinal cord 
ventral horns.   
3.3.4 C9ALS cases show different patterns of p62-positive inclusion 
pathological dependency when compared to sALS cases 
It was next sought to determine whether there was a relationship between the 
levels of p62-positive inclusion pathology shown within CNS regions in both 
C9ALS and sALS cases. Firstly, the relationship between neuronal and glial 
inclusions within the three CNS regions (spinal cord, motor cortex and anterior 
frontal cortex) was studied using Kendall correlation tests. The results of this 
study are presented in table 3.4 and figures 3.2 and 3.3. 
Analysis of the spinal cord inclusion counts in C9ALS cases consistently revealed 
positive correlations between neuronal and glial inclusion pathology and between 
both anterior horn and corticospinal tract glial inclusion counts (figure 3.2A-C). 
However, sALS cases only showed a significant relationship between grey matter 
and white matter glial cell counts, but no relationship was found between motor 
neurone and glial inclusions (figure 3.3A-C). 
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Evaluation of the motor cortex glial inclusion counts again showed a significant 
correlation between the counts in grey matter and white matter in both disease 
groups (figure 3.2F and figure 3.3F). For the sALS cases, there was a 
significant correlation between neuronal and glial inclusions in both the white 
and grey matter (figure 3.3D,E). In contrast, neuronal inclusion pathology was 
not correlated with glial pathology in the motor cortex of C9ALS cases (figure 
3.2D,E). 
The anterior frontal cortex, as with the spinal cord and motor cortex, showed 
positive correlations for the white and grey matter glial inclusion pathology in 
both C9ALS and sALS cases (figure 3.2I and figure 3.3I). The neuronal 
pathology in the frontal cortex of both C9ALS and sALS groups was positively 
correlated with glial pathology in the grey matter (figure 3.2G and figure 3.3G) 
but not in the white matter (figure 3.2H and figure 3.3H).  
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Area Tested variables z p Tau 
C9orf72 ALS 
 
SC neuronal vs. SC glial GM* 1.985 0.04714 0.369761 
SC neuronal vs. SC glial WM** 2.8277 0.004689 0.5480769 
SC glial GM vs. SC glial WM** 2.9729 0.00295 0.5741693 
 
MCx neuronal vs. MCx glial GM 0.5457 0.5853 0.1057741 
MCx neuronal vs. MCx glial WM 0.9449 0.3447 0.184466 
MCx glial GM vs. MCx glial WM* 2.2324 0.02559 0.4327123 
 
FCx neuronal vs. FCx glial GM** 2.8873 0.003886 0.5378341 
FCx neuronal vs. FCx glial WM 1.5453 0.1223 0.293147 
FCx glial GM vs. FCx glial WM** 2.9938 0.002755 0.5642881 
 
MCx neuronal vs. SC glial WM -0.2745 0.7837 -0.05555556 
MCx glial GM vs. SC glial WM -0.4386 0.6609 -0.08839914 
MCx glial WM vs. SC glial WM -0.11 0.9124 -0.02234672 
Sporadic ALS 
 
SC neuronal vs. SC glial GM 1.8917 0.05854 0.2111265 
SC neuronal vs. SC glial WM 1.8934 0.05831 0.214516 
SC glial GM vs. SC glial WM*** 5.9384 2.878 × 10-9 0.6601866 
 
MCx neuronal vs. MCx glial GM*** 4.0755 4.591 × 10-5 0.4491098 
MCx neuronal vs. MCx glial WM*** 3.3018 9.605 × 10-4 0.3677013 
MCx glial GM vs. MCx glial WM** 2.6521 0.007999 0.2733926 
 
FCx neuronal vs. FCx glial GM*** 3.3799 7.252 × 10-4 0.3792862 
FCx neuronal vs. FCx glial WM 1.1753 0.2399 0.1342031 
FCx glial GM vs. FCx glial WM*** 3.9674 7.265 × 10-5 0.414105 
 
MCx neuronal vs. SC glial WM 1.7054 0.08812 0.225486 
MCx glial GM vs. SC glial WM* 2.1912 0.02843 0.2724669 
MCx glial WM vs. SC glial WM 0.5139 0.6073 0.06439714 
Table 3.4: Correlations between p62-positive inclusion pathology of different 
areas. SC=spinal cord, MCx=motor cortex, FCx=frontal cortex, GM=layer V of the grey matter 
(for MCx and FCx) or ventral horns (for SC), WM=white matter under the cortex (for MCx and 
FCx) or corticospinal motor tracts (for SC). p, tau statistic, and z values calculated using the 
Kendall tau rank correlation coefficient. *p<0.05, **p<0.01, ***p<0.001. 
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Cell 
populations 
Interpretation of results 
C9orf72 ALS 
Neuronal vs. 
grey matter 
glia 
A positive correlation exists between the p62-positive pathology of the 
ventral horn motor neurones and that of the surrounding glia in the grey 
matter, suggesting that a common factor is affecting all cell types equally. A 
similar result was seen in the prefrontal cortex, but not in the motor cortex. 
This could mean that the pathology in the precentral gyrus of C9ALS cases has 
a different origin for neuronal and glial cells. 
Neuronal vs. 
white 
matter glia 
No correlations could be found between these in the examined cortical areas, 
meaning that neuronal and subcortical glial (myelinating the proximal part of 
their axons) pathologies occur independently of each other, maybe because 
of different origins. However, a positive correlation was found between 
ventral horn neurone pathology and that of the glia in the descending 
dorsolateral motor tracts of the spinal cord. This suggests that the pathology 
levels of the glia supporting the axons of the upper motor neurones could 
directly affect lower motor neurone degeneration or vice versa. 
White 
matter vs. 
grey matter 
glia 
The levels of pathology between glia in the grey and the white matter 
correlated in all the studied areas, probably meaning that there is a common 
factor that causes all glia in a given area to degenerate. 
Cortical vs. 
spinal cord 
No relationship could be seen between the pathology levels seen in the 
precentral gyrus and those of the supporting glia in the spinal cord motor 
tracts, meaning that they might happen independently of each other. 
Sporadic ALS 
Neuronal vs. 
grey matter 
glia 
Sporadic cases show positive correlations between cortical neuronal 
pathology and that of the surrounding glia. Most of these cases have no p62-
related pathology in the cerebral cortex, but where it can be found, it affects 
neurones and glia at the same level. However, the ventral horns show no 
correlation between motor neurone and glial pathologies unlike C9ALS cases, 
where glial pathology is more common. 
Neuronal vs. 
white 
matter glia 
Amongst the studied areas, only the precentral gyrus of sALS cases shows a 
correlation between pyramidal neurone pathology and that of the proximal 
glia in the white matter below. Added to the above, these results might 
indicate that the motor pathways of the few sALS cases with high pathology 
in this area share a common affection between neurones and glia. 
White 
matter vs. 
grey matter 
glia 
As seen in the C9ALS cases, the levels of glial pathology correlate within each 
of the three studied areas. It seems that what affects glial degeneration in a 
particular area does not distinguish grey matter from white matter glia and all 
are affected in the cases where pathology is present. 
Cortical vs. 
spinal cord 
The only correlation that reached significance was that between motor 
cortical glia and the supporting glia in the dorsolateral motor tracts of the 
spinal cord. As the latter did not correlate with the white matter glia under 
the motor cortex too, it is hard to find a logical reason for this correlation, 
which might be a false positive. 
Table 3.5: Interpretation of the correlation data for p62-positive 
pathology. 
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Figure 3.2: Pathological correlations in C9ALS. Significant correlations 
were observed in the spinal cord between glial p62 inclusion pathology in the 
ventral horns and the corticospinal tracts, and that on ventral horn neurones (A, 
B). The pathology found between those glial cells themselves also significantly 
correlated (C). Only glial cell pathology significantly correlates in the motor 
cortex, between that on the grey matter and that on the underlying white matter 
(F). The same is seen in the frontal cortex (I), where neuronal inclusion pathology 
also correlates with grey matter glial pathology. No correlation is seen between 
the pathology in the motor cortex and that observed in the corticospinal tracts. 
*/**p < 0.05/0.01. p values calculated using the Kendall tau rank correlation 
coefficient. The shadowed area shows the 95% confidence interval.  
145 
 
 
 
Continues on the next page  
146 
 
 
Figure 3.3: Pathological correlations in sALS. Glial p62 inclusion 
pathology in the ventral horns of the spinal cord correlates with that found in the 
corticospinal tracts (C), but none of the pathology on those areas correlates with 
ventral horn neuronal pathology. Conversely, motor cortex neuronal pathology is 
correlated to glial pathology in the neighbouring grey matter (D) and in the 
subcortical white matter (E). However, glial pathology in the motor cortex and 
the underlying white matter do not show a correlation (F). In the frontal cortex, 
neuronal pathology is correlated to grey matter glial pathology (G), but not to that 
in the white matter (H). Glial pathology in these two locations correlates 
significantly (I). Only a weak significant correlation was found when comparing 
grey matter glial pathology in the motor cortex with corticospinal pathology (K), 
but no relationship in pathology between these areas was generally found (J, L). 
*/**/***p < 0.05/0.01/0.001. p values calculated using the Kendall tau rank 
correlation coefficient. The shadowed area shows the 95% confidence interval.  
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Thus, overall, for the spinal cord, motor cortex and frontal cortex glial pathology, 
there was a correlation in both groups between the grey and white matter within 
each region.  The relationship between neuronal and glial pathology within these 
regions is more complex: for the spinal cord, a relationship between neuronal and 
glial pathology was seen only in the C9ALS but not sALS cases in spite of greater 
statistical power in the latter group.  However, for the anterior frontal and motor 
cortices, the sALS cases showed positive correlations between neuronal and grey 
matter glial pathology.  This was not seen in C9ALS cases potentially due to less 
statistical power or due to more than one type of p62-positive protein pathology 
caused by expanded C9orf72 mRNA. 
We also investigated the relationships between pathology levels in different CNS 
regions (figure 3.2J-L and figure 3.3J-L). Firstly, we examined whether there 
was a relationship between inclusion pathology present in motor cortex neurones 
and the glia that support their axons in the spinal cord dorsolateral spinal tracts. 
Secondly, we investigated whether there was a relationship between the inclusion 
counts in glia of those dorsolateral spinal tracts and the glial pathology in the 
motor cortex grey matter or white matter. There was very little evidence for any 
of these relationships save for a correlation between the number of layer V glial 
inclusions in motor cortex and corticospinal glial inclusions in the spinal cord of 
sALS but not C9ALS cases (p=0.02843, tau=0.2724, z=2.1912). In general, glial 
pathology levels showed greater correlations within CNS regions than between 
them, indicating that the p62-related pathology burden in the 2 different motor 
areas is independent of each other. 
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3.3.5 Relationship of p62-positive inclusion pathology to disease 
severity 
We wished to assess the possibility that the different levels of glial p62-positive 
inclusion pathology found above were related to the progression of the illness or 
to the different age of the patients at death. To assess this, correlation tests were 
performed between the levels of pathology found in each area, and the duration 
of the disease and the age at death. 
No correlations were found between glial p62-positive inclusions and the 
duration of the disease (p ≥ 0.08912, tau=-0.145, z=-1.7001) or the age at death 
(p ≥ 0.2593, tau=-0.1158, z=-1.1279) in any of the studied areas in either disease 
group. 
3.3.6 Summary of p62 findings 
 
At this point, a specific, more severe glial p62-related pathology has been defined 
for our cohort of C9ALS cases, especially in the cortical areas. Additionally, even 
though the spinal cord glial pathology levels do not differ between sALS and 
C9ALS, only the latter shows a significant dependency of that pathology and that 
of the motor neurones in the ventral horns. Although the morphology of the 
affected glial cells indicates they are likely to be oligodendrocytes, it was 
necessary to show the co-localisation of oligodendroglial markers and the 
observed p62-positive inclusions. This was attempted and is explained in the next 
section. 
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3.4 Optimisation of oligodendrocyte specific protein + p62 
immunohistochemistry in CNS tissue 
After counting the inclusions in the sections stained with the anti-p62 antibody, 
the next step was to determine which type of glial cell (oligodendrocytes, 
astrocytes or microglia) contained the inclusions in C9ALS and sporadic cases. 
Morphologically, it appeared that the affected cells were mainly oligodendrocytes. 
However, double staining techniques were used to label both p62 and one of 
either oligodendrocytes, astrocytes or microglia in order to confirm the affected 
cell types. 
In the CNS, oligodendrocyte specific protein (OSP) is specifically produced by 
oligodendrocytes (Bronstein et al., 1997). For this reason, an antibody which 
specifically binds to this protein was thought to be a good option for double 
staining with p62. Other classic markers of oligodendrocytes such as the 
transcription factors SOX-10 or OLIG2 had either not been trialled or had been 
unsuccessfully trialled respectively in our laboratories, whereas an optimised 
working protocol for OSP existed, which made it preferable for this project. Our 
laboratory also has a well-established method to label p62 with 3,3'-
diaminobenzidine (DAB), so a method which stained OSP in a contrasting colour 
was sought. 
3.4.1 OSP single-staining IHC 
Firstly, the anti-OSP 53041 antibody (Abcam) was trialled because it had already 
been successfully used in our laboratories. This antibody is raised against the full-
length OSP protein. The first step was to repeat the standard IHC protocol using 
the 53041 antibody, using several dilutions within the range recommended by the 
manufacturer, and the peroxidase-red chromogen: the tissue showed a level of 
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background staining that was too high for oligodendrocytes to be identified 
(figure 3.4A). The next approach was to try a rapid protocol that we had used 
successfully in the past, using the peroxidase (figures 3.4B) and phosphatase 
red chromogens (figure 3.4C). It was found that both similarly gave excessive 
levels of background staining.  
As the last approach for this antibody, formalin-fixed, paraffin-embedded tissue 
was stained with multiple dilutions of the 53041 antibody, within the range 
recommended by the supplier, and the peroxidase-red chromogen. Figure 3.4D 
shows a representative example of how fixed tissue appeared after this treatment: 
an intricate web of processes was seen in grey matter, whereas white matter 
showed another extremely unclear pattern which consisted of a large amount of 
processes and cell bodies (not shown).  
The next step was to try a different anti-OSP antibody (7474). This antibody is 
raised against the 15 C-terminal amino acids of the OSP protein. A rapid staining 
protocol was applied to frozen brain tissue, using a high concentration of primary 
antibody (1:10) and DAB (the existing protocol for this antibody). Many 
positively-stained oligodendrocytes were visible, which suggested the antibody 
worked well for IHC (figure 3.4E). Since this method showed that the anti-OSP 
7474 antibody stained oligodendrocytes effectively, a standard, non-rapid, IHC 
protocol was performed on frozen tissue, using different dilutions of primary 
antibody (1:50/100/200/500/1000), and the alkaline phosphatase (AP)-Red 
chromogen. This method did not show the same oligodendrocyte staining pattern, 
staining mainly the blood vessels, due to the endogenous phosphatase activity 
within vessels, as well as a very small number of oligodendrocytes (figure 3.4F). 
It was hypothesised that the AP kit did not work well with this antibody, so a 
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peroxidase-based red chromogen was tried in a standard IHC protocol using 
frozen CNS tissue, which showed the same staining pattern (figure 3.4G).  
The above protocols did not allow the identification of individual 
oligodendrocytes, so the next step was to try the 7474 antibody with a rapid 
staining protocol, using the three different chromogens: the two red ones, and 
DAB as a positive control. All three methods gave clear labelling of individual 
oligodendrocytes, but the AP-red chromogen (figure 3.4H) was chosen to use 
in further experiments since the peroxidase-red condition (figure 3.4I) had a 
colour closer to that produced by DAB (figure 3.4E), which would lead to less 
contrast when performing the double-staining experiments. 
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Figure 3.4: Anti-OSP antibody optimisation. A, B, C: Anti-OSP 53041 
antibody produces too much background staining for any individual 
oligodendrocyte to be identified, whether standard peroxidase-red (A), rapid 
peroxidase-red (B), or rapid AP-red (C) staining is used. D: Anti-OSP 53041 
antibody labels oligodendrocyte processes in formalin-fixed, paraffin-embedded 
tissue, which does not allow for the identification of individual oligodendrocytes. 
E: The rapid DAB (brown) staining protocol with the anti-OSP 7474 antibody 
confirms it labels oligodendrocytes in frozen tissue. F, G: Standard AP-red (light 
red) and peroxidase-red (darker red) staining with the anti-OSP 7474 antibody 
labels few oligodendrocytes in frozen tissue. H, I: Rapid AP-red and rapid 
peroxidase-red protocols worked well with the anti-OSP 7474 antibody, but the 
rapid AP-red protocol was chosen for double staining because the colour it 
provides contrasts better with the one DAB provides. Black arrows point toward 
positively stained oligodendrocytes. The scale bars represent 50 µm. 
All these images were taken from frozen precentral gyrus sections coming from 
the same block. D shows layer V of the cortex, while the rest show the underlying 
white matter.  
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3.4.2 OSP + p62 double-staining IHC 
Since the rapid IHC protocol had worked for both anti-p62 and anti-OSP 7474 
antibodies individually, this was the first approach taken toward double staining 
of frozen tissue sections, using a 1:10 dilution for each primary antibody. A case 
with a high degree of p62 pathology was chosen to test the technique since it 
should show a large number of p62-positive inclusions. p62 DAB IHC was 
performed before OSP AP-red IHC, and the resultant staining can be seen in 
figure 3.5A. No traces of red OSP staining could be found, and while some of 
the brown staining had the appearance of standard inclusions, others resembled 
the oligodendroglial staining seen in figure 3.4I. It was decided that the 
experiment would be repeated following the double-staining standard protocol, 
starting with a rapid OSP AP-red IHC (1:10 dilution) followed by a standard p62 
DAB incubation (1:100 dilution) overnight –thus, reversing the order of the 
antibody incubations. In figure 3.5B it can be appreciated that the result of this 
was the opposite of what happened before: lots of red-labelled oligodendrocytes 
could be seen, but no inclusions were visualised. The same procedure was tried, 
but the order in which the primary antibodies were applied was reversed, leading 
to sections in which there appeared to be some positively-stained 
oligodendrocytes, but these appeared in an unusual red/brown colour (figure 
3.5C). It was hypothesised that this could be caused by cross-reactivity between 
staining steps, which was initially thought to be unlikely because a 15 min avidin 
& biotin-blocking step was always done in between both IHC steps. Thus, the 
avidin-biotin complex added in the first IHC should not interact with the 
chromogen added in the second step. Therefore, the avidin & biotin-blocking step 
was increased to 30 min, to reduce cross-reactivity. This rendered sections in 
which OSP again seemed to be labelled by DAB in brown, but this time, a few red 
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dots could be appreciated, unlike before (figure 3.5D,E). This looked promising, 
so the same approach was tried (30 min avidin & biotin block), but with reversal 
of the order of the IHC steps again, doing OSP IHC before p62. The resulting 
sections (figure 3.5F) still showed the unusual red/brown colour, but a few 
oligodendrocytes were apparent with a redder colour than in the previous 
experiments, although the staining obtained was not enough to differentiate 
oligodendrocytes from inclusions, so a different approach was needed. 
In summary, attempts of the double labelling of OSP and p62 with Vector Red 
and DAB resulted in a likely cross-staining which did not allow distinguishing 
between oligodendrocytes and inclusions.  
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Figure 3.5: Initial optimisation of the OSP and p62 double-staining 
IHC. Representative images of the unsuccessful double-staining IHC protocols 
attempted are shown. OSP should be labelled in light red (AP-Vector red), and 
p62 should be labelled in dark brown (DAB). In all of them, speckles in colour 
between light red and brown can be seen, without the possibility of distinguishing 
OSP labelling from p62 labelling in most labelled cells. A: p62 1:10 followed by 
OSP 1:10, rapid IHC. B: OSP 1:10 rapid IHC followed by p62 1:100 standard IHC. 
C: p62 1:100 standard IHC followed by OSP 1:10 rapid IHC. D: p62 1:100 
standard IHC followed by OSP 1:10 rapid IHC, double avidin & biotin-blocking 
time. E: p62 1:200 standard IHC followed by OSP 1:10 rapid IHC, double avidin 
& biotin-blocking time. F: OSP 1:10 rapid IHC followed by p62 1:100 standard 
IHC, double avidin & biotin-blocking time. All images show subcortical 
precentral gyrus white matter from frozen tissue.  
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3.4.3 OSP fluorescent staining 
The next method attempted was to label OSP with a fluorescent marker, using an 
FITC-labelled secondary antibody, along with the traditional DAB peroxidase-
based IHC to label p62. This should show brown p62 inclusions in brightfield and 
green-fluorescent oligodendrocytes. It was first necessary to confirm the antibody 
worked using the immunofluorescence protocol, so the rapid IHC protocol was 
performed. All the tissue sections stained presented with a green granular 
background, even the negative control (figure 3.6A,B), for which no anti-OSP 
antibody was used. This was possibly caused by autofluorescence and non-
specific binding of the secondary antibody. However, the clear oligodendroglial 
staining pattern seen when using chromogenic IHC methods was not seen 
(figure 3.6C). The next step involved using Sudan black to mask 
autofluorescence. This resulted in darker sections with no visible fluorescence 
(not shown). 
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Figure 3.6: 
Unsuccessful OSP 1:10 
fluorescent IHC. A: 
Negative control for which 
no primary antibody was 
used. Green puncta were 
seen, which may represent 
autofluorescent lipofuscin 
or non-specific binding of 
the secondary antibody. B: 
Case with C9orf72 
expansions. C: Non-ALS, 
healthy control. No 
noticeable differences were 
found among the three 
tissue sections. All images 
show subcortical 
precentral gyrus white 
matter from frozen tissue.  
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3.4.4 Other attempts at double staining OSP and p62 
A series of other chromogens with high contrast were used to co-stain OSP and 
p62. These are detailed in table 3.3. The first chromogen pair was DAB for OSP 
first, then Nickel-DAB (Ni-DAB) for p62. Ni-DAB is a modified version of DAB 
that labels using black colour. This resulted in a mixed black/brown overall colour 
again, which did not allow for a clear differentiation of OSP and p62 labelling. 
After that, NovaRED for OSP, then DAB or Ni-DAB for p62 was pursued. 
NovaRED and DAB provided the clearest co-staining we had seen so far for these 
two antigens (figure 3.7), but many oligodendrocytes still showed an amalgam 
of red and black. Following that, we attempted to stain oligodendrocytes in blue 
using the Vector Blue alkaline phosphatase kit, and then p62 using DAB or Ni-
DAB. Nuclei would be stained in green using Vector Methyl green, for contrast 
with the blue colour (not shown). Neither of the two techniques provided the 
desired results, showing unclear p62 protein deposits and inconsistent 
oligodendrocyte staining. After all these failed attempts, it was decided not to 
pursue this double staining any longer, and to use another marker for 
oligodendrocytes. 
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Figure 3.7: Best attempt at double staining of OSP and p62. The black 
arrow highlights acceptable contrast in an oligodendrocyte (OSP-NovaRED) with 
a p62-positive protein deposit (p62-DAB). Staining was not generally as clear as 
this, showing oligodendrocytes with poor contrast between the two chromogens. 
This image shows subcortical precentral gyrus white matter from frozen tissue.  
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3.4.5 Nogo-A staining of oligodendrocytes 
Neurite outgrowth inhibitor (Nogo-A) is a protein which was first found to be 
expressed by neurones as an inhibitor of neurite growth during brain 
development and after axonal injuries (Chen et al., 2000). The apparition of 
mature oligodendrocytes expressing Nogo-A also impairs axonal recovery after a 
demyelinating event in the CNS. Nogo-A is expressed predominantly by 
oligodendrocytes and some neuronal subpopulations after the development of 
the brain (Kuhlmann et al., 2007, Buss et al., 2005, GrandPre et al., 2000). As it 
can be seen in those studies, Anti-Nogo-A antibodies only label differentiated 
oligodendrocytes in the white matter of the mature CNS. In the grey matter, 
oligodendrocytes can be distinguished from Nogo-A-expressing neurones due to 
the much stronger staining presented by oligodendrocytes (Kuhlmann et al., 
2007) and, in the areas studied in this analysis, due to the larger size of the motor 
neurones. 
The Nogo-A antibody (Abcam) was optimised using serial dilutions, first 
performing a microwave antigen retrieval method. This resulted in a small subset 
of oligodendrocytes being stained. Serial dilutions were also performed using a 
pressure cooker for the antigen retrieval step at either pH 6 of pH 9. It was 
decided that a dilution of 1:50 for the Nogo-A antibody and antigen retrieval using 
a pressure cooker at pH 9 were optimal for the staining of oligodendrocytes, 
presenting distinct cell bodies and low levels of non-specific background staining 
(figure 3.8A). 
The next step was to optimise the p62 antibody to work using this antigen 
retrieval method. For this, serial dilutions of the p62 antibody were used, and it 
was determined that a dilution of 1:100 worked best at pH 9. Using these 
conditions plus the Nogo-A optimal conditions, a final attempt was made for the 
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double staining of oligodendrocytes (Nogo-A-NovaRED) and inclusions (p62-
DAB). This resulted in a clear staining of inclusions, but all of them had some red 
‘aura’ surrounding them, which made it impossible to distinguish whether the 
inclusion was in an oligodendrocyte or not (figure 3.8B,C). 
After this, it was decided to stop pursuing the co-staining of oligodendrocytes and 
p62-positive inclusions because too much effort and time was put into different 
approaches that produced no results. The use of anti-Olig2 antibodies -a classic 
marker for oligodendrocytes-, to stain oligodendrocytes was not trialled due to 
the fact that nobody got it to work in our laboratories after repeated attempts. 
The next step would be explaining the protein components of the p62-positive 
inclusions using markers for proteins usually found in this kind of inclusions in 
most cases of ALS and in C9ALS specifically.  
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Figure 3.8: Nogo-
A/p62 double IHC. 
Representative images 
showing the results of 
the attempt at double 
Nogo-A/p62 staining. A: 
Single staining using 
Nogo-A antibody and 
DAB as chromogen. B, 
C: Double staining of 
Nogo-A (Vector Red) 
and p62 (DAB) using 
20× (B) and 100× (C) 
objectives respectively. 
The contrast between 
the two chromogens is 
often not completely 
clear. This lack of 
contrast allows for a 
high chance of false 
positives. All images 
show subcortical 
precentral gyrus white 
matter from fixed tissue.  
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3.5 Elucidating the components of glial p62-positive inclusions 
Next, it was decided to try to elucidate principal protein components of the glial 
p62-positive cytoplasmic inclusions. The most likely possibilities were TDP43 
and dipeptide repeats. DPR are a product of repeat-associated non-ATG-
translation of the expansion in the C9orf72 mutant mRNA. There are five possible 
DPR polypeptides from the different sense and antisense reading frames that can 
be read in the expansion: poly-AP, poly-GP, poly-GR, poly-AG, and poly-PR. The 
literature shows that most neuronal TDP43-negative inclusions in C9ALS motor 
cortex contain DPR, but glial DPR are usually not found in the grey matter or the 
white matter of these cases (Mackenzie et al., 2013). To confirm this finding in 
our cohort, the 6 C9ALS cases with the greatest number of glial inclusions in the 
precentral gyrus white matter were selected. The amount of glial DPR and 
pTDP43 inclusions present in this area was quantified using the same counting 
protocols and compared to the glial p62 inclusions. Representative inclusions can 
be seen on figure 3.9B,C. This revealed that the burden of p62 pathology was, 
on average, 3 times larger than that of pTDP43 (Mann-Whitney p=0.02472, 
W=3.5, figure 3.9A) and that the amount of glial DPR in this area is negligible 
compared to the amount of p62/TDP43-containing inclusions (figure 3.9A). 
Therefore, we confirmed previous findings that glial inclusion pathology cannot 
be explained by DPR in the precentral gyrus (Mackenzie et al., 2013) and 
additionally established that it could not be accounted for by pTDP-43 pathology. 
The sALS group, however, shows a similar amount of pTDP-43 inclusions 
compared to the total p62-positive inclusions (p=0.618, figure 3.10). 
Having established a marked excess of p62-positive inclusions in C9ALS cases in 
the precentral gyrus and the prefrontal cortex, and that this pathology could not 
be accounted for by DPR or pTDP43, we next sought to ascertain the burden   
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Figure 3.9: Quantification of glial DPR inclusions in the precentral 
gyrus white matter in C9ALS. It is evident from these results (A) that the 
inclusion pathologic inclusions in the precentral gyrus white matter do not 
contain DPR, which is negligible in this area. Post hoc tests done using the Mann-
Whitney U test, comparing the scores of p62-positive and TDP43-positive 
inclusions and each different type of DPR inclusion (indicated by the bars 
underneath). The number of p62-positive inclusions was also significantly higher 
than the number of TDP-43-positive inclusions. **p<0.01. B shows the positive 
control tissue used for the poly-GR antibody, which is representative of all the 
positive controls for the different DPR. The positive controls were cerebellar 
FFPE sections of a C9ALS case with particularly elevated levels of DPR inclusions 
in the granular layer of the cerebellum (arrows). C shows a glial poly-AP DPR 
cytoplasmic inclusion (arrow) in the subcortical white matter of a prefrontal 
gyrus FFPE section. 
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Figure 3.10: Comparison of glial TDP43 and p62-positive cytoplasmic 
inclusions in the precentral gyrus white matter in sALS. The number of 
p62–positive cytoplasmic inclusions (UCI) in the sALS group is similar to that 
of pTDP-43 cytoplasmic inclusions in this area.  
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of phosphorylated TDP43 (pTDP43) inclusions in the motor cortex and the spinal 
cord of our cohort. pTDP43 aggregation was quantified using an anti-pTDP43 
antibody (BD Transduction Laboratories) and the same counting protocols used 
for p62-positive inclusions. This was done for spinal cord and motor cortex 
sections. pTDP43-positive inclusions were also counted in sALS and control 
tissue to compare the burden of pTDP43 pathology between C9ALS and these 
groups. 
3.5.1 pTDP43 inclusions vs. p62-positive inclusions 
Two types of analyses were used to assess to which extent glial pTDP43 pathology 
was related to glial p62 pathology in C9ALS cases. Firstly, the 6 C9ALS cases from 
the study cohort harbouring the highest burden of glial p62 pathology in the white 
matter under the motor cortex were selected. 
Then, using a larger cohort (n=12), correlation tests were performed between the 
numbers of both types of glial inclusions, to ascertain whether a dependency 
could exist between them in the spinal cord or the motor cortex. No relationship 
was found in any of the studied areas (ventral horns: p=0.2743, tau=-0.2568915, 
z=-1.0932; corticospinal lateral tracts: p=0.08581, tau=-0.4036867, z=-1.7179; 
motor cortex: 0.6304, tau=0.1068733, z=0.48114; precentral gyrus white matter: 
p=0.1682, tau=0.3076923, z=1.3779). Therefore, it was concluded that p62-
positive glial inclusion pathology was mostly independent of pTDP43 glial 
pathology in the spinal cord and in the precentral gyrus. 
3.5.2 Group comparison of glial pTDP43 inclusion counts 
Having established that TDP-43 could not account for the full burden of p62-
positive glial pathology, it was none the less of interest to know if there were 
intergroup differences in the burden of TDP-43 inclusion pathology similar to 
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that seen for p62. Kruskal-Wallis tests revealed that there were inter group 
differences in glial pTDP43 inclusions were found in the grey matter (2= 6.2902, 
p=0.04306, figure 3.11E) and the underlying white matter (2= 9.1922, 
p=0.01009, figure 3.11F) in the precentral gyrus. In the spinal cord, differences 
between groups were found in the glial pTDP43 inclusion scores in the ventral 
horns (2= 9.4053, p=0.009071, figure 3.11B) and the lateral corticospinal 
tracts (2= 6.1422, p=0.04637, figure 3.11C) 
Mann-Whitney post hoc tests confirmed that the glia showed a significantly 
greater number of pTDP43 inclusions in the C9ALS group when compared to 
controls in the grey matter (W=72.5, p=0.0107, figure 3.11E) and white matter 
(W=76.5, p=0.003712, figure 3.11F) of the precentral gyrus. This difference 
between the glial scores of C9ALS and controls was also seen in the ventral horns 
(W=66, p=0.001044, figure 3.11B) and the lateral corticospinal tracts (W=61.5, 
p=0.004507, figure 3.11C) of the spinal cord. However, the sALS group did not 
show any differences in the glial pTDP43 inclusion count when compared to 
C9ALS (ventral horns: p=0.6507; corticospinal tracts: p=1; motor cortex grey 
matter: p=0.2583; precentral gyrus white matter: p=0.1457, figure 
3.11B,C,E,F) or to controls (ventral horns: p=0.1574, corticospinal tracts: 
p=0.3575, motor cortex grey matter p=0.6501, precentral gyrus white matter: 
p=0.2133, figure 3.11B,C,E,F). 
3.5.3 Group comparison of neuronal pTDP43 inclusion counts 
Kruskal-Wallis tests showed that there were intergroup differences in the 
neuronal pTDP43 score in the ventral horns (2=9.6095, p=0.008191, figure 
3.11A). Post hoc M-W tests revealed significant differences between the neuronal 
pTDP43 scores of both ALS groups and controls (C9ALS vs controls: W=3, 
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p=0.002125; sALS vs controls: W=30, p=0.02844, figure 3.11A) in the ventral 
horns. Conversely, there were no differences in the number of motor cortex 
neuronal pTDP43 inclusions amongst the three study groups (p=0.4149, figure 
3.11D). 
In summary, there seems to be a greater glial pTDP43 pathology in C9ALS cases 
compared to controls, but no significant difference between C9ALS and sALS 
cases in either area. This pattern is different from that shown by inclusions on 
p62 immunohistochemistry, in which clearly a greater pathology was seen in the 
C9ALS cohort in the precentral gyrus compared to the sALS group. This confirms 
that both ALS groups present glial pTDP43 aggregation, which could potentially 
affect the processing and transport of certain mRNA molecules in 
oligodendrocytes.  
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Figure 3.11: Scoring of cytoplasmic pTDP43 aggregates. A-C: neuronal 
and glial pTDP43 inclusion counts in ventral horns (A-B) and corticospinal tracts 
(C). D-F: neuronal and glial inclusions in the motor cortex grey matter (D-E) and 
in the underlying white matter (F). G: representative examples of pTDP43 
inclusions. Both images show subcortical precentral gyrus white matter from 
fixed tissue. GM=grey matter, WM=white matter. Post hoc p-values calculated 
with the Mann-Whitney’s U test are shown. *p<0.05, **p<0.01. 
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3.6 Discussion 
3.6.1 Glial p62-positive inclusion pathology is more prevalent in the 
cortex of C9ALS and cannot be completely explained by DPR or 
pTDP43. 
Here, we present a series of quantitative pathological findings in our cohort of 
familial C9ALS and sALS cases. First, we analysed the post mortem pathology 
concerning the p62-positive cytoplasmic protein deposits (inclusions) found in 
the relevant regions of the spinal cord, precentral gyrus, and anterior prefrontal 
cortex. The results of the study show how C9ALS cases present a common glial 
and neuronal inclusion pathology in both the prefrontal lobe and the precentral 
gyrus when compared to both sALS and control cases. The sALS group also 
showed significantly more p62-positive inclusions than the controls in the same 
regions. However, no difference could be found between the ALS groups in the 
spinal cord regarding glial inclusion pathology, even though both ALS groups 
showed more glial and neuronal inclusions than the control group. This confirms 
that glial inclusions in the prefrontal cortex and the precentral gyrus is a common 
feature of the ~90% of ALS cases which are sporadic and the ~5% of C9ALS cases, 
but it is far more prevalent in C9ALS. This is consistent with previous findings 
(Cooper-Knock et al., 2012). Additionally, glial inclusion pathology in the 
corticospinal tracts and the ventral horns, which is typically composed of pTDP43 
(Neumann et al., 2006), is relevant in both types of ALS. 
Then, it was established that glial inclusion pathology in the grey matter is 
correlated with the inclusion pathology of the glia in the adjacent white matter, 
in the precentral gyrus, the spinal cord, and the anterior prefrontal cortex, for 
both sALS and C9ALS cases. A direct correlation was not found between the 
inclusion pathology in the precentral gyrus and that of the spinal cord or 
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prefrontal lobe. This suggests that glial inclusion pathology in these three areas 
occurs independently. 
The current study also confirmed that the glial inclusion pathology found in the 
precentral gyrus white matter could not be explained by C9ALS-related DPR 
protein aggregates. This supports the findings of Mackenzie et al. (2013), who 
used double labelling immunofluorescence to describe the lack of DPR inclusions 
in any of the three main types of glial cells in the grey/white matter of different 
cortical areas. Their study confirmed this, not only for C9ALS but also for cases 
harbouring the C9orf72 mutation with other disease phenotypes, such as FTD. 
The results also show that the levels of glial pTDP43 pathology found in the 
precentral gyrus of C9ALS cases, but not of sALS cases, are quantitatively smaller 
than those of glial p62-positive inclusions in the same area. This means that 
pTDP43 alone cannot fully explain p62-related pathology. Leaving the question 
as to precisely what proteins are aggregating in this cell type in C9 cases. 
Repeated attempts at double-labelling to confirm the oligodendroglial lineage of 
the cells affected by inclusions were not successful. However, p25 has recently 
been used successfully as a suitable oligodendrocyte marker for this purpose. 
According to the emerging literature, about 80-90% of the pTDP43-
immunoreactive cells in the grey matter and precentral gyrus white matter are 
oligodendrocytes (Fatima et al., 2015, Rohan et al., 2014). The consistency of an 
increased glial pTDP43 pathology in the motor cortex of our C9ALS cases 
combined with the fact that most of them are very likely localised to 
oligodendrocytes suggest that there is likely to be a particular mechanism by 
which oligodendrocytes degenerate in C9ALS as compared to sALS. 
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Neuronal pTDP43 aggregation is especially prevalent in the ventral horn 
neurones of all ALS cases, but not in the neurones populating the motor cortex. 
The high levels of p62-positive inclusion pathology combined with low levels of 
pTDP-43 pathology in the motor cortex of C9ALS cases are consistent with the 
existing literature (Troakes et al., 2012). 
In summary, the attempts to explain what the protein components of most of the 
p62-positive inclusions are by using DPR and pTDP-43 antibodies, and whether 
those inclusions co—localise with oligodendrocytes specifically, did not work as 
expected. Therefore, it was desirable to ascertain whether there was any evidence 
for mRNA transport deficiency in oligodendrocytes in the motor pathways of the 
CNS in sALS and C9ALS patients, and this was attempted in the next chapter.  
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CHAPTER 4 
Analysis of myelination and MBP mRNA transport in ALS 
4.1 Introduction 
Thus far, pathological studies have established that there is a significant burden of glial 
pathology –in the form of cytoplasmic p62-positive inclusions- in ALS and, on 
morphological grounds, this appears to affect oligodendrocytes. Specifically, this was 
observed to be most prominent in the corticospinal tracts of the spinal cord of both ALS 
groups and the white matter of the precentral gyrus of the C9ALS group. 
It was thus hypothesised that whatever causes glial p62-positive and pTDP-43 pathology 
would also affect mRNA transport, which is a key biological process in oligodendrocytes, 
which needs to transport MBP mRNA. This would, therefore, be expected to affect MBP 
expression in the corticospinal tracts in sALS and C9ALS. 
The first aim was to quantify the expression of a number of proteins related to 
myelination and axons using Western blot (figure 4.1A). To control for the degradation 
of the protein in the tissue due to post-mortem delay, an internal non-motor control area 
was included by quantifying the same proteins in the dorsal columns (somatosensory) of 
the same cases (figure 4.1B). The correlation between the relative protein amounts to 
the post-mortem delay was assessed for all the measured proteins, and none were found 
to be statistically significant (all p ≥ 0.48). Additionally, no significant differences were 
found amongst the three cohorts in terms of post mortem delay (p=0.4317). 
IHC was also performed for the same proteins to help understand whether there 
were any differences in the localisation of the expression in either C9ALS or sALS 
cases. Thus, these two techniques would complement each other, one providing 
spatial characterisation (IHC), while the other would assess the relative levels of 
expression (Western blot). 
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qPCR was also performed in order to assess overall levels of mRNA from the 
genes encoding the proteins measured using Western blot. After the total RNA 
had been purified from homogenised corticospinal dorsolateral motor tract and 
dorsal somatosensory tract samples, a quality check was performed to ensure that 
its integrity was sufficient for qPCR analysis. This was achieved by using an RNA 
electrophoresis pico-chip (figure 4.2A), which determined that the RNA 
integrity number (RIN) for the tested RNA samples was between 3.5 and 5.1 out 
of 10 (figure 4.2B). These RINs are within the acceptable range for qPCR of 
brain tissue with control genes (Koppelkamm et al., 2011). Only four random 
mRNA samples were tested for quality control as representative samples of the 
cohort. Retrospectively, all the samples should have been tested for quality 
assurance, but it was not possible anymore at the time of writing this thesis. 
The measured mRNAs were MBP and PLP (components of myelin); 
HNRNPA2B1 (splice variant that encodes hnRNP-A2) which is involved in MBP 
mRNA transport; and 18s rRNA, that was used to normalise the data. 18s rRNA 
was also used to check whether the DNA quantity was acceptable for qPCR 
(figure 4.3). One sample reached the Ct value for 18s rRNA after the 35th qPCR 
cycle and was disregarded in the statistical calculations.  
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Figure 4.1: Analysis of protein levels in spinal cord tissue. A and B 
show Western blots performed using protein extracts from the dorsal sensory 
columns and the lateral motor tracts of ALS patients and controls. They were 
conducted for neurofilament heavy chain protein, β-tubulin, hnRNP-A2, PLP, 
and MBP. This image shows bands of single membranes that were used for 
the statistical analyses shown in the next sections. The results for the control 
group have been repositioned on the left for easier interpretation. These 
results were analysed using Kruskal-Wallis tests. Where Kruskal-Wallis tests 
showed significance (p < 0.05), Mann-Whitney tests were used to compare 
the cohorts in pairs. Full-membrane images can be found in Appendix 1. 
 
 
 
 
 
Figure 4.2: Tissue-extracted RNA pico-chip electrophoresis. A 
shows the results of RNA electrophoresis using a pico-chip using the extracted 
RNA from a small subgroup of the full cohort. B shows densitometry spectra 
of the fluorescence emitted by different sizes of RNA. These four samples were 
the only samples that were analysed. With such a small number, no statistical 
methods were used to compare the RIN of the different groups. RIN=RNA 
integrity number (out of 10). [s]=RNA size. FU=Fluorescence units.
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Figure 4.3: qPCR for 18s rRNA. Representative 18s rRNA qPCR showing that 
the synthesised cDNA was sufficiently concentrated for levels to be measured 
using qPCR. To get accurate and reproducible results and in order for that RNA 
sample to be considered, Ct for 18s rRNA had to be reached before the 35th cycle. 
dR: baseline-subtracted fluorescence reading. 
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4.2 Protein transport (PLP) vs mRNA transport (MBP) 
In the introduction, it was described how MBP depends on mRNA transport, 
while PLP depends on protein transport for myelination. To measure this 
relationship, we calculated the MBP/PLP ratio and found out that in the dorsal 
columns there are no differences between the groups (Kruskal-Wallis p=0.2319, 
2=2.9231, figure 4.4A). However, the lateral corticospinal tracts of C9ALS 
cases presented a 4-fold difference in the MBP/PLP ratio compared to controls 
(Kruskal-Wallis p=0.0132, 2=8.6538; C9ALS vs controls: p=0.0285, W=0, 
figure 4.4B), as hypothesised. Just a 2-fold drop in the MBP/PLP ratio was 
found in sALS cases (sALS vs controls: p=0.0285, W=1, figure 4.4B), which was 
significantly higher than in the C9ALS group (p=0.0285, W=1, figure 4.4B). 
One possible cause of the lower MBP/PLP protein ratios shown by the Western 
blot in ALS cohorts could be a reduction in the amount of MBP mRNA or an 
increase in the amount of PLP mRNA rather than issues pertaining to mRNA 
transport per se.  
The ratio of [MBP mRNA]/[PLP1 mRNA] was measured using qPCR to establish 
if there was a difference in their transcription. No differences were found in the 
regions analysed (Kruskal-Wallis corticospinal tracts: p=0.484, 2=0.0638, 
figure 4.4D; dorsal columns: p=0.601, 2=1.01, figure 4.4C). 
Using immunohistochemistry for MBP and PLP on blocks of motor cortex and 
spinal cord from control, C9ALS, and sALS cases, the ratio of area stained for 
MBP to that stained for PLP was then calculated. The idea was to see whether the 
effects observed using Western blot could be replicated using a less labor-intense 
technique such as IHC, even though IHC was less likely to have the same 
sensitivity than Western blot for this matter. Images from the precentral gyrus 
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white matter and from the lateral corticospinal tracts were captured, and using 
an image analysis method involving colour deconvolution, the percentage of the 
image that was positive for MBP or PLP was quantified. 
It can be observed in figure 4.5C, D, that the percentage area stained for MBP was very 
similar to the percentage area stained for PLP in both the lateral corticospinal tracts 
(Kruskal-Wallis p=0.8557, 2=0.31167, figure 4.5C) and the precentral gyrus white 
matter (Kruskal-Wallis p=0.6642, 2=0.81833, figure 4.5D) for all groups.  
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Figure 4.4: Intergroup comparison of MBP protein and mRNA levels 
normalised to PLP. The MBP/PLP protein ratio (assessed by Western blot) did 
not vary between any groups in the dorsal sensory tracts of the spinal cord (A), 
while the C9ALS group presented a dramatic decrease of this ratio in the 
dorsolateral motor tracts (B). At the mRNA level (assessed by qPCR), none of the 
groups showed a significant difference in the MBP/PLP ratio in any of the two 
regions (C and D). *p < 0.05. 
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Figure 4.5: Relationship between MBP- and PLP-stained areas. A 
(p=0.8557, 2=0.31167) and B (p=0.6642, 2=0.81833) show there are no 
differences amongst groups in the MBP/PLP ratio regarding the stained areas in 
either region using IHC.   
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4.3 Analysis of MBP and PLP in the precentral gyrus and the spinal 
cord. 
To further elucidate the MBP/PLP protein ratio alterations seen in C9ALS, the 
expression of MBP and PLP were analysed separately across the study groups. 
After normalising MBP levels using β-tubulin, a Kruskal-Wallis test indicated 
differences amongst the groups for the amount of MBP in both the corticospinal 
motor tracts (2=6.04, p=0.0488, figure 4.6B) and the dorsal columns (2=6.5, 
p=0.0388, figure 4.6A). A consistent greater than 50% reduction in the total 
amount of MBP was found in the corticospinal tracts of the C9ALS cases (W=0, 
p=0.0286, figure 4.6B). Both the C9ALS and sALS groups showed a significant 
~40% reduction in the dorsal column MBP compared to controls (C9ALS vs. 
controls: W=1, p=0.0310; sALS vs. controls: W=0, p=0.0429, figure 4.6A). No 
statistical difference was found between sALS and controls in the dorsolateral 
motor tracts or between the two ALS groups in either area (p ≥ 0.343, figure 
4.6A,B). 
Regarding PLP expression, it was not found reduced in the corticospinal tracts of 
the ALS cohorts (Kruskal-Wallis p=0.06904, 2=5.35, figure 4.6D). However, 
it was surprising to find that the total amount of PLP in both ALS groups was 
reduced by about a half when compared to the control group in the dorsal 
columns (Kruskal-Wallis p=0.00971, 2=9.27; C9ALS vs controls: p=0.0286, 
W=0; sALS vs controls: p=0.0286, W=0, figure 4.6C). 
The above results indicate that both MBP and PLP are affected in the dorsal 
columns of ALS patients, while only MBP is affected in the corticospinal tracts. 
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Regarding the mRNA levels, no differences were found between the groups after 
quantifying MBP or PLP1 mRNA in either the corticospinal motor tracts (all p ≥ 
0.351, figures 4.6E-H). 
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Figure 4.6: 
Expression of 
MBP and PLP 
proteins and 
mRNAs in the 
dorsolateral 
motor tract and 
the dorsal 
sensory column. 
MBP and PLP levels 
were lower for both 
ALS groups in the 
sensory columns 
(A, C), but only 
C9ALS presents 
with lower MBP 
levels in the motor 
tract (B) and 
normal PLP levels 
(D). No changes 
were seen for MBP 
or PLP mRNA 
levels (E-H). 
*p<0.05.
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4.4 MBP and oligodendroglial pathology vs axonal density in the 
corticospinal tracts 
We hypothesised that oligodendrocyte dysfunction precedes and causes axonal 
degeneration in C9ALS, due to impairment of MBP mRNA transport and thus 
myelination. However, the possibility of MBP expression being affected by 
reduced axonal density could not be disregarded. A way to normalise the 
myelination data is therefore needed so that it reflects whether myelination levels 
in the examined tissue could have been caused by axonal loss. The SMI31 
antibody was used to stain phosphorylated neurofilament protein and thereby 
visualise axons in spinal cord sections. The axonal density was assessed in the 
lateral corticospinal tracts in controls, sALS, and C9ALS cases. 
A Kruskal-Wallis test showed no significant intergroup differences in axonal 
density in the dorsolateral motor tracts (p=0.121, figure 4.7) between control, 
C9ALS and sALS cases. However, a significant negative correlation was found 
between the number of p62-positive glial inclusions and the pooled axonal 
densities (p=0.00815, z= -2.65, tau= -0.399, figure 4.8). This indicates that 
axonal loss in the lateral corticospinal tracts could be associated with the glial 
pathology found in that area. However, the causal relationship remains to be 
elucidated - axons may degenerate due to the lack of oligodendroglial support, or 
oligodendroglia may be affected if axons degenerate. 
Using Western blot, Kruskal-Wallis tests showed intergroup differences in the 
MBP/Neurofilament ratio in both the lateral corticospinal tracts (2=9.27, 
p=0.00971, figure 4.9B) and the somatosensory dorsal columns (2=7.539, 
p=0.0231, figure 4.9A). We found that in both C9ALS and sALS cases, this ratio 
was reduced to about 25-50% of that found in controls in both the corticospinal 
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motor tracts (C9ALS vs. controls: W=0, p=0.0286; sALS vs. controls: W=0, 
p=0.0286, figure 4.9B) and the dorsal columns (C9ALS vs. controls: W=0, 
p=0.0286; sALS vs. controls: W=0, p=0.0286, figure 4.9A). Moreover, C9ALS 
cases showed a significant ~50% reduction in the MBP/Neurofilament ratio 
compared to the sALS cohort in the corticospinal tracts (C9ALS vs sALS: W=1, 
p=0.0286, figure 4.9B) However, as was seen using immunohistochemistry, the 
amount of neurofilament protein was not reduced in either area for the ALS 
cohorts (dorsal columns: 2=5.81, p=0.0548, figure 4.9D; corticospinal tracts: 
2=2.42, p=0.298, figure 4.9C). 
Thus, the evidence from both immunohistochemistry and Western blotting implies that 
ALS cases do not show axonal loss in the corticospinal tracts at the level of the cervical 
cord to anywhere near the degree seen for loss of MBP. As the myelin loss is 
disproportionately greater than any axonal loss (indeed, the latter was not detectable by 
our measures), this implies that the myelin loss is not secondary to axonal degeneration 
in this area. It would be of interest to replicate the experiment using lumbar sections of 
the spinal cord to elucidate whether the rate of degeneration of more distal axons shows 
the same results. The cervical axonal density data shows a considerable variance, and it 
shows that axonal loss might be dependent on oligodendroglial pathology in the 
corticospinal tracts regardless of whether the patients have ALS. 
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Figure 4.7: Comparison of the axonal density in the corticospinal 
tracts. No differences were identified between the three groups regarding axonal 
density, using a Kruskal-Wallis test. A representative image of the analysed 
pictures can be found in the Materials and Methods chapter, figure 2.3. 
 
 
 
 
 
 
 
 
Figure 4.8: Correlation between glial inclusion counts and axonal 
density in the corticospinal tracts at the cervical spinal cord level. A 
significant correlation was found between these two variables in the overall 
population (Kendall tau= -0.399, p= 0.00815, z= -2.61). 
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Figure 4.9: Western blot results for neurofilament protein heavy 
chain. A and B show the expression of neurofilament protein (NF) relative to 
the control group in the dorsal columns and the corticospinal tracts respectively. 
C and D show the relative expression of PLP in the dorsal sensory columns and 
the corticospinal tracts respectively. *p ≤ 0.05 for Mann-Whitney post hoc tests. 
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4.5 Quantification of hnRNP-A2 
We examined the expression of hnRNP-A2, a key component of MBP mRNA transport 
granules, in the lateral corticospinal tracts of the spinal cord and in the precentral gyrus 
white matter by immunohistochemistry: hnRNP-A2-positive and negative glial nuclei 
were counted to calculate the proportion of glial nuclei that were positive in these areas 
(figure 4.10D). 
As noted above, we had hypothesised that oligodendrocyte pathology, as indexed by p62-
positive inclusions which are most pronounced in the precentral gyrus white matter, may 
also cause mRNA transport deficits. It was therefore hypothesised that there would be a 
negative correlation between the percentage of hnRNP-A2-positive glia (figure 4.10A) 
and the burden of glial inclusions in the C9ALS cases in this region. This negative 
correlation was indeed statistically significant (p=0.0114, =-4.39, figure 4.10B). 
Regarding the corticospinal tracts of the spinal cord, Kruskal-Wallis analysis revealed 
significant differences amongst the groups (χ2=8.9579, p=0.01135, figure 4.10C). Post 
hoc tests showed that the sALS group had a smaller number of hnRNP-A2-positive nuclei 
in the lateral corticospinal tracts of the spinal cord compared to the C9ALS group (p= 
0.012348). No statically significant differences were found when the sALS cases were 
compared to the control group (p=0.0559). This could be due to a low number of cases 
in our control group, which confers a low statistical power (β=0.54). 
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Figure 4.10: Quantification of nuclei positive for hnRNP-A2. A and C 
show the group comparison of the percentage of nuclei which were labelled for 
hnRNP-A2 in the corticospinal tracts (A) and the precentral gyrus white matter 
(C). B shows the significant negative correlation found between the p62-positive 
inclusion score and the percentage of nuclei stained for hnRNP-A2 in the white 
matter under the motor cortex in individual C9ALS cases (p=0.0114). D shows a 
representative picture for hnRNP-A2 staining: Red circles indicate nuclei below 
the threshold (negative), and green circles indicate positive nuclei. This image 
shows subcortical precentral gyrus white matter from fixed tissue. * p < 0.05. 
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The lack of MBP relative to PLP in the corticospinal tracts of C9ALS cases 
described above could be due to a depletion of the hnRNP-A2 protein. When the 
quantity of this protein was measured using Western blot in the dorsolateral 
corticospinal tracts, ALS cases showed no significant reduction of hnRNP-A2 
(Kruskal-Wallis p=0.0775, 2=5.12, figure 4.11B). No differences could either 
be observed in the dorsal columns of our groups (Kruskal-Wallis p=0.981, 
2=0.0385, figure 4.11A). This indicates that hnRNP-A2 is not reduced in either 
the dorsolateral corticospinal tracts or the dorsal somatosensory columns of the 
C9ALS cases. 
The relative levels of hnRNP-A2 mRNA were also measured to determine 
whether any difference in the levels of hnRNP-A2 protein could be caused by a 
reduction in mRNA. No differences were found amongst the groups regarding the 
levels of this mRNA molecule (Kruskal-Wallis corticospinal tracts: p=0.594, 
2=1.04, figure 4.11D; dorsal column: p=0.189, 2=3.34, figure 4.11C). 
The conclusions that we can derive from these data is that the lower amount of 
MBP protein found in the spinal cord of our C9ALS cohort is not caused by a lack 
of hnRNP-A2 protein or mRNA. 
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Figure 4.11: hnRNP-A2 expression levels. The protein and mRNA 
expression levels (quantified using Western blot and qPCR respectively) did not 
vary in the different study groups in either the dorsal column (A, C) or the 
corticospinal tracts (B, D). 
  
192 
 
4.6 Quantification of oligodendrocyte precursor cells (OPCs) 
OPCs are the progenitor cells which differentiate into mature oligodendrocytes for 
oligodendrocyte turnover and remyelination of axons after events incurring a loss of 
myelin. Having shown that greater glial inclusion pathology loads are associated with a 
reduction of glia expressing hnRNP-A2 in the white matter of the precentral gyrus, it was 
hypothesised that there would be a commensurate alteration in the numbers of OPCs. 
This alteration would be shown as a negative correlation between the number of OPCs 
and p62-positive inclusions in the precentral gyrus. OPCs were immunostained (figure 
4.12F) using the MAP2+13 antibody (Shafit-Zagardo et al., 1999) and counted in the 
spinal cord ventral horns and lateral corticospinal tracts, the motor cortex grey matter, 
and the precentral gyrus white matter. 
As seen before with hnRNP-A2-positive cells, there was a significant negative correlation 
between the number of stained OPCs and the number of p62-positive inclusions in the 
precentral gyrus white matter, with fewer OPCs in the tissue which had more inclusions 
(p=0.0429, z=-2.02, tau=-0.431, figure 4.12E). 
There were no significant differences in the number of OPCs between the groups in either 
the spinal cord ventral horns (Kruskal-Wallis χ2=1.11, p=0.575, figure 4.12A), lateral 
corticospinal tracts (Kruskal-Wallis χ2=2.49, p=0.288, figure 4.12B), or the precentral 
gyrus white matter (Kruskal-Wallis χ2=3.04, p=0.219; figure 4.12D).  
In the motor cortex, a significant alteration in the number of OPCs was found (Kruskal-
Wallis χ2=6.66, p=0.0359, figure 4.12C). Post hoc tests revealed that this corresponds 
to an increased number of OPCs in the C9ALS group compared to controls (W=71, 
p=0.00558). The sALS group was not statistically different from the C9ALS group 
(p=0.663) or the controls (p=0.344).   
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Figure 4.12: Quantification of OPCs. A and B show that there were no 
differences amongst the three groups regarding OPC counts in the ventral horns 
(A) and the corticospinal tracts (B). C and D demonstrate the comparison 
between the groups in the motor cortex grey matter (C) and the precentral gyrus 
white matter (D). A significant difference between OPCs in control and C9ALS 
was found in the grey matter. E shows a significant negative correlation in the 
precentral gyrus white matter, between the inclusion score and the OPC counts. 
F shows a representative picture of an OPC in the motor cortex stained for 
MAP2+13. This image shows subcortical precentral gyrus white matter from fixed 
tissue. Post hoc analyses were performed using the Mann-Whitney test. *p<0.05.  
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4.7 Attempt at MBP in situ hybridisation to address a possible 
dysfunction in MBP mRNA transport 
In situ hybridisation was attempted in order to label MBP mRNA in human tissue. 
It had been hypothesised that MBP mRNA transport is impaired in ALS. This 
technique would help visualise MBP mRNA transport in the oligodendrocytes of 
ALS cases to determine whether there was any evidence of such an impairment. 
To accomplish this, both an antisense probe and a sense probe –as a negative 
control- were used. 
Unfortunately, the multiple trials at staining MBP mRNA in human tissue did not 
show the distinct puncta staining pattern surrounding oligodendroglial bodies. 
Instead, the sense probe –which should not stain the tissue- produced 
nonspecific staining as can be seen in figure 4.13B, which did not differ much 
from what it could be observed when using the antisense probe figure 4.13A. 
Therefore, this technique could not be used to assess MBP mRNA transport in 
our human post mortem tissue. 
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Figure 4.13: In situ hybridisation of MBP mRNA. A: Antisense probe 
complementary to MBP mRNA’s sequence to enable its staining. B: Sense probe 
matching the sequence of MBP mRNA, which should not provide any staining. In 
both cases, both neurones and glia showed unspecific cytoplasmic and nuclear 
staining. These images show ventral horns from fixed cervical spinal cord sections. 
Scale bar corresponds to 25 m.  
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4.8 Discussion 
4.8.1 mRNA levels do not differ, but the levels of MBP do 
Quantitative PCR revealed that there were no differences between controls and 
the ALS groups regarding the levels of the mRNA encoding MBP, PLP1 and 
HNRNPA2B1. The differences in levels of any of these proteins are, therefore, not 
caused by differences at the point of transcription. It was hypothesised that there 
would be a reduction in the MBP protein –which is dependent on mRNA 
transport- when normalised to PLP levels –which is not-  in the motor tracts of 
ALS cases. Western blots primarily revealed that the MBP/PLP ratio was 
dramatically lower in the corticospinal tracts of C9ALS cases compared to 
controls. This was not seen for sALS cases. This loss could have potentially been 
caused by a reduced translation of hnRNP-A2 (for MBP mRNA transport), or by 
a degeneration of the axons passing through the section. The latter was 
considered unlikely since the amount of neurofilament heavy chain protein 
present in the region was not different from that of controls, and neither was the 
axonal density. We found no evidence for reduced hnRNP-A2 levels; these were 
in fact generally higher in C9ALS cases. The fact that the MBP/PLP ratio was so 
dramatically reduced for the C9ALS group supports our hypothesis that MBP 
mRNA transport and translation are impaired in C9ALS. 
It has been argued by one group that the rate of degradation of MBP post mortem 
is too high for it to provide a reliable measurement of protein levels (Barker et al., 
2013). These researchers incubated fresh deep brain white matter tissue lysates 
at room temperature and at 4°C for variable amounts of time to simulate post-
mortem delay. Myelin proteins were quantified using ELISA, which revealed that 
MBP (but not PLP) was significantly degraded with time in this way. While ELISA 
is a more sensitive technique than Western blotting, the main difference with our 
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approach is that the proteins in post-mortem tissue are in a very different 
environment compared to proteins in tissue lysate –as they were used in their 
study. Proteins in lysate are surrounded by detergents which very likely affect the 
structure, binding pattern, and stability of proteins, which may lose the 
protection conferred by their local environment in the tissue. Additionally, room 
temperature is reasonably higher than the 2-4°C at which bodies are kept in the 
morgue before dissection and autopsy. Furthermore, an older study showed that 
unfrozen brain tissue does not lose MBP when left at room temperature overnight 
(Ansari et al., 1976). They showed the same for frozen tissue. They suggested that 
although MBP is an excellent substrate from brain acid proteinases, it is protected 
from them as long as the myelin lamellae are not disrupted. The results shown 
above (MBP levels vs post mortem delay) show no correlation between post-
mortem delay and MBP levels in the specimens used and not significant 
differences amongst the three groups in our study. 
4.8.2 Different myelination markers reveal possible relationships 
between C9ALS and myelination defects in the precentral gyrus. 
In the previous section, it was stablished that the C9ALS cohort has a distinct 
greater pathology in the precentral gyrus in the form of p62-positive protein 
inclusions, and a spinal cord inclusion pathology similar to that of sALS cases. 
Then, markers related to myelination and MBP mRNA transport were quantified 
to test the hypothesis that MBP mRNA transport is impaired in ALS. A negative 
correlation was found between p62-positive inclusion counts and the percentage 
of glial cells labelled for hnRNP-A2 in the white matter of the precentral gyrus. 
This correlation was not seen in the corticospinal motor tracts in the spinal cord, 
which suggests that the pathogenic action of mutant C9orf72 favours the 
forebrain. 
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The number of available oligodendrocyte precursor cells in the white matter of 
the precentral gyrus was also reduced with higher inclusion counts in C9ALS, 
thereby further supporting the idea that the pathology in glial cells caused by 
mutant C9orf72 might cause oligodendroglial dysfunction. It is also clear from 
our results that the p62-tagged proteins aggregated in glia in the precentral gyrus 
are not primarily constituted of pTDP43 or any of the C9orf72 DPR. Further 
investigation may elucidate which proteins are aggregated and tagged with p62 
in the oligodendrocytes and whether they are involved in their degeneration. 
There are some potential candidate proteins based on co-localisation studies: 
- RNA Binding Motif Protein 45 (RBM45) is an RNA-binding protein which has 
been found to co-localise with ubiquitylated inclusions in the spinal cord of ALS 
patients, with a higher abundance of RBM45-positive inclusions in C9ALS 
(Collins et al., 2012). 
- Rho guanine nucleotide exchange factor (RGNEF) regulates the GTP/GDP 
exchange in Rho GTPases, some of which are expressed by oligodendrocytes 
(Erschbamer et al., 2005). RGNEF has been found to co-localise with p62-
positive inclusions in motor neurones of C9ALS cases, and it would be of interest 
to investigate their co-localisation in oligodendrocytes as well. 
- TDP-43 missing the C-terminus. The antibody used in this study binds to the C-
terminus of TDP-43, which leaves the possibility for the N-terminus to be part of 
those protein inclusions. 
4.8.3 Loss of myelin proteins in the corticospinal tracts is not C9ALS-
specific, but a common feature of ALS. 
sALS cases showed a reduced number of hnRNP-A2-expressing cells in the 
corticospinal tracts of the spinal cord. This difference was not seen in C9ALS. 
However, MBP is greatly reduced in both ALS cohorts compared to PLP in this 
area. The only study to compare both MBP and PLP in health and ALS to date is 
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a short paper from nine years ago, which studied the lipid and protein 
composition of myelin in groups of three SOD1G93A mice at different ages 
(Niebroj-Dobosz et al., 2007). The authors showed a reduction in both MBP and 
PLP protein compared to controls, and electron micrographs showed 
degeneration of myelin sheaths in the spinal cord. 
Axonal loss in the corticospinal tracts was then quantified to investigate the 
relationship between glial pathology in the pyramidal tract and the axons they 
support. Interestingly, our study shows a negative correlation between the 
number of glial inclusions and the density of axons in the corticospinal cords of 
the pooled cohort. Funfschilling et al. (2012) and Lee et al. (2012) have both found 
that axonal metabolism is critically dependent upon the provision of glucose and 
lactate by oligodendrocytes. Thus, pathology in human glia might hinder 
metabolite export to axons in ALS. 
4.8.4 Final remarks 
The C9ALS group showed changes indicative of altered MBP mRNA translation 
and thus myelination in the precentral gyrus. The spinal cord, however, presented 
a generalised loss of MBP, and several myelination markers were related to the 
aggregation of proteins in oligodendrocytes, accompanied by axonopathy. The 
approaches here described, however, have the limitation of using human post 
mortem tissue. Therefore, these results indicate the state of the brain at the time 
of death, not providing much data as to how the disease develops at the cellular 
level, and when and how the loss of myelin is initiated in relationship to neuronal 
degeneration. This should then be addressed further by analysing models of 
C9ALS and ALS caused by mutations in TARDBP, which help understand the 
development of the disease. In the following chapters, this is addressed by 
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attempting to generate transgenic strains of zebrafish that should help 
understand how mRNA transport might impair myelination in ALS. 
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RESULTS: Part II 
 
Development of in vivo systems for investigating the 
molecular basis of glial pathology in ALS 
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CHAPTER 5 
Generation of C9orf72 
hexanucleotide repeat transgenic zebrafish 
5.1 Introduction 
IHC studies using human post-mortem tissue showed that cases harbouring 
expanded C9orf72 presented a severe glial pathology which correlated with loss 
of expression of myelination markers in the precentral gyrus compared to 
sporadic cases of ALS with non-expanded C9orf72. To investigate this further and 
establish developmental cause-effect relationships, which cannot be achieved 
using only human post-mortem tissue, zebrafish models containing CCCCGG-
expanded mRNA were desirable.  
The aim of this part of the project was to make vectors which allowed the 
oligodendrocyte-specific transcription of versions of the C9orf72 hexanucleotide 
repeat expansion (C9HNR) containing 5-6 bp interruptions every 10-13 repeats. 
These vectors would theoretically allow the toxic phenotype caused by GGGGCC 
expansions, except for the dipeptide repeat (DPR) toxic proteins, products of the 
RAN-translation of pure repeats – thanks to the interruptions. However, a recent 
study shows that these RNA sequences also cause the formation of toxic DPRs 
(Stopford et al., 2017). This was not known at the beginning of our study. The 
zebrafish mbpa gene is only expressed by oligodendrocytes in the CNS, making 
its promoter a desirable one to regulate the transcription of the C9HNR 
expansions. Ideally, the expression vector used should also produce a green 
fluorescent protein (GFP) expression marker. 
5.2 Construction of the zebrafish expression vector 
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The strategy chosen to make the expression vectors was to excise the mbpa 
promoter and the interrupted C9HNR sequences from existing plasmids, and 
then to clone those fragments into linearised Gateway 5’-entry and middle entry 
vectors (figure 1A, B). The vectors containing our desired inserts, and the 
destination vector – containing a poly-adenylation (poly-A) signal and Gateway 
recombination sites, would then be recombined in a Gateway recombination 
reaction, which should generate the desired expression vector in a single-step 
reaction. This would render a vector with the HNR sequences downstream of the 
mbpa promoter, followed by the gene for GFP and a poly-A tail (figure 1C). This 
mbpa promoter was the same used by Jung et al. (2010) successfully and reliably 
labelling myelinating oligodendrocytes. Interrupted C9HNR repeats have 
previously been used in drosophila (Mizielinska et al., 2014) although in their 
case, the interruptions added stop codons every 12 repeats, totally blocking DPR 
translation. The use of Gateway vectors produced using the Tol2 kit provided by 
Kwan et al. (2007) has proven to be a useful tool to integrate transgenes into the 
zebrafish genome. As an example, Don et al. (2017) have created a triple 
transgenic line which expresses 3 different fluorescent proteins regulated by 
different promoters. Motor neurones express blue fluorescent protein under the 
regulation of the motor neurone-specific -3mnx1 promoter, TDP-43 expression is 
accompanied by the expression of GFP, and the cell death reporter Annexin V has 
mCherry (red fluorescence) as a reporter. These studies support our choice of 
expression vector for the study of the effect that C9HNR cause in 
oligodendrocytes. 
5.2.1 Cloning the zebrafish mbpa promoter 
A pGEM plasmid construct containing the mbpa promoter was obtained from 
Kim Lab (Jung et al., 2010). The plasmid was extracted from the filter paper that 
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it was sent in, and the extract was then used to transform competent bacteria, 
which were then grown for midiprep purification of the plasmid. After this, the 
purified plasmid was digested with EcoRI, presenting a fragment of the expected 
size (mbpa promoter ~ 2000bp, vector ~ 2800bp) (figure 5.1A). The plasmid 
was also sequenced to confirm the sequence of the mbpa promoter. The 5’entry-
multiple-cloning-site (5’E-MCS) vector – obtained from the Lawson lab (Kwan et 
al., 2007)- was linearised, and the mbpa promoter insert excised from the pGEM-
mbpa promoter construct, both via sequential digestion with SacII and SalI 
(figure 5.1B). The linearised vector and promoter fragment were then gel 
purified, and the vector dephosphorylated using rSAP. The agarose gel showed 
bands of the correct sizes (figure 5.2A). 
Competent bacteria were transformed with the ligated 5’E-[mbpa promoter] 
plasmid, and some of them released a DNA band of the correct insert size after 
linearizing them with SalI (figure 5.2B). These plasmids were then sequenced 
to confirm that the insert was indeed the desired mbpa promoter. 
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Figure 5.1: Gateway cloning strategy to construct the hexanucleotide repeat 
(HNR) expression vector for zebrafish. Putting interrupted C9HNRs and a 
fluorescent reporter under the influence of the mbpa promoter should direct their 
transcription specifically to oligodendrocytes in zebrafish. A: The mbpa promoter was 
excised from its original plasmid by using the restriction enzymes SacII and SalI. It was 
then cloned into a similarly digested 5’ entry Gateway plasmid. B: The interrupted 
sequence of C9HNRs was purified from the original plasmid by digesting it with SalI and 
EcoRV, and then cloned into the middle entry Gateway plasmid. C: Mixing the two 
resulting vectors, along with the p3E-GFPpA and pDestPA2 vectors, and Gateway 
clonases, should trigger recombination events to provide the desired expression vector, 
with the different fragments in the correct orientation: The mbpa promoter would have 
allowed for the transcription of the C9HNRs and GFP mRNA to happen specifically in 
oligodendrocytes in the CNS; the C9HNR sequence did not include a Kozak consensus 
sequence so that it would not be translated by ribosomes, but the GFP gene was ATG-
driven and included an upstream Kozak consensus. This should have allowed for the 
translation of GFP and the easy visualisation of cells which transcribed C9HNR 
sequences. 
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Figure 5.2: Construction of the 5’-entry vector containing the mbpa 
promoter. A: Digested pGEM-mbpa promoter (pGEM-T easy ~3000bp; mbpa 
promoter ~2000bp) and 5’-entry-MCS vectors (~2800bp), using SacII and SalI. 
B: Purified and linearised 5’-entry construct containing the mbpa promoter 
(~4800bp). Marker: Hyperladder 1kb.  
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5.2.2 Sub-cloning of hexanucleotide repeats  
pcDNA 6.2 GW/emGFP-miR plasmids containing inserts with 10, 51 and 102 
interrupted GGGGCC C9HNRs were previously generated by Dr Adrian 
Higginbottom in SITraN. The interruptions consisted of TCGA insertions every 
10-12 GGGGCC repeats and were incorporated to improve the stability of the 
C9HNRs (Stopford et al., 2017). The plasmids were midi-prepped and sequenced 
to check the repeat lengths and linearised using EcoRV to visualise the size of the 
inserts in a gel (figure 5.3). The interrupted C9HNRs were excised from their 
respective plasmids, via double digestion with EcoRV and SalI in a single reaction. 
This led to visible DNA fragments of the correct size for 10x and 51xHNR. 
However, for the 102xHNR, just 1 or 2 colonies survived after plating the whole 
transformation content, and these contained contracted versions of the C9HNR 
(~30-50 repeats). This led us to conclude that the 102xHNR is toxic for bacteria 
and that the only bacteria that survive the transformation process are those which 
recombine the 102xHNR repeats to form shorter versions of it. Due to this 
problem, only the 10xHNR and 51xHNR fragments were purified from an agarose 
gel. In retrospect, a different strain of E. coli should have been used, as the one 
being used was not prepared to amplify unstable sequences. 
The ME-MCS plasmid was obtained from the Lawson laboratory and showed a 
single band after SalI digestion (figure 5.3) since the ME-MCS plasmid has only 
one SalI digestion site (figure 5.4). The ME-MCS vector was linearised with 
SmaI and SalI to perform a cloning reaction in conjunction with the C9HNR 
fragments. 
The 10x/51xHNR sequences were then ligated into the SmaI/SalI-linearised ME-
MCS plasmid, transformed, grown and purified. The constructs were then 
digested to confirm the vector and insert sizes (figure 5.5A, B). They were then 
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sequenced to confirm the insert size since the small size of the C9HNRx10 insert 
means that a considerable mass of DNA is needed for it to be observed using 
agarose gel electrophoresis. All colonies picked from the ME-10xHNR plate 
contained the correct insert (figure 5.5B). However, the colonies picked from 
the ME-51xHNR plate yielded chromatograms which were complicated to read: 
The beginning of the C9HNR sequence could be easily read in the sequence file, 
but the repeats became more difficult to read after about ~15 GGGGCC 
repetitions. Nonetheless, the chromatogram peaks can still be traced to get an 
approximation of the expansion length. This problem was due to the difficulties 
which arise when trying to sequence GC-rich strands of DNA. Sequencing the 
DNA with betaine (used for sequencing of CG-rich sequences) did improve the 
quality of the sequencing slightly (figure 5.6). Figure 5.7 shows an example of 
the shortening of the 102xHNR : Only 51 repeats were identified tracing the peaks 
on the chromatogram. 
Due to the low resolution of the sequencing of the ME-51xHNR clones, 1 µg of 
each of 4 clones was digested with SalI and NotI to check the C9HNR size. The 
gel in figure 5.5B shows that 3 out of 4 of the DNA preparations showed an 
insert of the correct size (~360bp). However, only one construct showed no 
additional bands, meaning that it contained only the vector and the correct insert, 
whereas the others showed smaller bands suggesting instability of the repeat. 
This construct was used to make the final Gateway construct. 
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Figure 5.3: Digestion of middle-entry vectors containing the three 
different C9HNR constructs. Result of performing double digestion of the 
plasmids with SmaI + SalI for ME-MCS, and SalI + EcoRV for HNR-containing 
plasmids. The HNR bands were gel purified. 
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Figure 5.4: Map of the ME-MCS plasmid. Plasmid map highlighting the 
single digestion site for SalI (in red square). 
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Figure 5.5: Digestion of the ME-MCS:HNRx10/51 clone. A: The plasmids 
showed the correct size (~2700bp and ~3000bp respectively) after digestion with 
SalI. B: Digestion of different ME-MCS:HNRx51 clones. Only the third one from 
the left showed a single band of the correct size (~360bp) when the C9HNRx51 
fragment was excised using SalI and BamHI.  
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Figure 5.6: Sequencing of purified middle entry plasmids for 
recombination containing 10xHNR and interrupted 51xHNR 
sequences. The GGGGCC repeats were normally sequenced for the ME-
10xHNR plasmid and using betaine for the ME-51xHNR plasmid, for which the 
reverse primer was used and therefore shows GGCCCC repeats. Numbers have 
been placed under the traces at the beginning of each repeat.  
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Figure 5.7: Sequencing of 
purified middle entry 
recombination plasmid 
containing the interrupted 
102xHNR sequence. 
Betaine and the reverse primer 
were used to sequence the 
interrupted GGCCCC repeats 
in this plasmid. Numbers have 
been placed at the beginning of 
each repeat. This sample 
presented the most repeats of 
any of the clones obtained 
attempting to generate the 
ME-102xHNR plasmid.
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5.2.3 Obtaining the 3’E-GFP construct 
The third component wanted in our Gateway constructs was a GFP reporter 
downstream of the repeats. Expression of this gene should indicate which cells in the 
zebrafish transcribed the C9HNR sequences. The 3’E-GFP plasmid is contained in 
the tol2-kit and harbours both a Kozak consensus and an ATG codon at the beginning 
of the coding sequence which were cloned into the final expression vectors along with 
the GFP coding sequence. The size of this plasmid was confirmed by linearising it 
with NotI followed by agarose gel electrophoresis (not shown). 
5.2.4 Obtaining the destination vector pDestPA2 
The pDestPA2 vector is the backbone with which the other three plasmids will 
recombine to generate the final Gateway expression construct. It also came with the 
tol2-kit and contains the ccdb gene which is toxic to bacteria, necessitating the use of 
a ccdb-resistant strain of E. coli for propagation. The plasmid size was confirmed by 
linearising it with SalI followed by agarose gel electrophoresis (figure 5.8A). 
5.2.5 Obtaining the capped transposase mRNA 
The pCS2FA-transposase plasmid includes the gene for a transposase which is 
necessary for the Gateway constructs to incorporate in to the zebrafish genomic DNA. 
The pCS2FA-transposase plasmid is also contained in the tol2-kit. This plasmid was 
grown and purified, then linearised using NotI. One microliter of the digest was used 
to confirm it was the right size (6034bp, figure 5.8B). The linearised DNA was used 
as a template to transcribe the transposase mRNA using SP6 RNA polymerase. It was 
then purified, alcohol-precipitated and resuspended in RNAse-free TE buffer. 
Figure 5.8C shows the synthesised mRNA on a non-denaturing agarose gel. 
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Figure 5.8: Preparation of the pDest-PA2 destination vector and the 
pCS2FA-transposase mRNA. A: SalI digestion of the destination vector 
pDest-PA2. B: NotI digestion of the plasmid containing the gene for the 
transposase, needed for efficient integration into zebrafish genomic DNA. C: SP6 
transcription product of the pCS2FA-transposase gene.  
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5.2.6 Gateway recombination reaction 
Once all the Gateway entry vectors and reagents had been prepared, the Gateway 
recombination reaction was performed using the purified 5’E-[mbpa-promoter], 
ME-10x/51xHNR, 3’E-GFP, and pDestPA2 plasmids. When mixed according to 
the protocol, the Gateway LR Clonase II enzyme should make them recombine as 
seen above in figure 5.1C. The resulting plasmids were expected to be 7620bp 
for the 10xHNR-containing construct (figure 5.9A) and 7881bp for the 51xHNR 
(figure 5.9B). After the Gateway reaction, the mix was transformed into bacteria, 
colonies grown, and the plasmids purified. Plasmids obtained from the 10xHNR 
reaction were used in a PCR reaction with primers flanking the HNR, producing 
a 120bp band. Figure 5.9C shows that there were some 10xHNR-containing 
constructs generating the right size product. Plasmids containing the 51xHNR 
were digested using BamHI, which cuts 159bp upstream and 10bp downstream 
of the HNR, to check the size of the plasmid and the size of the C9HNR. This 
process was expected to release a 490bp band and a vector band at 7385bp. As 
figure 5.9D shows, one clone contained the correct insert and vector size. These 
were sequenced and were confirmed to contain the desired inserts in the correct 
orientation (Figure 5.9E, F). These plasmids were injected in zebrafish 1-cell 
embryos along with the capped transposase mRNA, which integrates the insert of 
the Gateway construct in the zebrafish genomic DNA. 
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Figure 5.9: Gateway recombination results. A, B: Gateway recombination 
constructs including the pDest-PA2 backbone, the mbpa promoter (brown), the C9HNR 
sequence (yellow), and the GFP gene (green). The BamHI digestion sites flanking the 
C9HNR sequences are indicated by red rectangles. C: PCR of the Gateway construct 
containing the C9HNRx10 sequence. The product size indicates the correct insert was 
found in the first three samples (single band at ~120bp), but sample 4 shows three bands, 
which was not what was expected. D: BamHI digestion of the Gateway construct 
containing the C9HNRx51 sequence. Only sample 1 shows a DNA fragment of ~500 bp, 
which was the expected size. E, F: Sequencing results of the samples labelled 1 in C and 
D. Green lines indicate the location of the C9HNR sequences. For F, the sequence is less 
clear due to the lack of efficiency of the DNA polymerase with repeat sequences. However, 
51 interrupted HNR (blocks of 12-10-17-12) could be counted on the chromatogram.  
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5.3 Injection of the Gateway constructs with the transposase mRNA 
into zebrafish embryos 
The [mbpa promoter]:10x/51xHNR:GFP:pDestPA2 constructs (final 
concentration: 30 pg/µl) were mixed with diluted transposase mRNA (final 
concentration: 25 pg/µl) and phenol red solution (final concentration: 0.1%) in 
the appropriate amounts, and this mix was injected directly into either the yolk 
sac (NWT = 86, N10xHNR = 32, N51xHNR = 26) or the fertilised cell (NWT = 101, N10xHNR 
= 28, N51xHNR = 40) of 1-cell stage zebrafish embryos . Figures 10A and 10B 
show how the injections were detrimental to the survival of the embryos when 
compared to wild-type controls from the same cohorts. About 25% more embryos 
died when injected with the plasmid containing C9HNRx10, and 50% when 
injected with that containing C9HNRx51 into the yolk mass. Of the surviving 
embryos, only 5-10% did not present with deformities which would have killed 
the embryos at later stages of development. The rest of the embryos (~70% for 
the 10xHNR construct and ~45% for the 51xHNR construct) presented normal 
development. None of the surviving embryos showed any green fluorescence in 
the brain or posterior lateral line nerve apart from that observed in auto-
fluorescent structures, which also fluoresced in uninjected wild-type embryos. 
To increase the chance of early integration of the plasmids, injection into the 
fertilised cell of 1-cell embryos was performed multiple times (as recommended 
by the Tol2 kit provider). Figure 5.10B indicates that the injection resulted in 
the death of ≥80% of injected embryos, and this was consistent every time the 
embryos were injected with the plasmids into the cell. Initially, this lethality was 
caused by poor injection technique. However, even with good injection technique, 
poor survival rates were observed and reducing the amount of DNA injected 10-
fold to reduce the effects of DNA toxicity also had little effect. After each round of 
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injections, the surviving embryos that developed normally (~10-15% for both 
constructs) did not show any fluorescence different from the autofluorescence 
observed in the controls, which suggests that the DNA had not been integrated 
into the genome or was not expressing. 
 
 
Figure 5.10: Kaplan-Meyer plots for zebrafish injected with the 
Gateway constructs. Injecting the plasmids into the yolk mass was less 
detrimental to the survival of the zebrafish embryos than injecting them into the 
cell. A: Kaplan-Meyer plot of the only time the embryos were injected in the yolk. 
B: Kaplan-Meyer plot from experiments where the embryos were injected into 
the cell. 
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5.4 Discussion 
After correct synthesis of the [mbpa promoter]:10x/51xHNR:GFP:pDestPA2 
DNA expression constructs, its injection into 1-cell zebrafish embryos did not 
produce any fluorescence, which was our marker to confirm integration of the 
construct in the host genome and expression. This was also our decision point as 
to whether to raise the injected embryos. 
The main weakness of the different approaches assayed in our experiments was 
the lack of positive controls. Without positive controls, knowing where the 
experiments failed is difficult to assess. Additionally, it could be argued that the 
C9HNR repeats, which seem prone to self-recombine due to the high homology 
of the repeat sequences, could have been spliced from the sequence during the 
Gateway recombination reaction. However, this seems unlikely because the data 
above (figure 5.9) clearly shows that the repeats were present in the final 
construct. Below is an account of possible reasons as to why injected fish did not 
show any expression. 
5.4.1 The mbpa promoter might not be active enough to provide a 
sufficient oligodendroglial expression of GFP in the constructs used.  
This option is very unlikely because this promoter has been used previously in an 
efficient manner (Jung et al., 2010). In that research, an expression construct 
consisting of the mbpa promoter inserted directly into the Tol2-GFP vector, 
upstream of the GFP gene, was injected in zebrafish, obtaining selective 
fluorescence in myelinating oligodendrocytes. A way to confirm whether it was a 
problem with the promoter that caused the lack of fluorescence in this specific 
construct would have been to inject embryos with plasmids identical to the above 
HNR-containing plasmids, but regulated by the Gal4-activated upstream 
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activator sequence (UAS) instead. This is not an ideal solution because of the low 
and inefficient expression shown by the UAS in zebrafish expressing transgenic 
Gal4 under the svtk promoter and the thymidine kinase promoter from Herpes 
simplex (Scheer and Campos-Ortega, 1999). Some improvements have been 
made in this respect since then to enhance the transcription of UAS-promoted 
sequences (Halpern et al., 2008), but their complexity rendered them out of the 
scope of this project. 
Other promoters that have been used to target oligodendroglial expression in 
zebrafish include the promoters for the zebrafish olig2 (Shin et al., 2003, Park et 
al., 2007) and olig1 (Schebesta and Serluca, 2009) genes and the mouse Plp gene 
(Yoshida and Macklin, 2005). Expression driven by the olig2 promoter labelled 
oligodendroglial precursor cells at early stages of growth, with the disadvantage 
(in our case) that these cells later follow different fates. For example, some 
neurones, such as the eurydendroid/Purkinje cells in the cerebellum, also utilise 
the olig2 promoter at embryonic stages and show fluorescence when harbouring 
a Tg[olig2:egfp] bacterial artificial chromosome (BAC) (Shin et al., 2003). 
However, only oligodendrocyte-fated glia showed expression of olig2 expression 
at post-embryonic stages (Park et al., 2007). Using the Tg[olig1:egfp] BAC, 
differentiating oligodendrocytes have been successfully labelled in zebrafish 
embryos (Schebesta and Serluca, 2009), but it remains to be ascertained whether 
the expression is maintained in adult zebrafish. The same can be said about 
zebrafish that express EGFP under the murine Plp (proteolipid protein) promoter 
(Yoshida and Macklin, 2005). 
5.4.2 The C9HNR segments might have prevented genomic DNA 
integration or expression of the GFP gene.  
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Pure C9orf72 expansions allow the mRNA to form complex secondary structures 
known as G-quadruplexes (Reddy et al., 2013). It would be interesting to 
elucidate whether G-quadruplexes still occur even in the interrupted sequences 
used in this experiment. However, another interrupted C9HNR sequence with a 
similar pattern of interruptions demonstrated that the tertiary structure is not 
affected by small interruptions in the sequence every 12 repeats (Mizielinska et 
al., 2014). However, as it was shown above, polymerases can struggle to copy 
these expansions with high efficiency. These factors could have contributed 
towards a poor recombination of the desired DNA fragment into the zebrafish 
genome, or to inefficient transcription or translation of the resultant 51xHNR-
containing mRNA. The latter is less likely to apply to the 10xHNR-containing 
fragment since it can be easily amplified by Taq polymerase and may form fewer 
or less complex secondary structures. 
Embryos injected with a plasmid containing the mbpa promoter followed by the 
GFP marker gene lacking C9HNR sequences would have helped to ascertain 
whether the lack of genomic integration was caused by an unviable expression 
vector due to the C9HNR fragments. There is also the possibility that low levels 
of expression would have produced sub-threshold levels of fluorescence which 
could have been tested using more sensitive detection methods. Grown injected 
embryos could have thus been subjected to in situ hybridisation or 
immunohistochemistry using probes for GFP or antibodies for GFP respectively. 
 However, the possibility of HNR expansions blocking GFP expression seems 
unlikely because other groups have successfully produced zebrafish models 
harbouring C9orf72 expansions with fluorescent reporters downstream of the 
repeats. A zebrafish strain harbouring ubiquitously expressed 80×(GGGGCC) 
upstream of a fluorescent GFP reporter has very recently been utilised (Ohki et 
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al., 2017) to investigate the effects of dipeptide repeats and GFP fluorescence was 
observed. Additionally, strains harbouring different numbers of GGGGCC repeats 
(8, 38, and 72) after a GFP gene and a stop codon were used to investigate the 
effect of the expansion size in GFP synthesis (Lee et al., 2016). These constructs 
were also successfully injected into neuronal cell models. Drosophila 
melanogaster models harbouring C9orf72 expansions with expression markers 
have also become abundant since Xu and colleagues created the first of such 
models. These flies carried a 30×GGGGCC:GFP construct interrupted in the 
middle of the expansion with an in-frame restriction site and preceded by either 
CNS or motor neurone promoters (Xu et al., 2013, Zhang et al., 2015). Later, a 
ubiquitous 58×(GGGGCC):GFP construct was also successfully used to 
investigate the effects of DPR polypeptides in flies (Freibaum et al., 2015). 
However, this construct would only allow for the expression of GFP if one of the 
three possible reading frames was translated into DPR, while the other two would 
not yield fluorescence. Another Drosophila model was created using a 
48×GGGGCC:(FLAG-HA-MyC) construct, having three different markers, each 
in frame with a different DPR product (Burguete et al., 2015). All these models 
show that it is possible to produce viable animals harbouring C9orf72 repeats 
with functional downstream reporters. 
Fluorescent in situ hybridisation for the C9HNR would have been useful to 
ascertain whether the expansions used in our studies were being transcribed in 
the zebrafish genome. Finally, if this technique did not report any HNR 
transcription, Southern blotting could have been performed in injected embryo 
DNA extracts to determine whether the construct was being integrated into the 
genome. However, this would be limited by the effects of mosaicism and the 
efficiency of integration.   
224 
 
CHAPTER 6 
Studying the influence of TDP-43 over 
MBP mRNA transport using zebrafish models 
6.1 Introduction 
The aim of this part of the project was to determine whether TARDBP mutations 
interfere with MBP synthesis either by a toxic gain of function of the mutant 
protein –sequestering relevant proteins such as hnRNP-A2- or a loss of function 
–TDP-43 could be an important component of mRNA transport granules. 
6.2 Analysis of oligodendrocyte development in tardbp knock-out 
zebrafish 
In order to address the loss of function hypothesis, the possible developmental 
consequences driven by depletion of the tardbp’s gene’s protein product, Tardbp, 
were studied in zebrafish. A knock-out (KO) zebrafish strain for tardbp that had 
been generated by TILLING (Targeting Induced Local Lesions in Genomes) was 
available to us (Hewamadduma et al., 2013). This strain contains an early stop 
codon in the tardbp gene, which truncates the resultant protein at its second 
RNA-recognition motif, which likely results in its rapid degradation by the cell 
since no traces of it can be found in homozygous fish. This feature makes the 
model useful to investigate oligodendrocyte development in the absence of 
Tardbp, although with the caveat that the tardbpl gene is up-regulated to 
compensate for this loss (Hewamadduma et al., 2013). 
To study oligodendrocyte development in this model, OPCs positive for sox10 
mRNA were counted in 3 dpf (days post-fertilisation) embryos, and 
oligodendrocytes and commissures positive for mbp were counted in the same 
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area of the brain in 5 dpf larvae. Both types of counting were performed on wild 
type (tardbp+/+), homozygous mutant (tardbp-/-), and heterozygous (tardbp+/-) 
animals. Due to the variability that was seen with the employed staining method 
and chromogen (BCIP/NBT), a quantitative measurement of the colour density 
would not provide accurate results. This means that quantification of each type 
of mRNA was not possible using this methodology. 
6.2.1 Counting of sox10-positive OPCs in 3 dpf zebrafish 
After counting sox10-positive cells in the area shown in figure 6.1E (figure 
6.1E-G), a Kruskal-Wallis test showed that 3 dpf embryos do not differ in the 
amount of OPCs regardless of their tardbp genotype (KW p= 0.7109, figure 
6.1A). This means that depletion of Tardbp does not lead to a loss of cells with an 
oligodendroglial fate at the 3 dpf stage. 
6.2.2 Counting of mbp-positive structures in 5 dpf zebrafish 
The first myelin sheaths begin to appear between 4 and 5 dpf. We hypothesised 
that a lack of Tardbp may hinder myelination in zebrafish by impairing the 
transport of mbp mRNA to the oligodendrocyte’s myelin compartment. 
Oligodendrocytes within the hindbrain’s midline could not be counted due to 
poor contrast. For this analysis, only those oligodendrocytes that were lateral to 
the hindbrain’s midline were counted. 
 mbp-positive oligodendrocyte cell bodies and axons were counted in the area 
shown by figure 6.1H. Due to the fact that multiple axons can be myelinated by 
a smaller number of oligodendrocytes, the number of oligodendrocyte cell bodies 
could potentially not have a direct effect on how many axons become myelinated. 
For this reason, we first analysed whether a higher number of oligodendrocyte 
cell bodies correlated with a greater number of myelinated axons in that area. A 
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Kendall test encompassing all the study animals corroborated this (Kendall p= 
0.001566. tau= 0.3846805), indicating that a smaller amount of Schwann cells is 
indeed correlated with less myelinated axons at this stage (figure 6.1B). 
The next step was to ascertain whether Tardbp-deficient zebrafish presented a 
different overall number of oligodendrocyte cell bodies or axons. tardbp-/- and 
tardbp+/- zebrafish showed an average of 20% fewer Schwann cells than 
tardbp+/+. However, a Kruskal-Wallis test did not show statistical significance 
amongst the groups (K-W p= 0.06315, figure 6.1C). This result might be caused 
due to the low statistical power this analysis presents at α= 0.05 (achieved 
power= 0.52). This indicates that a positive result will not be detected 48% of the 
time for this effect size at α= 0.05, using this number of embryos. Regarding the 
number of myelinated axons, it was not any different from group to group (K-W 
p= 0.6117, figure 6.1D). It could be the case that the number of mbp mRNA-
positive axons was the same, but that the actual amount of mbp mRNA present 
at the end of the oligodendrocytic processes varied from group to group. 
Qualitatively, we noticed that tardbp-/- fish presented a paler staining pattern 
than tardbp+/+ or tardbp+/- (figure 6.1H-J). To investigate this, a quantitative 
fluorescent technique could be used in a future experiment.  
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Figure 6.1: Whole-mount in situ hybridisation analysis of the 
expression of sox10 and mbp mRNAs in zebrafish embryos. A: Relative 
number of sox10-positive cells compared to the average of the WT control group 
in 3 dpf embryos. B: Positive significant correlation between the numbers of 
oligodendrocytes and mbp-positive commissures. C, D: Intergroup comparison 
of the numbers of mature oligodendrocyte cell bodies and the number of 
commissures containing mbp mRNA. E-G: Representative images of sox10 
staining for the different tardbp fish genotypes at 3 dpf. H-J: Representative 
images of mbp staining for the different tardbp fish genotypes at 5 dpf. Yellow 
rectangles in E and H show the areas in which oligodendrocyte cell bodies and 
commissures were counted for each marker.  
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6.3 Producing zebrafish lines that express mutant Tardbp using 
CRISPR/Cas9 
In the previous section, no reduction could be seen in the number of 
oligodendrocytes in tardbp-/- zebrafish. Therefore, we aimed to produce a line of 
zebrafish that included human TDP-43 exon 6 point mutations in well-conserved 
residues of the zebrafish tardbp gene using clustered regularly interspaced short 
palindromic repeats/Cas9 (CRISPR/Cas9) technology (as detailed in the 
Materials and Methods section, 2.2.3).  
6.3.1 Testing the target sequences for the presence of SNPs 
Once the target sequences had been identified, we had to confirm that there were 
no SNPs in the G nucleotides of the PAM sequences, which are essential for Cas9 
to cleave the DNA. To achieve this, 24 WT zebrafish embryos were raised for two 
days then genomic DNA extracted for PCR and sequencing of the target 
sequences. The PCR was conducted using the exon6 primers described in 
section 2.2.3.2. The PCR products were run on an agarose gel as shown in 
figure 6.3. Twenty-two of the samples showed a single product. These were 
purified using the ExoSAP protocol (section 2.2.2.3) and sequenced using the 
exon6 primers. The results indicated that there were no common SNPs in the 
target sequences or the p.A379→T PAM site. However, the p.G347→V PAM 
sequence contained the SNP (A/C)GG (figure 6.4). Due to the fact that the SNP 
does not affect the G nucleotides of the PAM site, it should not influence the 
efficiency of Cas9 cleavage. 
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Figure 6.2: tardbp exon 6 SNP-screening PCR. 1-22: PCR of the exon 6 of 
the zebrafish tardbp gene for 22 WT embryos. Sample 23 dried out during the 
PCR. Primers for the DISC1 gene were used as a positive control, presenting a 
band at the right size. Non-template control shows no PCR product. All samples 
were run on the same gel with two running fronts, and for visualisation purposes, 
samples 15 onwards have been moved next to the rest. 
 
  
Figure 6.3: Alignment of the tardbp exon six target sequences. A: The 
target sequence containing the coding sequence for tardbp’s p.A379 (yellow) and 
its PAM site (grey) do not contain any SNPs, so the gRNA should easily bind to it, 
and Cas9 should nick the sequence before the PAM site. B: The target sequence 
containing the coding sequence for tardbp’s p.G347 (yellow) does not present any 
SNPs, and the PAM site (grey) contains an SNP in the first nucleotide. This 
nucleotide is allowed to be variable, so this should not present an impairment to 
the gRNA and Cas9 activities.  
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6.3.2 Guide RNA synthesis 
The guide RNAs need to be transcribed from a DNA template. These DNA 
templates need to include the protospacer sequence, the gRNA scaffold plus a T7 
RNA transcription promoter for in vitro transcription. This promoter is not 
included in the gRNA because the T7 polymerase only transcribes what comes 
after the promoter. 
The oligonucleotides (Integrated DNA Technologies) were subjected to PCR for 
rapid amplification using the T7 primer and the gRNA primer. The product bands 
at 120bp can be seen in figure 6.5A. The bands were extracted from the gel and 
precipitated to purify the template DNA. Figure 6.5B shows the DNA bands 
after ethanol precipitation. The template DNA was next used for the production 
of the guide RNAs. 
To obtain the guide RNAs, in vitro transcription with RNA polymerase was 
performed. The template DNA was then digested with DNAse, and the RNA 
molecules were then ethanol precipitated. Figure 6.5C shows the RNA products 
in a non-denaturing agarose gel. They ran slightly slower than similar-length 
double-stranded DNA due to the lower negative charge of single-stranded RNA 
of the same length, but the bands were clean and free of other nucleic acid 
residues. These guide RNAs were then ready for injection along with Cas9 protein. 
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Figure 6.4: Synthesis of the gRNAs for Cas9 guidance. A: PCR products 
resultant from using T7 and gRNA primers with the oligonucleotide. They both 
should be 120bp long, so the bands indicate a successful PCR. B: Gel-purified and 
ethanol precipitated PCR products. C: T7-transcription products using the DNA 
templates from B. The ladder is a DNA ladder and the RNA molecules, which 
should have a size of 100bp, run higher (slower) than their DNA counterparts.  
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6.4 Microinjection of zebrafish with gRNA/Cas9 
We sought to test the efficiency of our gRNAs before designing donor sequences 
to introduce the desired mutations. WT zebrafish embryos at the 1-cell stage were 
microinjected in the yolk with 2 nl of solutions containing one of the gRNAs (1.6-
fold dilution), Cas9 protein (40 pg) and phenol red, while uninjected embryos 
served as controls. The embryos were grown for 51 hours and then culled in 
tricaine.  Figure 6.6A shows the survival curve for each of the groups showing 
that the injected embryos survived normally compared to the controls. Genomic 
DNA was extracted from the gRNA-injected embryos to determine whether Cas9 
had cut the tardbpa gene by amplifying the target sequence using PCR and 
sequencing the purified amplicon with custom primers directed at that region. 
The sequence should include indel mutations surrounding the target region if 
efficient mutagenesis has occurred because of error prone homology-directed 
repair. After PCR amplification using the Ex6.1 primers and sequencing the 
products using the forward Ex6.1 primer, no insertions or deletions could be 
observed beyond the target sequences (Figure 6.6B, C). The same results were 
found after multiple trials, indicating that our guide RNAs were not effective at 
all. The same Cas9 protein and phenol red solution were used by another person 
who was using a different gRNA on embryos from the same lay. The success of 
this person’s injections indicated that there was not a problem with the Cas9 
protein or the phenol red, and the lack of success of our injections was likely due 
to the inefficiency of our gRNA. gRNA inefficiency is very common, and it can be 
found in a number of studies (Xu et al., 2015, Doench et al., 2014, Moreno-Mateos 
et al., 2015). 
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Figure 6.5: gRNA/Cas9 injection results. A: The survival plot shows that 
none of the cohorts suffered a significant amount of death during the 51 hours the 
embryos were raised. B, C: Sequence alignment of segments of the PCR products 
obtained using Ex6.1 primers from embryos injected with the p.A379->T gRNA 
(B) and the p.G347->V gRNA (C). There is no evidence that Cas9 nicked the 
genomic DNA in these regions since the target sequence (yellow) and the PAM 
site (grey) remain intact, and no mutations or loss of sequence quality were 
observed anywhere near the target sequences. The reference sequence of these 
regions is marked WT and boxed in red for comparison. 
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6.5 Discussion 
To study the effects of tardbp dysfunction, we used in situ hybridisation of mRNA to 
characterise the development and maturation of oligodendrocytes in the Tardbp-
lacking zebrafish model (Hewamadduma et al., 2013). Our results showed no overall 
differences in the numbers of OPCs or mature, myelinating oligodendrocytes. It is of 
importance to note that this Tardbp-lacking strain of zebrafish uses an alternatively 
spliced form of the tardbpl mRNA which provides a full-size Tardbp protein 
(Tardbpl) to counteract the loss of Tardbp. This could rescue any dysfunctions that 
could be caused by a lack of Tardbp in zebrafish. It will be of interest for future studies 
to assess myelination in double Tardbp/Tardbpl mutants and in embryos produced 
by breeding Tardbpl knock-outs and Tardbp knock-in mutants to ascertain whether 
a total loss of function or a toxic gain of function impair myelination. 
Future work should address the amount of Mbp generated and compare it to that of 
Plp or other myelin proteins synthesised in the cell body. This can be achieved using 
both Western blotting and whole-mount fluorescent immunohistochemistry on 
embryos from the same lines discussed here. This could be done by staining embryos 
using fluorescently-tagged antibodies which would follow a 1:1 relationship between 
fluorescence intensity and protein concentration. As mentioned in chapter 4, 
C9ALS human post-mortem tissue does show a loss of MBP in the dorsolateral motor 
tracts and the dorsal sensory tracts of the spinal cord which is not accompanied by a 
loss of PLP in the same regions. Due to the wide variety of ALS-causing TARDBP 
mutations, a stable zebrafish line with specific human mutations in Tardbp is 
desirable to model the disease and understand the functions that TDP-43 plays in 
ALS 
Therefore, the design and testing of guide RNAs for tardbp which was pursued as the 
first steps towards making tardbp mutant knock-in zebrafish, where translated 
protein would harbour human mutations in conserved residues. We investigated this 
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gene under the hypothesis that Tardbp is involved in the transport of Mbp, and that 
ALS-causing mutations in Tardbp impair MBP mRNA transport and correct axonal 
myelination by oligodendrocytes. The overall process to produce the guide RNA 
molecules to target Cas9 nuclease activity was successful, producing good purified 
RNA with no traces of RNA/DNA contaminants. Unfortunately, injection of neither 
of the guides resulted in mutations around the PAM site. This lack of effectiveness 
was likely due to one of two reasons: suboptimal methodology or the guide RNAs 
were not effective in targeting the genomic regions. The latter option is unlikely for 
one of the guides since very recently a group successfully created the p.A379->T 
model using the same gRNA sequence utilized in this study in the same zebrafish 
strain (Armstrong et al., 2016). However, they used a modified version of the 
Streptococcus pyogenes Cas9 mRNA containing a double nuclear localisation signal 
which has a 75-99% biallelic mutagenesis success rate (Jao et al., 2013). This mutant 
line will be of interest to investigate the effects of human TARDBP mutations in the 
zebrafish nervous system. In particular, it will display any toxic effects that may be 
caused by mutant Tdp-43 (gain of function), but any loss of function will be 
compensated by Tardbpl (Hewamadduma et al., 2013). Thus, this strain can help to 
address the loss of function/gain of function conundrum regarding mutations in 
TARDBP. 
The zebrafish Tardbp protein shares significant homology with human TDP-43 
including other amino acids which are also found mutated in ALS cases. The reason 
why we did not target other mutations is that there would have been no easy way to 
screen injected fish to detect the mutation. What made the selected sequences ideal 
for the later screening is the fact that they contained a restriction site that would be 
turned into a different restriction site after modifying the sequence. This would make 
it straightforward to genotype the fish using PCR amplification and restriction 
enzyme digests. 
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It is true that there are other available methods by which the desired directed 
mutagenesis could have been achieved. For example, Zinc-finger nucleases (ZFN) 
and Transcription activator-like effector nucleases (TALENS) are similar to the 
CRISPR/Cas9 system in that fact that they cause double-stranded breaks at specific 
points in the zebrafish genome. Both ZFN and TALENS rely on the engineering and 
screening of proteins, making them costly and very time-consuming and challenging. 
That added to the fact that engineered ZFN and TALENS would not guarantee 
mutagenesis even when they have demonstrated binding activity, made these 
systems unfeasible to use given the budget and the time scope for this project. 
However, the CRISPR/Cas9 system relies on the engineering and screening of gRNA 
sequences, reducing the costs and time scale considerably and making this approach 
much more desirable. Additionally, the efficiency of the CRISPR/Cas9 system has 
been shown to be superior to other nuclease-based systems, and obtaining new gRNA 
sequences in case the designed one do not work as desired can be done relatively 
quickly and inexpensively. 
Another possible approach by which it would have been possible to obtain the desired 
mutations or even other ALS-causing mutations in tardbp, would have been the use 
of TILLING mutants. These are fish whose male progenitor has been subjected to a 
highly mutagenic agent before fertilisation. Those embryos constitute a living library 
and are posteriorly grown to breed and screened for single point mutations in the 
target gene (Wienholds et al., 2002). As an example, the tardbp-/- strain used in this 
study was generated and screened by TILLING (Hewamadduma et al., 2013). Two 
obvious disadvantages of this system are the possibility of introducing additional off-
target mutations, and the fact that it needs to be done on a much larger scale than 
that needed for CRISPR/Cas9. High-throughput techniques have been generated to 
alleviate the latter (Draper et al., 2004), but the problem of the off-target effects still 
remains.  
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CHAPTER 7 
Discussion 
7.1 Neuronal research and glial research in ALS 
The roles that different ALS-causing mutations have in the degeneration of 
neurones and glial cells still need to be fully understood. A vast number of studies 
have investigated neuronal pathology in ALS to date, finding commonalities in 
the pathology presented by different genetic mutations and in sporadic cases, 
such as the cytoplasmic deposition of phosphorylated TDP43 in the ventral horn 
motor neurones. Such studies have also differentiated distinct forms of neuronal 
pathology affecting specific areas of the brain of patients harbouring different 
ALS-causing genetic mutations. This has greatly helped with investigating the 
molecular mechanisms which underlie the different neuronal pathologies found 
in ALS caused by different mutations. Regarding glial cells, the mechanisms 
underlying glial involvement in ALS have been studied for about 20 years, when 
reactive astrogliosis was found in G85R SOD1 mice (Bruijn et al., 1997) and 
decreased kinetics of sodium-dependent glutamate transport was seen in ALS 
brains (Rothstein et al., 1992). Since then, the involvement of astrocytes and 
microglia in ALS has been studied thoroughly. However, oligodendrocytes were 
mostly ignored as mechanistic sources of neurodegeneration in ALS up until a 
few years ago (Lee et al., 2012, Kang et al., 2013, Philips et al., 2013), even though 
evidence for oligodendroglial involvement in ALS was presented almost 30 years 
ago (Yamada et al., 1990). That study showed the abundance of complement-
activated oligodendrocytes in the motor cortex, brainstem and spinal cord of ALS 
patients compared to controls. These are oligodendrocytes which are labelled 
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with antibodies for proteins of the complement system, suggesting that they are 
in the process of being opsonised in ALS tissue. 
7.2 MBP shortage in the cervical spinal cord does not correlate with 
motor axon degeneration or with a general shortage of myelin 
proteins 
In this doctoral investigation, neuropathological and mechanistic approaches 
were taken to ascertain to which extent oligodendrocytes contribute to the 
neuropathology seen in ALS. We determined that the levels of MBP are 
diminished in ALS patients, while PLP levels remain similar to controls in the 
lateral corticospinal tracts. It seems, therefore, that there might be a selective 
reduction of MBP in the motor areas of the spinal cord white matter in ALS. The 
fact that this reduction in MBP does not correspond to a reduction of the axonal 
density in the corticospinal motor tracts suggests that axonal degeneration is not 
the cause of oligodendroglial degeneration in the lateral corticospinal tracts of the 
spinal cord. Previous studies revealed not only oligodendroglial dysfunction in 
ALS using human tissue (Lee et al., 2012, Kang et al., 2013), but also some 
molecular mechanisms underlying the dysfunction using G93A SOD1 mice (Lee 
et al., 2012, Kang et al., 2013, Philips et al., 2013). Some of these studies show a 
reduction in monocarboxylate transporter 1 (MCT1) in ALS patient tissue and in 
SOD1 mice, which indicates that oligodendrocytes are not providing enough 
metabolic support to the neighbouring axons (Lee et al., 2012, Philips et al., 2013). 
Additionally, the oligodendroglial turnover rate was abnormally high in ALS 
patients’ brains, which was accompanied by demyelination in the grey matter of 
the motor cortex and the ventral horns of the spinal cord of ALS patients (Kang 
et al., 2013). In the same study, a substantial reduction in MBP was demonstrated 
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in these two regions, which was not shown for 2',3'-Cyclic-nucleotide 3'-
phosphodiesterase (CNPase), a myelin protein present everywhere in the cells. 
Some of the pathological studies in human post mortem tissue presented in this 
thesis could benefit, however, from the inclusion of a larger pool of tissue 
pertaining to neurologically healthy controls and sporadic cases of ALS. This is 
especially relevant for the Western blot and qPCR studies, where it would be 
desirable to obtain data for a larger number of cases from all the cohorts to 
increase confidence in the data and the statistical power. However, some of the 
large changes observed between the cohorts for the MBP/PLP ratio suggest an 
mRNA-transport-dependent myelin loss in the motor tracts of C9ALS cases is 
likely. Also, the generalised loss of both MBP and PLP in the dorsal column –an 
extramotor region- in either ALS group compared to controls, provides further 
evidence of general oligodendroglial dysfunction in ALS. If this was indeed the 
case for the rest of the brain, the fact that ALS affects mainly the body’s motor 
function could be due to the fact that motor neurones are very energy-demanding 
compared to smaller neurones. It would have been of interest to study whether 
this reduction in the dorsal columns was accompanied by a loss of axonal fibres 
in the same area since secondary sensory neurones also extend over long 
distances. 
7.3 The aggregation of C9ALS-related dipeptide repeats and TDP-43 
cannot explain all the glial protein inclusion pathology in C9ALS 
brains 
We also showed that glial cells have a distinct pathology in some relevant regions 
of the frontal lobe such as the precentral gyrus and the prefrontal cortex in C9ALS 
compared to sporadic cases of ALS. There is a large number of p62-positive 
protein aggregates which cannot be explained by just C-terminal pTDP43 or DPR 
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aggregation in our C9ALS cohort. RNA-Binding Motif Protein 45 (RBM45) 
(Collins et al., 2012), Rho guanine nucleotide exchange factor (RGNEF) 
(Erschbamer et al., 2005) and N-terminal TDP43 seem like good candidates for 
proteins which could potentially be part of those inclusions. It would be advisable 
to perform further immunohistochemical studies to elucidate whether they 
actually are part of the inclusion bodies, including co-localisation studies where 
possible. Cytoplasmic aggregation of p62-labelled protein in some 
neurodegenerative diseases has also been related to a dysfunction of 
nucleocytoplasmic transport, especially that of TDP43 in most forms of ALS: 
Molecules larger than ~40 kDa–this includes TDP43 (43 kDa) - need active 
transport to shuttle into the nucleus through the nuclear pore complex (NPC) 
(Rout and Aitchison, 2000). The proteins which form the NPCs are extremely 
long-lived (Savas et al., 2012) and they assemble in an elastic network after 
mitosis, with a very low turnover rate in non-dividing cells (Daigle et al., 2001, 
D'Angelo et al., 2009), such as neurones and oligodendrocytes. With ageing, 
NPCs deteriorate, and this might lead to the cytoplasmic aggregation of proteins 
which normally shuttle between the nucleus and the cytoplasm (D'Angelo et al., 
2009). Irregularities in the nuclear membrane shape and mislocalisation of 
nuclear transporters were found in sALS and SOD1 fALS cases (Kinoshita et al., 
2009). However, this alone does not explain why aggregated proteins are mostly 
specifically located to the cytoplasm. To address this, it is important to consider 
that shuttling into the nucleus through the NPCs is only possible through the 
interaction of importin proteins with the nuclear localisation signal (NLS) found 
in karyophilic proteins. This interaction is tightly regulated by the local 
concentration of GTP-bound Ran-GTPase (Ran-GTP) in the cytoplasm, which 
disrupts the binding of importins to their cargo. For Ran-GTP to hydrolyse GTP 
to GDP and form Ran-GDP –which does not disrupt importin-cargo interactions-, 
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it needs first to bind Ran-GTPase activating protein 1 (RanGAP1) (Freitas and 
Cunha, 2009). This means that a disruption of the Ran-GTP/RanGAP1 
interaction in the cytoplasm would result in the impairment of the nuclear import 
of importin-dependent molecules. Interestingly, a recent study found that 
RanGAP1 accumulates with expanded C9orf72 mRNA in post mortem brain 
tissue, induced pluripotent stem cell (iPSC)-derived neurones from C9ALS 
patients, and expansion-expressing Drosophila cells (Zhang et al., 2015). These 
authors also claim to hold unpublished evidence of RanGAP1 mislocalisation in 
brain tissue of sALS patients (Zhang et al., 2016a). A decrease of 50% in protein 
import and the mislocalisation of Ran-GTP to the cytoplasm was also found in 
iPSC-derived neurones, along with the cytoplasmic aggregation of NPC 
scaffolding proteins (Zhang et al., 2015). This is highly relevant to the observed 
mislocalisation of TDP43 in ALS, which was observed to happen later than 
nucleocytoplasmic transport deficiency in iPSC-derived neurones (Zhang et al., 
2015). This also explains why most ventral horn neurones present abnormalities 
in the nuclear envelope shape, even those without TDP43 aggregation (Kinoshita 
et al., 2009). Additionally, TDP43 mislocalisation to the cytoplasm coincided 
with Ran-GTP cytoplasmic mislocalisation in the hepatic tsBN2 cell line (Winton 
et al., 2008). All this evidence strongly suggests that the disruption of 
nucleocytoplasmic transport is one of the main causes of protein cytoplasmic 
mislocalisation and aggregation in ALS. Therefore, it would be useful for our 
study to use immunohistochemistry to determine whether the p62-positive and 
TDP43 inclusions found in the cortical and subcortical oligodendrocytes of 
C9ALS and sALS cases also contain RanGAP or other proteins related to nuclear 
transport. This could potentially affect other similar proteins such as FUS, which 
is also rapidly shuttled between the nucleus and the cytoplasm (Zinszner et al., 
1997). FUS aggregation has been observed not only in ALS cases bearing FUS 
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mutations (Vance et al., 2009, Huang et al., 2010), but also in sALS and non-
SOD1 fALS (Keller et al., 2012, Deng et al., 2010). Some of the reports showed no 
trace of FUS aggregation in sALS cases (Neumann et al., 2009, Vance et al., 2009) 
but this may have been due to a very small number of sALS cases in their study 
(N = 2 and N not mentioned respectively). TDP43 and FUS are both part of 
transport granules (Fujii et al., 2005, Freibaum et al., 2010). Therefore, 
disruption of their normal function due to their cytoplasmic aggregation may 
have an impact on mRNA processing and transport, which is crucial for the 
synthesis of MBP and the subsequent formation of myelin. Our results are 
consistent with this hypothesis, but in vivo experiments should be carried out to 
study the development of MBP loss in sALS and C9ALS and establish whether 
there is a cause-effect relationship between the observed protein aggregation and 
defects in mRNA transport. A recent study found that iPSC-derived neurones 
from C9ALS patients harbouring 600-1600 GGGGCC repeats present impaired 
mRNA transport in the dendrites along with dendrite branching defects 
(Burguete et al., 2015). Furthermore, they also show evidence of the GGGGCC-
containing mRNA being itself transported and localised to the dendrites. It would 
also be relevant to optimise the in situ hybridisation for MBP mRNA attempted 
here, to clarify whether the glial pathology is accompanied by the impaired 
transport of it. 
One promising reported model that could help understand how the glial and 
neuronal aggregates found in C9ALS develop is the mouse line expressing 
(GGGGCC)66 by adeno associated virus. This strain replicates the human TDP43, 
DPR and RNA foci pathology of C9ALS, which other models focusing on specific 
pathogenic mechanisms of mutant C9orf72 have failed to show (Chew et al., 
2015). Other interesting models are the bacterial artificial chromosome (BAC)-
244 
 
transgenic mice that also express GGGGCC expansions, but at a relatively lower 
level (O'Rourke et al., 2015, Peters et al., 2015, Liu et al., 2016). These models 
contain an artificial gene with 100 to 1000 GGGGCC repeats, and they all 
replicate the pathology found in C9ALS, including C9orf72 mRNA foci and DPR 
inclusions. However, two of these models do not present neurodegeneration or 
p62 and TDP-43 pathology as seen in the patients’ brains (O'Rourke et al., 2015, 
Peters et al., 2015), while the other does (Liu et al., 2016). It would be interesting 
to use these models in future studies in order to study oligodendroglial 
dysfunction and demyelination in C9ALS and to test new drugs which may 
alleviate the pathology shown by cell models of C9ALS. An example of this can be 
found in the Huntington’s disease zQ175 mouse model whose neurones show 
disruption of the nucleocytoplasmic transport, caused by mutant Huntingtin 
expression of RAN-translated proteins (Grima et al., 2017). 
7.4 iOligodendrocytes will be useful to understand oligodendroglial 
dysfunction in different types of ALS 
Unfortunately, sporadic ALS does not have a generalised model. However, in the 
last decade, the induction of patient-derived fibroblasts directly into motor 
neurones (iMotor Neurones) and glia (iAstrocytes, iOligodendrocytes) has been 
developed and used to investigate neurodegenerative diseases (reviewed in 
Myszczynska and Ferraiuolo, 2016). This has allowed for the production of 
neuronal and glial models with the exact genome ALS patients have without 
artificial genetic alterations which could affect the expression of endogenous 
genes. Also, an advantage of these directly induced neurones and glia over those 
derived from human induced pluripotent stem cells is the fact that they do not 
lose the age-dependent signatures which are lost in the latter (Mertens et al., 
2015). Directly-induced neurones and glia from ALS patients will likely provide 
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scientists with the possibility of investigating the pathology and mechanisms of 
degeneration unique to individual patients while they are still alive, resulting in 
personalised drug screening and therapies. Being able to use the patients’ own 
cells as models of their own disease, researchers may find in these in vitro models 
a way to understand the mechanisms underlying sALS. Related to the study 
presented in this thesis, iOligodendrocytes from different types of familial ALS 
and from sporadic ALS have shown a reduced secretion of lactate compared to 
those derived from controls (Ferraiuolo et al., 2016). Interestingly, this was not 
observed for iOligodendrocytes from patients harbouring the C9orf72 mutation, 
which secreted as much lactate as those from controls. These authors’ results also 
suggest that oligodendrocytes from different ALS origins are toxic to motor 
neurones using a common mechanism that involves SOD1 and a lower amount of 
lactate production. However, this was not seen for the C9ALS group, suggesting 
that the toxicity oligodendrocytes exert has a different underlying mechanism in 
these cases. 
7.5 The limitations of human post mortem studies can be overcome by 
the use of in vivo models  
Future studies will need to perform in vivo studies in ALS models to overcome 
the limitations that post mortem studies offer. Human post mortem tissue 
provides a great window into the disease pathology at the time of death but is 
weak at providing details about the development of that pathology. However, 
applying different techniques on post mortem brains can determine genomic and 
proteomic targets to investigate further using in vivo models such as mice, 
zebrafish, or drosophila. In the case presented here, it would be ideal to ascertain 
the molecular pathways which lead to the observed oligodendroglial pathology 
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and the motor tract loss of MBP. Here, we intended to accomplish this by 
producing transgenic and mutation-carrying zebrafish lines. 
One of those strains would have expressed C9orf72 expansion mRNA specifically 
in oligodendrocytes, using a GFP reporter to indicate transgenesis. Unfortunately, 
this was unsuccessful, and it would be desirable that it is retried in the future 
using positive control fluorescence-inducing Gateway constructs to troubleshoot 
potential problems and mistakes. The other two strains were intended to harbour 
point mutations that cause ALS in humans, in conserved amino acids of the 
Tardbp protein. CRISPR/Cas9 technology was used to achieve this, but the choice 
of gRNA did not seem to trigger the nuclease activity of Cas9 upon the desired 
sequence. 
If these zebrafish lines were made in the future, there is the possibility that tardbp 
mutants will be rescued by their non-mutant tardbp-like (tardbpl) gene. 
tardbpl’s mRNA undergoes alternative splicing in response in tardbp-/- fish 
(Hewamadduma et al., 2013, Schmid et al., 2013), producing a larger Tardbpl 
protein which mimics Tardbp. Double knock-outs (tardbp-/-;tardbpl-/-), however, 
show motor neurone and axonal defects and vascular dysfunction, unlike single 
knock-outs of either gene (Hewamadduma et al., 2013, Schmid et al., 2013). 
These two studies are based on nonsense mutations which introduce a stop codon 
prematurely in the mRNA reading frame, rendering dysfunctional truncated 
proteins. It would be of interest to see how missense mutations in Tardbp, which 
cause ALS in humans when present in TDP-43, affect the splicing pattern of 
tardbpl in zebrafish. A promising strain to study one of the Tardbp mutations was 
recently produced using CRISPR/Cas9 (Armstrong et al., 2016), although their 
study did not look into the matter any further. This is due to the fact that the new 
line needs to be out-crossed for a few generations to eliminate any off-target 
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mutations, usually caused by the high homology of the gRNA’s target sequence 
with other regions of the genome. 
The use of the CRISPR/Cas9 system for the editing of genomic DNA has increased 
exponentially. This is due to the fact that it presents clear advantages over other 
similar methods such as Transcription activator-like effector nucleases 
(TALENS) and Zinc finger nucleases (ZFN), which rely on protein-DNA 
interactions rather than RNA-DNA interactions. The production of specific 
proteins is much more costly than producing specific gRNAs to target the desired 
sequence, and it makes it easier to introduce multiple mutations at once. A few 
years ago, this was demonstrated by mutating five different genes with single 
injections in embryonic stem cells using five specific gRNAs and mRNA encoding 
Cas9 (Wang et al., 2013). In 10% of cells, all alleles for the five genes were mutated 
together, which shows just how efficient the system is. 
7.6 Final remarks 
The pathology data presented here certainly provides evidence that mRNA 
transport disruption should be studied thoroughly in oligodendrocytes as a 
possible consequence of protein sequestration and aggregation, and a cause of 
ALS. Future studies should address whether TDP-43 is part of the MBP mRNA 
transport granules and whether the interaction of hnRNP-A2 and TDP-43 and/or 
expanded C9orf72 mRNA is detrimental to the transport of hnRNP-A2-
dependent granules and to MBP synthesis.
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APPENDIX 1 
Full membrane images of the Western blot membranes 
 
 
 
 
 
 
 
 
 
 
 
 
These are the overlay images of the membranes used for the densitometries described in section 
2.1.3.5. The black lines indicate the height at which the protein levels were measured. Any 
artifacts caused by the contact of the containing plastic bag were not visible in the analysed 
images. The images on the left and the right correspond to the dorsal column and dorsolateral 
motor tract samples respectively. As explained in section 2.1.3.4, the three first proteins were 
probed in ascendant order of abundance (hnRNP-A2→MBP→β-Tubulin) to avoid photographic 
saturation of the images for less-abundant proteins. For PLP and SMI31, the membrane was cut 
because their antibody had been raised in the same species animal as one of the other three, 
which would cause cross-reactivity of the secondary antibodies. The lanes, from left to right, 
belong to the following cohorts in both membranes: 1: Size marker; 2-5: C9ALS; 6-9: sALS; 10-
13: controls. 
